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CAN PREOPERATIVE C125 LEVELS PREDICT LIKELY STAGE
OF DISEASE AND LIKELIHOOD OF OPTIMAL DEBULKING
IN OVARIAN CANCER
S. Abdul, M.E.L. Paterson, J.A. Tidy
Sheffield Gynaecological Cancer Centre, Gynaecological Oncological
Surgery, Royal Hallamshire Hospital, Sheffield, UK
Objective: Assess if preoperative Ca125 levels can predict stage &
likelihood of debulking in ovarian cancer.
Methods: Ca125 assessed in 591 patients with ovarian cancers man-
aged in Sheffield.
Results: (Table 1) Ca125 was raised (.35IU) in: 85% of all ovarian
cancers; 89% of epithelial ovarian cancers (EOC); 100% of primary
peritoneal tumours (PPT); 60% of borderline tumours. Ca125 levels
increased from FIGO stage I to IV and were significantly higher in
stage III/IV compared to stage I, and in patients with residual dis-
ease compared to those with no residual disease post-operatively
(p = 0.02 Independent sample t-test). No significant difference in
Ca125 was seen between optimally or sub-optimally debulked
patients. Receiver operator curves (ROC) curves using Ca125 as a -
diagnostic predictor, show good separation of stage I from stage II/
III/IV disease and of patients with no residual disease from those
with residual disease, with AUC (area under curve) values of 0.69-
0.82. If Ca125 cut-off levels for predicting residual disease and stage
II/III/IV disease are selected as 284IU & 205IU respectively, sensitivi-
ty of 71% and 74%, and specificity of 70% and 74% respectively are
achieved.
Conclusions: Pre-operative Ca125 levels can be used as a predictor
of patients likely to have residual disease and FIGO stage greater
than stage I disease, with sensitivities and specificities of 70-74%.
Ca125 cannot however accurately predict exact stage or likelihood
of optimal versus sub-optimal debulking.
000121
BOWEL SURGERY IN OVARIAN CANCER- RISK FACTORS
AND PROGNOSIS
S. Abdul, M.E.L. Paterson, J.A. Tidy
Sheffield Gynaecological Cancer Centre, Gynaecological Oncological Sur-
gery, Royal Hallamshire Hospital, Sheffield, UK
Objectives: To determine the likelihood of bowel resection in
patients undergoing surgery for ovarian cancer, identify factors asso-
ciated with increased risk and determine prognosis.
Methods: Data was collected prospectively and analysed from 842
patients with ovarian, managed in the Sheffield gynaecological can-
cer centre between 1985 and 2002. The study was a case control
study comparing patients undergoing bowel resection with patients
not needing bowel resection.
Results: (Table 1) Bowel resection was performed in 8.6% of patients.
The risk of bowel surgery increased significantly (p , 0.0001 v2 test)
from 1st (5.8%) to 2nd operation (22%), with presence of bowel dis-
turbance (21.9% versus 6.3% with no bowel disturbance), with FIGO
stage III/IV disease (12.8% versus 2% for stage I/II) and Ca125
levels 2500 (12.9% versus 4.8% with Ca125 , 2500). There was no
significant change in risk with other symptoms or factors. Overall
5-year all cause survival was 41%. Tumour histology, FIGO stage,
postoperative residual disease and bowel resection were all prognos-
tic factors. Bowel resection was associated with a significantly worse
5-year survival (14%).
Conclusions: Patients with bowel disturbance, Ca125  2500, FIGO
stage III/IV disease or undergoing second operations for ovarian
cancer are at increased risk of bowel resection and should be selec-
tively offered stoma marking and counselling. Bowel resection is as-
sociated with poor prognosis and should be performed only if it will
result in optimal debulking or relieves imminent bowel obstruction.
000122
ENDOMETRIAL CANCERS: EPIDEMIOLOGY, MANAGEMENT
AND PROGNOSIS. SHEFFIELD CASE SERIES OF 664 PATIENTS
S. Abdul, M.E.L. Paterson, J.A. Tidy
Sheffield Gynaecological Cancer Centre, Gynaecological Oncology, Royal
Hallamshire Hospital, Sheffield, UK
Objective: To determine epidemiology, management and outcome
of endometrial cancers managed in Sheffield.
Methods: Prospective case series of 664 patients.
Results: Age = 33-93years, mean = 65. 57% had medical co-
morbidity: Hypertension = 46%; Ischaemic heart disease = 24%;
Diabetes mellitus = 9%. Presenting symptoms: Postmenopausal
Bleeding = 79%, inter-menstrual bleeding = 3%, vaginal discharge =
3.6%, menorrhagia = 6%, post coital bleeding = 2%, irregular bleeding
= 1.5%, pain = 2.6%, Others = 2.8%. Symptom duration = 0-72 months.
Investigations performed: USS = 55% (Abnormal in 92%; Endometrial
thickness (ET) = 1.3-73 mm, mean = 16.9 mm. ET , 5 mm in 8.75%);
Hysteroscopy = 72%; Pipelle = 48%; D&C = 35%; TCRE = 0.7%, 2.3%
diagnosed after hysterectomy; biopsy of vaginal mass = 0.9%. Surgery
performed in 96%: Abdominal hysterectomy = 89%; Radical hysterec-
tomy = 5.5%; Vaginal hysterectomy = 2.5%; Subtotal hysterectomy =
0.3%; Exenteration = 0.3%; Bilateral salpingo-oophorectomy = 90%;
LSO = 1.4%; RSO = 1.4%; Omentectomy = 5.6%; Omental biopsy =
0.5%; Pelvic lymphadenectomy = 4%; Pelvic node sampling = 2.7%.
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Ascites was present in 5.4% & was positive of malignant cells in 32%.
Washing taken in 98% & positive of malignant cells in 7%. Myometrial
invasion: Nil = 4%, superficial = 18%, , 50% = 37%, 50% = 0.5%,
.50% = 40%. FIGO staging: I = 68%; II = 16%; III = 14%; IV = 1.5%.
Histology: Adenocarcinomas = 89.5%; Mixed Mullerian = 5.1%;
Stromal sarcomas = 2.1%; Leiomyosarcomas = 1.5%; Adenosarcomas =
0.2%; Adenosquamous carcinomas = 0.2%; others = 1.5%. Of Adeno-
carcinoma: Papillary serous = 47.5%; Endometrioid = 37.5%; Clear
cell = 12.5%; mixed cell type = 2.5%. Tumour grade: 1 = 52%; 2 = 29%;
3 = 19%. Adjuvant treatment: Nil = 65%; Radiotherapy = 32%; Chemo-
therapy = 1%; Hormonal therapy = 1.5%. 5-year survival: All uterine
tumours = 56%; Adenocarcinomas = 61%; others = 33%. With FIGO
stage I = 72%; II = 58%; III = 33%; IV = 29%.
Conclusions: Endometrial cancer is a disease of the elderly, presents
mainly with PMB and at stage I, investigations have changed with
time. It is managed mainly surgically and has a 5-year survival of 56%.
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CERVICAL IMPEDANCE SPECTROSCOPY FOR SCREENING OF
CIN: RESULTS OF A PROSPECTIVE STUDY OF 176 PATIENTS
S. Abdul, M.E.L. Paterson, J.A. Tidy
Sheffield Gynaecological Oncology Centre, Gynaecological Oncological
Surgery, Royal Hallamshire Hospital, Sheffield, UK
Objective: Assess performance of electrical impedance spectroscopy
(EIS) in separating CIN from normal cervical tissue using the MKIII
impedance probe.
Methods: Prospective observational study of 176 women referred to
colposcopy with abnormal Pap smears. A pencil probe measured
EIS from cervical epithelium. Colposcopy and probe positioning
were video recorded to allow correlation between results from col-
poscopy, histopathology and EIS measurements. EIS derived pa-
rameters R,S,R/S,C and Fc were assessed in CIN and normal
epithelium. The performance of the probe in identifying women
with CIN was assessed.
Results: From Squamous epithelium to CIN1 and CIN2/3: R falls
by 48-80%, S rises by 28-59%, Fc rises by 40-150% (Table 1). Tissues
separated include (Mann-Whitney test p , 0.0001): CIN2/3 from
squamous (R,S&Fc), mature metaplasia (R,S,C&Fc) and columnar (C);
CIN1 from squamous (R&S),immature metaplasia (C&Fc), columnar
(S,C&Fc); Squamous from immature metaplasia (R,S,C&Fc), mature
metaplasia (R), columnar (R,S,C,Fc). ROC curves using parameters
R,S,C,Fc & R/S for separating CIN1 & CIN2/3 from normal tissue
types give area under curve values from 0.51-0.89 (Table 2). If the
women were categorised on the basis of any impedance results for
R/S of 0.64 as cut-off between classifying points as normal or CIN,
then sensitivity = 66.3%, specificity = 49, PPV = 67.7% and NPV =
55% for detection of CIN are obtained.
Conclusions: The EIS MKIII probe has similar sensitivity and speci-
ficity to currently used screening tests in detecting CIN and is an
exciting potential real time screening tool for CIN. Further work is
needed to improve separation of CIN from immature metaplastic
tissue, to improve the performance of the probe in clinical use.
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PAP CYTOLOGY SCREENING FAILURE: INFLUENCES OF
THE PATIENT, PHYSICIAN, AND LABORATORY
A.S. Alobaid1, A. Spence2, P. Drouin1, P. Goggin3, M. Dawes4,
M. Deschamps5, E. Duarte-Franco6, A. Ferenczy7, E. Franco6
1Gynecology Oncology, University of Montreal, Notre-Dame Hosp CHUM;
2Department of Epidemiology and Statistics, McGill University, Montreal;
3Systemes de Soins et Services, Institue National de Sante Public du Que-
bec; 4Department of Family Medicine, McGill University, Montreal; 5Unite
de Sante Physique, Direction de la Sante Public; 6Division of Cancer Epi-
demiology, McGill University, Montreal; 7Department of Pathology and
Obstetrics & Gynecology, McGill University, Montreal, QC, Canada
Objectives: 1. To identify and to rank the failures along the cancer
care continuum that led to development of invasive cervical cancer
(ICC). 2. To explore reasons for these failures.
Methods: Study subjects are women living in Montreal diagnosed
with ICC between 1998-2004 (n = 120/year) and are identified
through the Quebec Tumour Registry. Data describing the process of
cervical cancer screening and diagnostic tests, treatments received
for pre-invasive lesions, physician recommendations, and patient
compliance with these recommendations are abstracted from hospi-
tal medical charts. Cytology labs are searched for similar data. Tele-
phone interviews with subjects are conducted using a pilot-tested
questionnaire. Demographics, Pap history, reasons for screening fail-
ure, names of attending physicians, and symptoms are collected dur-
ing the interview. Further data is obtained from physicians’ office
medical files. The normal, equivocal, and low-grade Pap smears
each subject had 5 years before final diagnosis are then retrieved
from cytolology labs and reviewed by a cytologist.
Conclusion: Data will be used to explore the natural history of ICC
in relation to the process of medical care provided within various
health care settings. From this we will develop public health initia-
tives and policies aimed at health care providers, women, and the
health care system in North American urban settings. This study
will provide information that can be used for health policy to reduce
the health disparities that occur, in terms of early prevention of ICC,
particularly amongst women of a low socioeconomic status.
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THE ROLE OF WT1 GENE IN THE CARCINOGENESIS OF
UTERINE SARCOMAS
A. Coosemans1,2, S.A. Nik3, S. Caluwaerts2, L. Verbist2,
V. Schelfhout4, E. de Jonge5, I. Dalle6, G. Jacomen7, J.J. Cassiman3,
I. Vergote1,2, P.H. Moerman8, F. Amant1,2
1Division of Gynecologic Oncology, Department of Obstetrics and Gyne-
cology; 2Laboratory of Experimental Gynecology; 3Center for Human
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Genetics, Katholieke Universiteit Leuven, Leuven; 4Department of
Pathology, UZ Gent, Gent; 5Department of Gynecology, Ziekenhuis
Oost-Limburg, Genk; 6Department of Pathology, AZ St-An, Bugge;
7Department of Pathology, Sint-Aarten, Duffel; 8Department of Pathol-
ogy, Katholieke Universiteit Leuven, Leuven, Belgium
Background: Wilm’s tumor gene (WT1), localised on chromosome
11, encodes a transcription factor and is important in the carcinogen-
esis of several tumors. Recent studies demonstrated the frequent
presence of WT1 immunohistochemically in endometrial stromal
sarcoma (ESS) (n = 10) and carcinosarcoma (CS) (n = 10). The aim of
this study was to confirm these results genetically and further ex-
plore the role of WT1 in uterine sarcomas.
Materials and Methods: After central review, 84 samples of tumoral
tissue were selected (27 CS, 38 leiomyosarcomas (LMS), 18 ESS and
4 undifferentiated sarcomas (US)). Immunohistochemistry was ap-
plied to all samples (WT1 antibody, clone 6F-H2, DAKO, 1:400 dilu-
tion). Quantification of WT1-mRNA was performed with real-time
PCR (RT-PCR) in 23 cases. WT1 protein was quantified on 12 frozen
samples by Western blotting (cytoplasmic and nuclear separately).
Results: The results on WT1 positivity in different subsets of uterine
sarcomas are presented the table below (n (%)).
Conclusion: Until now, the potential role of WT1 in the carcinogene-
sis of uterine LMS was unknown. Molecular data in the different
subtypes of uterine sarcomas confirm involvement of WT1 in their
carcinogenesis. Apart from a diagnostic importance, these data
might be useful in the development of new treatment strategies for
this aggressive entity.
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THE VALUE OF [18F] FLUORODEOXYGLUCOSE POSITRON
EMISSION TOMOGRAPHY IN PLACENTAL SITE TROFO-
BLAST TUMOR
A. Coosemans1, P.H. Moerman2, H. Hellemans3, S. Ceyssens4,
I. Vergote1, F. Amant1
1Division of Gynecologic Oncology, Department of Obstetrics and Gyne-
cology, Leuven; 2Department of Pathology, Katholieke Universiteit
Leuven, Leuven; 3Department of Gynecology and Obstetrics, Sint-Lucas
Hospital, Brugge; 4Department of Nuclear Medicine, Katholieke Uni-
versiteit Leuven, Belgium, Leuven, Belgium
Gestational trophoblastic disease (GTD) is rare. Placental site tropho-
blastic tumor (PSTT) is a rare form of GTD, specified by its lower sen-
sitivity to chemotherapy and its lower production of human
choriogonadotrophin (hCG). PSTT consists of intermediate tropho-
blasts, producing human placental lactogen (HPL). This hormone
causes insulin resistance during normal pregnancy, leading to hypo-
glycemic and hyperglycemic conditions. Consequently, HPL could in-
terfere with the sensitivity of [18F] fluorodeoxyglucose positron
emission tomography (PET). Although 6 cases on the clinical use of
PET in choriocarcinoma have been reported, the value of PET in PSTT
remains unknown. The present case describes a 26-year-old woman,
diagnosed with PSTT for which she underwent abdominal hysterec-
tomy. Because of non decreasing hCG, PET-CT was performed, indi-
cating residual and metastatic lesions of PSTT in lung, pelvis and
para-aortal lymph nodes. Metastatic spread was confirmed histopath-
ologically. Both the primary and metastatic tumor had a positive HPL
staining. The patient received 18 cycles of EP-EMA (Etoposide-Pati-
nol and Etoposide-Methotrexate-Actinomycin) followed by 11 cycles
ME (Methotrexate-Etoposide). Tumor regression was confirmed by
serial PET-CT. Although HPL might interfere with PET sensitivity,
these findings suggest that PET is a valuable diagnostic tool in PSTT.
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LUNG METASTASIS OF THE RECURRENT CERVICAL CANCER
A. Andrijono, M.F. Aziz, N. Kampono, L. Nuranna, S. Purbadi
Division of Oncology, Department of Obstetrics and Gynecology, Faculty
of Medicine University of Indonesia, Dr. Cipto Mangunkusumo General
Hospital, Jakarta, Indonesia
Introduction: Recurrent cervical cancer constitutes of the serious
problems in the management of cervical carcinoma. One of the fac-
tors compounding the management of recurrent cervical carcinoma
is the case of lung metastasis.
Objective: To identify response to therapy for recurrent cervical car-
cinoma in the lung.
Methods: This study was a historical cohort trial in the cases of recur-
rent cervical cancer in the lungs encountered between 1990 and 2004
at Dr. Cipto Mangunkusumo General Hopsital, Jakarta. Diagnosis
and Therapy response of metastasis was made on the basis of radio-
imaging photos 90) (chest x-ray and CT Scan). Therapy regimen of
PVB (cisplatinum 60 mg/m2, vinblastine, bleomycin 15 mg/day 1.8),
PC regimen (paclitaxel 150 mg/m2 and carboplatin 300 mg/m2).
Results: Therapy response was assessed clinically and radiologically.
There were 22 cases of recurrent cervical cancer with lung meta-
stasis, and 17 patients received PVB therapy. In terms of therapy
response, partial response was found in 7 cases (41.17%). As many
as 5 patients received PC therapy, and 4 cases (80%) showed partial
clinical response. Mean duration of therapy response to complaint
of cough was 7.8 months, and mean PC was 11.75 months. From
these preliminary results, it was evident that regimen of paclitaxel-
carboplatin/cisplatinum provided better response.
Conclusion: PVB regimen in recurrent cervical cancer in the lung
provided partial response of 41.17%, while PC provided partial
response of 80%.
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PREMATURE OVARIAN FAILURE AFTER TREATMENT FOR
HODGKIN’S LYMPHOMA
S.I. Verschuuren1, M.B. van’t Veer2, T. Stijnen3, C.W. Burger1,
A.C. Ansink1
1Department of Gynaecologic Oncology; 2Department of Haematology;
3Department of Epidemiology and Biostatistics, University Medical Cen-
tre Rotterdam, Rotterdam, The Netherlands
Background: The purpose of this study is to determine 1. the effect
of treatment for Hodgkin’s lymphoma on ovarian function 2. the in-
terventions to relieve postmenopausal symptoms.
Methods: 77 consecutive patients treated for Hodgkin’s lymphoma
stage I and II between 1989 and 2003 in the Rotterdam region were
approached for this study. All patients had been treated in EORTC
trials (H7, H8, H9). After stratification in three major treatment
groups, type of agents and dosage of chemotherapy and/or radio-
therapy were determined by randomisation in trials.
Results: After informed consent 66 patients filled in a questionnaire.
After anti-tumour treatment 13 patients developed treatment re-
lated post menopause, 35 patients had a spontaneous cycle, and 18
patients could not be classified as they used hormonal contraception.
Women who developed treatment related post menopause had a sig-
nificant higher average age at the time they started treatment for
Hodgkin’s lymphoma than women who remained premenopausal
(p , 0.002). Only 6 of these 13 women (46%) received hormonal sub-
stitution. In total, 21 women conceived after anti-tumour treatment,
and 28 children were born. All pregnancies were the result of sponta-
neous conception.
88 Abstracts
# 2005 IGCS, International Journal of Gynecological Cancer 15, 86–119
Conclusions: The effect of anti-tumour treatment for Hodgkin’s
lymphoma on ovarian function is age dependent. In our study, this
effect was proven by an odds ratio of 1.18 per year. There is a striking
inconsistency regarding the management of ovarian protection dur-
ing anti-tumour treatment. Protocols for assessment and manage-
ment of loss of ovarian function after anti-tumour treatment should
be developed and standardised.
000129
RESEARCH THE EFFECTS OF HORMONE REPLACEMENT
THERAPY WITH TIBOLONE OR ESTROGEN1PROGESTRONE
ON VAGINAL LATE EFFECTS OF RADIOTHERAPY IN CERVI-
CAL CANCER
I. Aslay1, S. Kucucuk1, H. Olmez1, S. Aktan2, R. Disci3, C. Alatli4,
S.D. Guler4, I. Ozbay5, G. Kemikler5, A. Ergen1
1Istanbul University Oncology Institution/ Radiation Oncology Depart-
ment; 2Istanbul University Medical Faculty/ Obstetrics And Gynecology
Department; 3Istanbul University Oncology Institution/Bioistatistic De-
partment; 4Istanbul University Oncology Institution/Pathology Depart-
ment; 5Istanbul University Oncology Institution/Radiation Physics
Department, Istanbul, Turkey
Objective: To evaluate the effects of hormone replacement therapy
(HRT) with tibolone (T) or estrogen1progesterone (EP) on vaginal
late effects of radiation therapy.
Materials and Methods: A prospective, randomized, double-
blinded, placebo-controlled study was designed. Between February
2004- March 2005, 48 patients (pts) with cervical carcinoma whose
radiotherapy has been completed at least 6 months before randomi-
zation were accepted in the study. After informed consents of the pts
were taken they were randomized T, EP and placebo (P) groups. To
evaluate the sexual functions FSFI test, vaginal late effects SOMA-
LENTS score, pathological changes vaginal smear tests were done in
the beginning and every 3 months. To measure the vaginal volume
and diameters vaginal imprints were taken first in the beginning
and after 6 months.
Results: Age, histopathology and stage were homogenous between
three groups. Vaginal imprint length, width and diameter were in-
creased in HRT groups significantly. The difference in vaginal vol-
ume was higher in the EP group than in the T group. FSFI scores
were improved in T group. SOMA- LENTS scores at 3 and 6 months
were significantly higher when compared the beginning and P
group scores. T group has significantly better scores when ana-
lyzed within and between groups. Pathologically, degeneration was
reduced significantly at 6 month only in EP group.
Conclusion: HRT can be recommended pts treated for cervical can-
cer who is suitable and has vaginal late effects of radiation.
000130
THE ACCURACY OF FROZEN SECTION DIAGNOSIS AT
SURGERY IN PRE-MALIGNANT AND MALIGNANT LESIONS
OF THE ENDOMETRIUM
S. Attard Montalto, M. Coutts, A. Papadopoulos, O. Devaja,
J. Summers, R. Jyothirmayi, P. Pickering
West Kent Cancer Centre. Maidstone Hospital. Maidstone Kent, London, UK
Objective: The purpose of this study was to correlate the histological
diagnosis made during intra operative frozen section examination
with the final definitive histology made on paraffin sections. Study
Design: Frozen section pathology results of patients with pre-op biop-
sy showing atypical hyperplasia or endometrial cancer (55 patients)
were compared prospectivelywith paraffin section pathology findings.
Those patients with curettage specimen showing atypical hyperplasia
had intra operative frozen section to determine whether an invasive le-
sion was present and determine if these patients required pelvic lym-
phadenectomy. The patients who had curettage showing endometrial
carcinomahad intra operative frozen section to identify poorprognostic
pathological factors including histological type, grade, depth of myo-
metrial invasion and cervical involvement.
Results: The correlation between frozen sections and paraffin histol-
ogy for histological subtype was 94.5% (52/55), grade of differentia-
tion 85.5% (47/55) and poorly differentiated tumours 85.7% (6/7).
Depth of myometrial invasion was accurately diagnosed in 90.7%
(49/54) while cervical involvement was detected in 87.5% (42/48).
Of the 22 patients with atypical hyperplasia on curettage specimen
who had intra operative frozen section, 14 patients had invasive ma-
lignancy, which was confirmed on both frozen section and subse-
quent paraffin section. The remaining 8 patients with a frozen
section diagnosing atypical hyperplasia, 6 were confirmed on paraf-
fin section while 2 had a small invasive lesion.
Conclusion: Intraoperative frozen section is a useful procedure to
identify poor prognostic pathological factors as well as diagnosing
endometrial cancer in patients undergoing hysterectomy for atypical
hyperplasia on curettage.
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GERM CELL TUMORS OF THE OVARY: A REVIEW OF 48 CASES
U.D. Bafna, K. Umadevi, R. Pallavi, K.G. Babu
Gynecologic Oncology, Kidwai Memorial Institute of Oncology, Banga-
lore, India
Aim of the study: To assess the response to therapy for patients with
dysgerminomatous and non-dysgerminomatous germ cell tumors of
the ovary.
Method: Forty-eight cases with germ cell tumors of the ovary seen
at Kidwai Memorial Institute of Oncology, Bangalore, India between
2001-02 were studied.
Results: Eighteen patients had dysgerminoma, eight endodermal
sinus tumor (EST), eight Immature teratoma, two embryonal carcino-
ma and 12 mixed germ cell tumors. Three patients with dysgerminoma
and FIGO stage Ia had unilateral salpingo-oophorectomy (USO) and
were kept under surveillance follow up. Forty-five patients received
combination of bleomycin, etoposide and cisplatin (BEP regimen) ei-
ther as neoadjuvant (NACT, 7 cases) or as adjuvant therapy (38 cases)
following definitive surgery performed at Kidwai Institute or else-
where. Forty-six patients achieved complete remission (CR). Two pa-
tients had progressive disease and could not be salvaged. All the
patients with dysgerminomatous tumors (18 cases, 100%) achieved
(CR) including three patients kept under surveillance. Twenty-eight of
30 (93.3%) patients with non-dysgerminomatous tumors achieved CR.
Three patients (all EST) had recurrent disease following CR within six
months, two of which were salvaged by second line chemotherapy
consisting of etoposide, ifosfamide and cisplatin (VIP regimen).
Conclusion: As in our previous study (Bafna et al, Int J Gynecol
Cancer, 11, 300-04, 2001) non-dysgerminomatous tumors fared
slightly worse than dysgerminomatous tumors. Neoadjuvant
chemotherapy followed by interval debulking was also effective in
this small study.
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STAGE III AND IV OVARIAN CANCER IN THE SOUTH
WEST OF ENGLAND: 5 YEAR OUTCOME ANALYSIS FOR
CASES TREATED IN 1998
J.L. Bailey1, J.B. Murdoch1, R.S. Anderson1, J. Weeks2, C. Foy3
1St Michael’s Hospital, Southwell St, Bristol; 2SWCIS, Grosvenor House,
Bristol; 3Gloucestershire Research and Development Support Unit, Glou-
cestershire Royal Hospital, UK
This study evaluates the 5-year outcome data for the management of
advanced ovarian cancer in the South West of England. Anonymised
Abstracts 89
# 2005 IGCS, International Journal of Gynecological Cancer 15, 86–119
data for 361 stage III and IV ovarian cancers registered between 1st
January 1998 and 31st December 1998 were obtained from the central
gynaecological tumour database. The following data were identified:
age at diagnosis, FIGO stage, ASA grade, tumour differentiation,
treating network and surgeon, amount of residual disease after de-
bulking surgery, current life status and date of death if applicable. Sur-
vival analysis was performed using Kaplan-Meier crude survival for
univariate analysis and multivariate analysis was performed by Cox
regression. In our data the 5 year survival for patients with stage III
was 16% and stage IV 10%. Survival analysis demonstrated that pa-
tients in whom the disease was debulked to less than 1 cm were more
likely to be alive 5 years after diagnosis than those with a 2 cm residu-
um (p , 0.0001). There was no significant survival difference for those
patients operated on by subspecialist surgeons despite these surgeons
being twice as likely to achieve optimal debulking. Therefore, there
must be other variables influencing survival apart from cytoreductive
surgery. While there is near complete data collection about ovarian
cancer surgery, our database on chemotherapy is incomplete. This is
clearly crucial for a complete view of cancer care in our region.
000133
REDUCING THE RATE OF POST MOLAR PERSISTENT GES-
TATIONAL TROPHOBLASTIC DISEASE THROUGH EARLY
DIAGNOSIS AND TREATMENT
A. Ben Arie1, H. Deutsch1, A. Agmon1, O. Lavie2, G. Beer2,
R. Dgani1, Z. Hagay1
1Obstetrics & Gynecology, Kaplan Medical Center, Rehovot; 2Obstetrics
& Gynecology, Carmel Medical Center, Haifa, Israel
Objective: To analyze the clinical presentation of hydatiform mole
cases in the recent years and to evaluate its effect on the time of diag-
nosis and the rate of persistent disease.
Methods: We reviewed charts of 68 consecutive cases of complete
moles and 95 cases of partial moles admitted to two medical centers
in Israel during the period 1998-2003, and analyzed the clinical fea-
tures, mode of presentation and rate of persistent disease.
Results: 50.3% of hydatiform molar pregnancies were diagnosed by
a routine early pregnancy ultrasound imaging while being asymp-
tomatic, 33.8% and 62.1% of complete mole and partial mole respec-
tively. The sonographic appearance was of a nonviable pregnancy in
38.9% and of suspected molar pregnancy in 61.1% of complete moles
and 68.9% and 31.1% respectively in partial moles. Evacuation of the
molar pregnancy occurred at a mean gestational age of 11  3 weeks
(mean  SD) for both complete and partial moles. An overall rate of
persistent disease was recorded in 12 of 163 (7.4%) patients. Persis-
tent gestational trophoblastic disease was documented in 8 of 68
(11.8%) in complete moles and in 4 of 95 (4.2%) of partial moles.
Conclusions: Compared to historic controls, there is a shift in the
presentation of complete and partial molar pregnancies. Higher
rates of asymptomatic patients are diagnosed following an ultra-
sound examination demonstrating a nonviable pregnancy or an ap-
pearance suggestive of a molar pregnancy. This change leads to
early termination of the pregnancy, with less associated complica-
tions and a reduced rate of persistent trophoblastic disease.
000134
PERIOPERATIVE MORBIDITY AND MORTALITY OF GYNE-
COLOGICAL ONCOLOGIC SURGERY IN ELDERLY WOMEN
I. Ben-Ami1,2, Z. Vaknin1,2, D. Schneider1,2, R. Halperin1,2
1Department of Obstetrics and Gynecology, Assaf Harofeh Medical Center,
Zerifin; 2Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Objective: The study compares perioperative morbidity and mortality
rates between elderly (70 years old) and younger (, 70 years old)
patients, undergoing surgery due to ovarian or uterine cancer.
Methods: The study cohort consisted of 171 women who underwent
explorative laparotomy due to uterine or ovarian cancer. Clinical
data included patients’ age, co-morbidities, chronic use of medica-
tions, body mass index (kg/m2), past and current surgical proce-
dures, surgical stage of the disease (by FIGO), histological type and
number of dissected lymph nodes as confirmed by histological
examination, optimal versus non-optimal debulking (defined as
residual tumor of less than 1 cm), the occurrence of perioperative
complications and postoperative hospital stay (days).
Results: 171 women were divided to 108 (63.2%) patients with uter-
ine cancer and 63 (36.8%) patients with ovarian cancer. Women hav-
ing uterine cancer were further subdivided to those , 70 years old
(72 women, 66.7%), and those 70 years old (36 women, 3.3%). Sim-
ilarly, women with ovarian cancer were subdivided to those , 70
years old (48 women, 76.2%), and those 70 years old (15 women,
23.8%). Excluding the occurrence of postoperative ileus and poorly
controlled hypertension in the elderly subgroup of women with
uterine cancer, the rate of early postoperative complications was
similar between the two subgroups.
Conclusion: Chronological age by itself should not be a contraindica-
tion for the treatment of elderly women with gynecologic malignan-
cy, since it is a poor predicting factor for perioperative morbidity.
000135
THE ROLE OF SALVAGE SURGERY IN OVARIAN CANCER
PATIENTS
M. Bidzin´ski, A. Dan´ska, G. Bidzin´ska, Panek, P. Sobiczewski,
P. Derlatka
Department of Gynaecological Oncology Memorial Cancer Centre,
Warsaw, Poland
Purpose: The aim of this study was the evaluation of value of sal-
vage surgery in ovarian cancer patients.
Material and Methods: Between Jan 1996 and Jan 2002, 36 patients
were treated because of ileus due to relapsed ovarian cancer. Two
groups of patients were compared. The first group consisted of 21
women who were treated by using surgery. The second group of
patients (N 15) was treated with conservative method. The FIGO
stage in all cases was classified as III or IV. These were comparable
group of patients according to age and performance status. The
main differences between both groups were number of intestinal
stenosis and willing to live. In case of 3 or more sites of stenosis,
patients were qualified to conservative treatment.
Results: Within the group of surgical treatment, in 15 cases ileos-
tomy was done. In other 6 cases gastrointestinal bypass was per-
formed. In 19 patients chemotherapy was continued after surgical
procegures. In this group of patients median time of survival was 9
months. In the conservative treatment group median survival was
3,2 months. No patients were treated with chemotherapy within ‘the
conservative group’. There was statistical difference in survival be-
tween both groups P = 0,003. Multivariate analysis confirmed that
the main prognostic factors that influenced on survival were: histo-
logic grade of tumor and effectiveness of surgery.
000136
RECURRENCE AND FERTILITY IN WOMEN WHO TREATED
WITH FERTILITY-SPARING SURGERY FOR OVARIAN TUMORS;
A RETROSPECTIVE STUDY
N. Boran, O¨. Karacxay, T. Turan, E. O¨ztu¨rkog˘lu, S. Kocx, G. Tulunay,
D. C¸avusxog˘lu, M.F. Ko¨se
Department of Gynecologic Oncology, Ankara Etlik Maternity and
Women’s Health Teaching and Research Hospital, Ankara, Turkey
Objectives: To assess the recurrence and fertility following fertility-
sparing surgical management of ovarian malignancies.
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Methods: 142 patients with ovarian tumors who underwent fertili-
ty-sparing surgery from 1991 to 2003 were evaluated from medical
records of Ankara Etlik Maternity and Women’s Health Teaching
and Research Hospital.
Results: The mean age was 21.7 (13-42). The histological types were 56
(39.4%) germ cell tumors, 9 (6.33%) epithelial tumors, 15 (10.56%) sex
cord stromal tumors, 62 (43.66%) borderline ovarian tumors. Clinic
stages were involved of 87 (61.2%) early stage, 14 (9.85%) advanced
stage and 41 (28.8%) unstaged. Among 142 patients, the fertility desire
was in 53 patients (37.3%). 19 women had 23 pregnancies. 19 women
had successful pregnancy with a total of 16 live births, 3 abortions,
3 unknown outcomes and 1 induced abortion. The recurrence observed
in 11 (7.74%) patients. The mean of disease free survival was 21.6
months (6-69). Disease related death occurred in one patient. The mean
duration of follow-up was 40.5 months (Range 1-126).
Conclusions: Fertility-sparing surgery for ovarian tumors should be
considered for women in reproductive age group who desire preser-
vation of fertility.
000137
THE PREDICTIVE VALUE OF PREOPERATIVE CA 125 LEVEL
FOR LYMPH NODE METASTASIS AND CLINICOPATHOLOG-
IC FEATURES AMONG ENDOMETRIUM CANCER PATIENTS
G. Bozdag, C. Taskiran, M. Gultekin, P. Dursun, K. Yuce, A. Ayhan
Hacettepe Univesity, School of Medicine, Department of Obstetrics and
Gynecology, Ankara, Turkey
Background: The accepted treatment option of endometrium cancer
mostly consists of hysterectomywith bilateral salpingo-oophorectomy,
peritoneal cytological sampling, pelvic/paraaortic lymphadenectomy.
The efforts topredict thepathological spread of thediseasemaycontrib-
ute to select the suitable cases that selective lymphadnectomyor less ag-
gressive surgery may be performed.
Objective: To evaluate the predictive value of preoperative serum
levels of Ca 125 in patients with endometrial cancer in relation to
clinicopathological parameters and lymph node metastasis.
Material and Method: A retrospective analysis of 215 consecutive
endometrium cancer patients between January, 1992 and July, 2004
was performed. In all patients, total abdominal hysterectomy, bilat-
eral salpingo-oophorectomy and washing cytology with complete
pelvic/para-aortic lymphadenectomy was performed. The Mann–
Whitney U, Kruskal–Wallis test and X2 Fisher’s exact test were em-
ployed to examine the effects of clinicopathological factors on serum
Ca 125 levels. All data are expressed as median.
Results: The median level of serum Ca 125 was comparable among
50 and .50 years aged groups (p . 0.05). Also, no significant dif-
ference was noted when patients were classified according to histo-
pathological stage, presence of high risk histology (non-
endometrioid), lympho-vascular space invasion, cervical and adnex-
ial involvement, pelvic/paraaortic lymph node metastasis and depth
of myometrial invasion (p . 0.05). Of interest, median serum Ca125
level was significantly higher when tumor size was . 2cm (18.8 vs
14.5 U/ml, p = 0.01), and washing cytology was positive (41.0 vs
23.5 U/ml, p = 0.012).
Conclusion: In contrast with earlier reports, the preoperative serum
Ca 125 level was not significantly different in the presence of meta-
static pelvic/paraaortic lymph node.
000138
THE PREOPERATIVE PLATELET COUNT IS HIGHER IN EN-
DOMETRIUM CANCER PATIENTS WITH THE ADVANCED
STAGE AND HIGH GRADE
G. Bozdag, C. Taskiran, M. Gultekin, P. Dursun, K. Yuce, A. Ayhan
Hacettepe University, School of Medicine, Department of Obstetrics and
Gynecology, Ankara, Turkey
Background: Although the exact mechanism is not known, the asso-
ciation between elevated platelet (PLT) counts and malignant neo-
plasia has been known since 1872. However, there is limited data
whether there is a clear correlation between preoperative PLT count
and prognostic factors of endometrium cancer.
Objective: To evaluate the predictive value of preoperative platelet
count for clinicopathologic features of endometrium cancer.
Material and Methods: A retrospective analysis of 155 endo-
metrium cancer patients between January, 1994 and July, 2004
whom were all treated with hysterectomy, bilateral salpingo-
oophorectomy, complete pelvic/para-aortic lymphadenectomy and
washing cytology. For univariate analysis the Mann–Whitney U
test and Kruskal–Wallis test were employed. All data are expressed
as median.
Results: No significant difference was noted when cases were classi-
fied according to the age (between 50 and .50 years aged groups),
presence of non-endometriod histology, .1/2 depth myometrial in-
vasion, pelvic/paraaortic lymph node metastasis and lenfovascular
space invasion (p . 0.05). However, the PLT count was found to be
higher in grade 3 patients both from grade 1 and 2 (316.500/ml vs
286.000 and 271.000, p = 0.03). Of note, advance staged (FIGO stage
III and IV) group had increased PLT count when compared with
early staged (FIGO stage I and II) group (309.000/ml and 273.500/
ml respectively, p = 0.004).
Conclusion: High preoperative PLT count may reflect poor prognos-
tic factors such as advanced stage and high grade histology in endo-
metrium cancer.
000139
THE CLINICAL VALUE OF PREOPERATIVE SERUM LIPID
PROFILE FOR THE CLINICOPATHOLOGIC FEATURES OF EN-
DOMETRIUM CANCER
G. Bozdag, P. Dursun, M. Gultekin, K. Yuce, A. Ayhan
Hacettepe University, School of Medicine, Department of Obstetrics and
Gynecology, Ankara, Turkey
Background: Although the presence, nulliparity, obesity, diabetes
mellitus and unopposed estrogen exposure are well known risk fac-
tors for endometrium cancer. However, there is paucity of data for
the relation between endometrial cancer and dyslipidemia.
Objective: To evaluate the relation between preoperative serum
lipid profile and clinicopathologic variables of endometrium cancer.
Material and method: The clinicopathologic features of 70 endome-
trium cancer patients, whom were all treated with hysterectomy,
salpingo–oophorectomy, pelvic/para-aortic lymphadenectomy and
peritoneal cytology were examined. The Mann–Whitney U and
Kruskal–Wallis tests were employed to examine the effects of clinico-
pathological variables on serum triglyceride (TRG), total cholesterol,
low density lipoprotein (LDL), high density lipoprotein (HDL) and
very low density lipoprotein (VLDL) levels. All data were expressed
as median.
Results: In patients 50 years of age, the serum VLDL (26 vs
32.9 mg/dl, p = 0.008) and TRG (129.5 vs 164.5 mg/dl, p = 0.008)
were significantly lower. The lipid profile was similar when cases
were classified according to the stage, presence of lenf node metasta-
sis, positive cytology and larger than 2 cm of diameter tumor (p .
0.05). However, serum HDL was 56.5 and 45.5 mg/dl in the endo-
metriod and non-endometriod histology groups, respectively (p =
0.03). Besides, both the VLDL (30 vs 7 mg/dl, p = 0.03) and TRG
(150 vs 135 mg/dl p = 0.03) levels were found to be diminished
when 1/2 myometrial invasion was observed. Also, all grade 3 tu-
mors had lower serum HDL levels both from grade 1 and 2 (44.5 vs
57.5 mg/dl and 57.0, respectively, p = 0.02).
Conclusion: Lower preoperative serum lipid levels may reflect poor
prognostic factors among endometrium cancer patients.
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000140
CAN A BIWEEKLY SCHEDULE REDUCE THE TOXICITY OF
CAELYX? A PHASE-II STUDY OF HEAVILY PRETREATED
PATIENTS WITH RECURRENT OVARIAN CANCER
G. Oskay-O¨zcelik1, J. Sehouli1, H.J. Hindenburg2, P. Klare3,
D. Ko¨nsgen1, A. Mustea1, G. Heinrich4, O. Camara5,
W. Lichtenegger1
1Gynecology University Hospital Charite´; 2Praxis Hindenburg, Berlin;
3Praxis Klare Berling; 4Praxis Heinrich Bad Sarow; 5Gynecology Univer-
sity Hospital, Jena, Germany
Caelyx is a novel pegylated liposomal doxorubicin formula-
tion and has been approved for the treatment of recurrent ovar-
ian cancer (ROC). Palmar-plantar erythrodysthesia (PPE) is the
dose-limiting toxicity and have an impact on patients’ quality
of life.
Methods: We performed a multi-institutional phase-II study to ana-
lyze the toxicity profile of PLD (20 mg/m2/q 14d) in heavily pre-
treated patients with ROC.
Statistic: 2-Step-Design, in case of a positive first step (n = 26):.2 re-
sponse 1 , 6 events of PPE (CTC Grade III/IV), a total number of
60 patients must be recruited; power: 80%, p , 0.05, based on a 10%
reduction of PPE (95% CI).
Results: A total of 64 patients were recruited (10/2001-02/2004).
553 courses (median: 7, range: 1-35) were evaluable. Median age
was 59 (38-81). Patients were generally heavily pretreated: 13 pa-
tients were in second-line, most of the patients were in third- or
fourth-line. Ten patients were in fifth-line. Overall, the treatment
was well tolerated. 30 patients developed skin toxicities: 18 pa-
tients with grade I, 9 with grade II and only 3 patients with grade
III. These side effects occurred after a median of 5 courses.
Heamatologic toxicity profile was favourable. Two patients
achieved complete response, five patients partial response and 13
stable disease.
Conclusion: Despite the heavy pretreatment of the patients these re-
sults suggest that this new schedule seems to be an effective and
well tolerated regimen, showing a low incidence of toxic skin reac-
tions. Supported by ESSEX Pharma Germany.
000145
UTERINE PAPILLARY SEROUS CARCINOMA ARISING OVER
ENDOMETRIAL POLYPS: A DIFERENTIAL BEHAVIOUR?
F.X. Caparro´s, C. Gomar, S. Martı´nez-Roma´n, A. Sanjua´n, A. Torne´,
J. Pahisa
Gynaecological Oncology, ICGON, Hospital Clı´nic, Barcelona, Spain
Objectives: To analyze if Uterine Papillary Serous Carcinoma
(UPSC) arising over endometrial polyps has different character-
istics from focal or diffuse varieties arising over endometrial
surface.
Materials and Methods: This study includes 43 patients with UPSC
diagnosed between January 1998 and March 2005. 8 of them origi-
nated over an endometrial polyp, 8 were diffuse superficial forms,
10 had focal superficial lesions, 2 had a different origin and in 12
cases origin was unknown. In superficial patterns, overall survival
was 21 months for focal and 17, 5 m for diffuse forms. Free disease
interval was 15 m and 11, 3 m respectively. In UPSC over polyps,
overall survival was 27, 3 m and free disease interval was 27, 3 m.
For all 43 cases, mean overall survival was 22, 5 m and free disease
interval was 16, 4 m.
Conclusions: Patients with UPSC arising over endometrial polyps
seem to have a longer overall survival and increased free disease
interval, though longer series are needed to determine prognostic
utility of initial location and therapeutic alternatives in these
cases.
000146
DIFFERENT LEUKOCYTE RECRUITMENT ACCORDING TO
THE MALIGNANCY POTENTIAL OF HIGH RISK HUMAN
PAPILLOMAVIRUS-INDUCED CERVICAL LESIONS
M.E. Capilna1, S. Monnier-Benoit2, J.L. Pretet2, C. Mougin2,
D. Riethmuller3
1Clinica de Obstetrica-Ginecologie i Targu-Mures, Targu-Mures, Roma-
nia; 2Laboratoire de Virologie et Biologie Celullaire, Besancon; 3Clinique
D’Obstetrique, de Gynecologie et de la Reproduction, Besancon, France
Objective: High Risk (HR) HPV are the etiologic agents for cervical
cancers. Infections by HR-HPV are generally cleared within a period
of 8 to 13 months. Viral persistence that allows the progression of
precancerous lesions to carcinoma is likely to depend on host fac-
tors. Among them, cellular immune responses targeted to the genital
mucosa might be essential. We thus decided to characterize popula-
tions of immune cells in HR-HPV infected precancerous and cancer-
ous cervical lesions.
Methods: Four biopsies from normal cervix, 4 CIN1 at high rate of
regression, 5 CIN3 at high rate of progression, and 11 invasive carci-
nomas were analyzed. All lesions were HR-HPV positive and low
risk-HPV negative. CD3, CD4, CD8 and CD45RO cells were identi-
fied by immunohistochemistry and their densities determined in the
stroma and in the epithelium.
Results: CD41 cells predominated in CIN1. While CD41 and
CD81 cells were equally represented in CIN3, these cells aggregate
as lymphoid follicles. Then, we observed a strong infiltration of
CD81 and memory cells in invasive cancers.
Conclusions: We identified a different distribution of immune cells
in HR-HPV lesions that might be specific of their malignant poten-
tial. Accumulation of CD41 cells in CIN1 is likely to be a regression
marker. Whether the phenotype of immune cells may be consistent
with an ongoing immune response in CIN3 and cancers, a poor dis-
tribution and/or functionality of these cells might explain their loss
of efficacy to eliminate lesions.
000147
PARTIAL TRACHELECTOMY: A NEW TREATMENT CHOICE
FOR PERSISTENT OR RECURRENT HIGH GRADE CERVICAL
INTRAEPITHELIAL NEOPLASIA
C.J. Jeng1,2, J. Shen3, S.H. Huang4
1Department of Obstetrics and Gynecology, Cathay General Hospital,
Taipei; 2School of Medicine, Fu-Jen Catholic University, Taipei, Taiwan;
3Division of Gynecologic Oncology, Department of Obstetrics and Gyne-
cology, California Pacific Medical Center, San Francisco, CA, USA; 4De-
partment of Pathology, Cathay General Hospital, Taipei, Taiwan
Objective: Some women with persistent or recurrent disease after
repeated conization for high grade cervical intraepithelial neoplasia
(CIN) may desire to preserve uterus if not fertility. In such case a par-
tial trachelectomy may become treatment of choice for them. We un-
dertook this prospective study to determine examine the feasibility
of partial trachelectomy as a treatment choice for persistent or recur-
rent high grade CIN.
Methods: Twenty premenopausal women with persistent or recur-
rent high grade CIN after initial LEEP and repeated conization re-
fused hysterectomy, thus elected to undergo excision of vaginal
portion of uterine cervix under general anesthesia in a tertiary uni-
versity-affiliated medical center. High risk human papillomavirus
(HPV) detection was done before initial loop electrosurgical exci-
sional procedure (LEEP) and 3 months after partial trachelectomy.
Follow-up PAP smear and colposcopy were done every 3 months
during the first 2 years. If both exminations were negative, they
were changed to yearly follow-ups.
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Results: The out-patient procedure is simple and takes only 6.5 mi-
nutes in average. High risk human papillomavirus (HPV) were erad-
icated after procedure in all cases. During an average follow-up of
48 months, no recurrent dysplasia was observed.
Conclusion: Partial trachelectomy is a reasonable alternative treat-
ment choice for those who suffer persistent or recurrent CIN, and
desire to preserve their uterine corpi.
000148
NERVE SPARING RADICAL HYSTERECTOMY AND BLAD-
DER FUNCTION
T.H. Cheung, S.K. Yip, W.K. Lo, S.F. Yim
Department of Obstetrics and Gynaecology, The Chinese Universtiy of
Hong Kong, Prince of Wales Hospital, Hong Kong, China
Radical Hysterectomy is the recommended treatment for patients
with early stage cervical carcinoma. Constipation, loss of bladder
sensation, incomplete emptying and voiding difficulties are common
after the operation. We attempted to preserve the autonomic nerve
supply to the bladder during radical hysterectomy and conduct uro-
dynamic study to assess the result. Twenty five stage 1B to 2A cervi-
cal carcinoma patients had urodynamic study before the radical
hysterectomy. Intra-operatively, the hypogastric nerves were identi-
fied, dissected off the genital tract before parametria were divided
and followed to the bladder. (A video can be displayed to show our
technique). Bladder training commenced 7 to 10 days after surgery
and suprapubic catheter was removed when residual urine volume
was below 150 ml. Urodynamic study was then performed within 2
weeks. Fifteen patients had urodynamic study before and after the
surgery and were included in the analysis. The median age of the
patients was 41. The median operative time was 240 minutes and
the median blood lost was 800 ml. We have found no change in the
volume of first sensation to void (162 vs 173 ml) and urine flow rate
(16 vs 15.6 ml/sec) before and after the operation. However, there is
a significant increase in the residual urine volume after surgery (19
vs 166 ml). Our technique appears successful in preserving the sym-
pathetic nerve supplies but less so the parasympathetic nerves sup-
plies to the bladder. This explains the insignificant change in bladder
sensation and flow rate but the increase in residual volume.
000149
HUMAN PAPILLOMAVIRUS GENOTYPING BY HPV DNA
CHIP IN KOREAN WOMEN
H.S. Lee1, H.S. Choi1, S.M. Kim1, J.H. Nam2, C.S. Park2
1Department of Obstetrics and Gynecology; 2Department of Patholo-
gy,Chonnam University Medical School, Gwangju, South Korea
A recently developed HPV DNA chip test is a polymerase chain re-
action (PCR) based microarray system that enables the rapid and
easy detection and genotyping 15 high-risk and nine low-risk HPV
types at once. In 2,361 women who were tested for HPV types by
HPV DNA chip, cervical Thin Prep cytology and biopsy were also
performed. High-risk HPV type was identified as positive in 29.1%
of the 482 histologically confirmed normal samples and in 86.1% of
the 609 samples of cervical intraepithelial neoplasia(CIN) and carci-
noma. HPV-16 (41.8%) was the most prevalent type in samples
with CIN II/III. The next common types were HPV-58 (16.7%),
HPV-33 (10.8%), and HPV-31 (7.7%) in CIN II/III. These four types
occupied 77.0% of the samples with CIN II/III. Among the 550 cases
confirmed CIN II/III, carcinoma in histology, the rate of diagnosing
HSIL or carcinoma in liquid based cytology was 83.5% and the de-
tection rate of positive high-risk HPV in HPV DNA chip test was
86.5%. The prevalent HPV genotypes also provide valuable informa-
tion about the development of vaccine, which was suitable for pre-
venting cervical carcinoma in Korean women.
000150
DETECTION OF HPV DNA AND MOLECULAR ANALYSIS OF
CELL CYCLE GENES IN ABNORMAL, LIQUID BASED CYTO-
LOGICAL, SAMPLES FROM THE UTERINE CERVIX
K. Chranioti1, A. Tserkezoglou2, I. Papaspyrou1, M. Nikolaidou2,
J. Georgoulakis3, S. Markidou3, G. Magiakos2, P. Karakitsos4,
E. Panotopoulou1
1Saint Savvas Hospital, Papanicolaou Research Center; 2Saint Savvas Hos-
pital, 1st Department of Gynecology; 3Saint Savvas Hospital, Department of
Cytology; 4Attikon Hospital, Department of Cytology, Athens, Greece
Aim: Carcinogenesis in cervical cancer is a multifactorial process. In
order to investigate the correlation of HPV types with cell cycle
genes we examined cytological samples with epithelial atypia of dif-
ferent degrees.
Methods: Thin prep test was performed in 348 samples with
ASCUS, LgSIL and HgSIL. In each case DNA extraction and PCR as-
says were carried out for b-globin, GP51/GP61 and HPV 6/11/
16/18/31/33. 162 GP51/GP61 samples (51 ASCUS, 98 LgSIL, 13
HgSIL) were randomly selected for molecular analysis and subse-
quently submitted to RNA extraction, RT-PCR and Multiplex PCR
for p53, bag, c-myc, bad, bax and bim. Statistical analysis was done
using Pearson Chi square and Fisher’s exact test.
Results: Distribution of HPV genotypes revealed that HPV 11 (38,5-
48%) and HPV18 (33,3-38,5%) were more commonly expressed in
this sample of Greek women while HPV 16 was identified in 53,6%
of HgSIL. HPV 6 was not uncommon (20,4-30,8%) and less than 10%
of all lesions expressed HPV 31 and 33. Anti apoptotic genes (bag,
bcl-2) presented intermediate (17,6-33,7%) and high (41,2-76,9%) lev-
els of expression respectively in all levels of cytologic atypia. C-myc
oncogene showed increasing levels of expression 22% vs 42% vs
76% in ASCUS, LgSIL, HgSIL respectively while bad, bax, bim, p53
showed low expression.
Conclusion: There was no statistically significant correlation of low
or high grade HPV types to cell cycle genes at the different cytologi-
cal abnormalities examined. However there was a trend of rising
bcl2 and c-myc expression with increasing level of atypia.
000151
FERTILITY-SPARING TREATMENT FOR EARLY STAGE ENDO-
METRIAL ADENOCARCINOMA
I. Mazzon2, G. Corrado1, G. Ferrandina1, A.C. Testa1, R. Longo3,
D. Morricone2, G. Scambia3
1Gynecologic Oncology Unit, Catholic University of The Sacred Heart,
Rome; 2Endoscopic Gynecologic Unit, Nuova Villa Claudia, Rome;
3Department of Oncology, Catholic University of The Sacred Heart,
Campobasso, Italy
Introduction: Endometrial carcinoma (EC) is a disease that affects
mainly peri- and postmenopausal women. It is relatively rare in
women under 40. The standard therapy for this malignancy is a total
hysterectomy, bilateral salpingo-oophorectomy, retroperitoneal
lymph node sampling and peritoneal fluid cytology. We evaluated
the outcome of conservative treatment of young women with EC.
Materials and Methods: Between September 2001 and July 2004 five
premenopausal patients were treated with hysteroscopic resection of
the EC, the endometrium near the lesion and of the myometrium un-
der the lesion followed by megestrol acetate (160 mg/day) for six
months as. Inclusion criteria were: age younger than 40, nulliparous,
confirmed EC with grade 1 differentiation, presence of progesterone
receptor, absence of myometrial invasion or extrauterine spread by
vaginal ultrasound and magnetic resonance imaging and a strong
desire to preserve fertility potential.
Results: Average age at diagnosis was 33 (range 27 to 39). All patients
had an initial response after 3 months from the start of the conserva-
tive treatment. Median follow-up time was 14 months (range 9 to 45).
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None of these patients developed recurrent disease during the follow-
up time. Two patients gave birth at 39 weeks of gestation. After coun-
seling, 3 out of 5 patients declared they were unwilling to undergo
hysterectomy after childbearing while the remaining two would accept
surgery after at least one successful pregnancy.
Conclusion: We think that these results indicate that this treatment
strategy is feasible in young women with early well-differentiated
EC who have a strong desire to preserve fertility potential.
000152
WHICH IS THE BEST TECHNIQUE FOR ENDOMETRIAL
SAMPLING? ASPIRATION (PIPELLE) VERSUS DILATATION
AND CURETTAGE (D&C)
F. Demirkıran1, E. Yavuz1, T. Besxe1, M. Arvas1, C. Sxaniog˘lu1,
D. Ko¨sebay1
Istanbul Univercity Cerrahpasx A Medical Faculty, Obstetrics and Gyne-
cology, Istanbul, Turkey
Objective: The aim of this study is to assess the diagnostic accuracy
of two endometrial sampling technique (Pipelle and D&C) by com-
paring histologic findings with this techniques with those obtained
by after hysterectomy.
Material and Methods: The study was conducted prospectively and
we analyzed endometrial sampling results of 422 patients, and 302
out of 422 had abnormal uterine bleeding. Pipelle and D&C was per-
formed within two weeks before hysterectomy. One hundred and
twenty-four patients had pipelle results before hysterectomy and
D&C was the biopsy technique before hysterectomy for 98 patients.
Results: Insufficient material rate for diagnosis were 2% and 6% for
D&C and Pipelle, respectively. Complete histopatologic identical re-
sults were obtained 70% between D&C and hysterectomy. The same
ratio was 64% for pipelle. Sixty percent of endometrial hyperplasia
and 75% of high grade lesions were diagnosed with pipelle. How-
ever, only 23% of focal lesions were established with this technique.
D&C diagnosed 67% of hyperplasia, 75% of high grade lesions and
37% of focal lesions. NPV and PPV of pipelle for focal lesions and
high grade lesion were 78%, 99% and 43%, 100%, respectively. With
respect to D&C, NPV and PPV were 80% and 76% for focal lesions.
The same results for high grade lesions were 98% and 100%.
Conclusion: BothD&Cand Pipelle are inadequate diagnostic and ther-
apeutic tool for focal endometrial lesions.However, diagnosticpowerof
pipelle are similar those of D&C. So, endometrial samplingwith pipelle
is an acceptable technique for global endometrial pathology.
000153
MANAGEMENT OF ADOLESCENT OVARIAN MALIGNAN-
CIES-A CONCEPTUAL DILEMMA
U.K. Devi1, U.D. Bafna1, C. Ramesh2
1Dept of Gynaec Oncology, Kmio; 2Dept of Epidemiology & Hospital
Cancer Registry, Kmio, Bangalore, India
Objective: To study the clinicopathological presentation, treatment
approach adopted and the treatment outcome of those Adolescent
girls presented with Ovarian Malignacies were reviewed.
Patients and Methods: A retrospective analysis of the 1733 patients
with ovarian Malignacies revealed 156 [9%] patients with Adoles-
cent ovarian Malignancies between January 1982 & September 2004.
All these patients were investigated, staged & treated according to
the guidelines of FIGO. The previous surgical details & slides were
reviewd by the institute pathologist. The data was analysed by using
chisquare database.
Results: Majority of them belong to Germ cell tumor [78.2%] and
less common is Epithelial ovarian cancer [16%], and stromal tumor
[5.8%]. Most of them presented with inadequate previous surgery
[88.2%] and all of them were subjected to adjuvant chemotherapy.
68.5% of them presented with advanced stage, 77.9% were alive
without disease, 12.8% of them progressed, 9.35% of them succumed
despite of the treatment. The followup ranged between 10 months to
168 months [medain 38.6 months].
Conclusion: This study indicates that the Adolescent girls present-
ing with Ovarian malignancy should be treated with conservative
surgery followed by optimal adjuvant chemotherapy. However the
relapsed & nonresponders requires judicious management.
000154
INDUCTION CHEMOTHERAPY IN ADVANCED EPITHELIAL
OVARIAN CANCER—A THERAPEUTIC DILEMMA?
U.K. Devi1, U.D. Bafna1, C. Ramesh2
1Dept of Gynaecological Oncology, Kmio; 2Dept of Epidemiology & Hos-
pital Cancer Registry, Kmio, Bangalore, India
Objective: To assess an alternative treatment approach for those pa-
tients unfit/unsuitable for surgery with Advanced Epithelial Ovari-
an Cancer and to study the quality of life issues in patients received
the Neoadjuvant chemotherapy.
Patients and Methods: The records of 1733 Ovarian cancer patients
presented at the Department of Gynaecological Oncology between
January 1982 & September 2004 revealed 913 patients with advanced
Epithelial Ovarian cancer. The Diagnosis was cofirmed either with
histology or Cytology. Those patients unfit/unsuitable for surgery
[n = 863] were subjected to two-three courses of Platinum/Taxol
based Neoadjuvant chemotherapy and the clinical response was as-
sessed at two-three weeks interval, & Interval Debulking surgery
was performed in those patients responded to chemotherapy. The
data was analysed by epichisquare database.
Results: Themedian age of the patientswas 47.38 years.Majority of the
patients showed complete or partial clinical response [84.3%], less than
10%had stabledisease,& less 5%hadmeatastaicAdenocarcinoma from
other sites. Optimal Cytoreduction was feasible in 88.4% of patients
during Interval debulking surgery avoiding the extensive bowel resec-
tion & aggresive surgical pocedures. Quality of life was comparatively
improvesd particulary in elderly patientsith with low performance sta-
tus. However, the Progression free interval & survival benefits seems to
be similar to that of the primary Cytoreductive surgery.
Conclusion: The present study confirms that the Induction chemo-
therapy is an alternative prudent option of treatment in patients un-
fit/unsuitable for primary surgery for Advanced Epithelial Ovarian
cancer. It has definetely improved the quality of life & reduced the
operative morbidity & mortality in selected group of patients with
advanced disease.
000155
LEVONORGESTREL INTRAUTERINE SYSTEM (MIRENA) AS
PRIMARY TREATMENT FOR WOMEN WITH EARLY ENDO-
METRIAL CANCER
K.K. Dhar1, T. NeedhiRajan1, M. Koslowski2, J.L. Beynon1,
R.P. Woolas1
1Department of Gynaecologic Oncology; 2Department of Histopathology,
St Mary’s Hospital, Portsmouth, UK
Background: Intrauterine progesterone therapy potentially provides
a simple alternative treatment for women with early endometrial
cancers who are at high risk for surgery.
Case Reports: Five women with Stage I grade 1 endometrial adeno-
carcinoma with positive progesterone receptor were primarily trea-
ted with levonorgestrel intrauterine system. All were assessed to be
in American Society of anaesthesiologists risk class IV and thus con-
sidered at high risk for perioperative complication. After insertion of
mirena intrauterine system one woman (20%) had histological re-
gression of disease within 6 months. Two of four women who did
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not respond to treatment subsequently had hysterectomy, which
showed endometrial cancer with myometrial invasion.
Conclusion: This report raises doubts about the effectiveness of intra
uterine progesterone therapy as a definitive alternative for the treat-
ment of early endometrial cancer. However, this option may offer an
interim measure whilst co-morbid conditions are stabilised before
definitive conventional treatment.
000156
NEOADJUVANT CHEMOTHERAPY WITH PACLITAXEL, IFOS-
FAMIDE AND CISPLATIN IN LOCALLY ADVANCED CERVI-
CAL CANCER: PHASE II TRIAL
F. Raspagliesi, F. Zanaboni, F. Vecchione, A. Ditto, F. Hanozet,
C. Anghileri, S. Kusamura
National Cancer Institute, Gynecol Oncol Unit, Milan, Italy
Purpose: Neo-adjuvant chemotherapy (NACT) followed by radical
surgery (RHND) represents an alternative to radiotherapy in locally
advanced cervical cancer, with encouraging results as survival rate
and pathologically confirmed response rate. Aim of this study was
to evaluate effectiveness and toxicity of paclitaxel, cisplatin and ifos-
famide (TIP) as NACT in cervical cancer.
Patients and Methods: From May 2002 to October 2004 33 stage IB2
to IIB cervical cancer patients were treated with TIP regimen; Pacli-
taxel: 175 mg/m2 day 1, Ifosfamide: 5 gr/m2 day 2-3 with Mesna,
Ciplatin: 50 mg/m2 day 1, every 3 weeks x 3. After 3 weeks from the
end of NACT pts were submitted to type 3 RHND.
Results: 30/33 enrolled patients were evaluable for response and
toxicity to NACT. Seven obtained a clinical complete response, 22
a partial response, 1 was stable, with an overall response rate of
97%. After RHND pathological CR were 23%, pPR 77%, while only
one patient with stable versus progressive disease at the end of che-
motherapy was not operated. Toxicity: grade 3 and 4 neutropenia
was registered in 29% and 55% of patients respectively, grade 1 and
2 anaemia in 68% and 29%. Sixteen patients were treated with G-
CSF. The median follow-up is seven months (range 1-59). The 3
years disease free survival rate is 62%.
Conclusion: In this experience NACT with TIP followed by radical
surgery seems to be a very active treatment for locally advanced cer-
vical carcinoma with acceptable toxicity.
000157
CHEMORADIATION AS A SPHINCTER SPARING TREAT-
MENT FOR VULVAR CANCER
P. Drouin1, M. Jolicoeur2, F. Goffin1, T.V. Nguyen2, A. Devieux2,
P. Gauthier1, D. Provencher1
1Division of Gynecologic Oncology; 2Division of Radio-Oncology,
CHUM - Hoˆpital Notre-Dame, Montreal, QC, Canada
Objective: To evaluate the role of chemoradiation as a sphincter
sparing option for advanced/recurrent vulvar cancer.
Methods: From October 1997 to July 2003, 24 patients with locally
advanced (n = 16) or recurrent (n = 8) diseases were selected for
sphincter sparing therapy. The median age was 65 years (range 25-
80 years). Biopsy-proven vulvar cancer (squamous, n = 22, adenocar-
cinoma, n = 2) were staged according to the FIGO (stage II, n = 4;
stage III, n = 17; stage IV, n = 3). All patients received external radia-
tion to a dose of 45 Gy (45-50, 4 Gy) to the primary and regional
lymph-node areas followed by electron boost (10-20 Gy) to the vulva
and clinically positive nodes or vulvar interstitial brachytherapy
(20 Gy). Chemotherapy consisted of platinum (n = 16) or mitomycin-C
(n = 8) based regimens.
Results: All patients reached initial complete clinical response. With
a median follow-up of 32 months (4,4-63,6 months), 6 patients (25%)
had a recurrence (5 local and 1 regional). The 2-year overall survival
was 85% and the disease-free survival was 78%. Acute toxicities in-
cluded urinary symptoms (G1 in 25%, G2 in 70,8%, G3 in 4%), diar-
rhea (G2 in 70.8%, G3 in 29.2%), perineal desquamation (G2 in
54.2%, G3 in 45.8%) and febrile neutropenia (12%).
Conclusion: Definitive chemoradiation is an effective option for ad-
vanced or recurrent vulvar cancer allowing organ and sphincter
preservation. Further follow-up is required to determine the long-
term outcome.
000158
COMPARISON OF E-CADHERIN EXPRESSION IN SQUA-
MOUS CELL CARCINOMA (SCC) AND CIN 3
P. Dursun1, M. Gultekin1, A. Usubutun2, T. Kucukali2, K. Yuce1,
A. Ayhan1
1Department of Obstetrics and Gynecology; 2Department of Pathology,
Hacettepe University Faculty of Medicine, Ankara, Turkey
Background: E-cadherin (E-cad), a calcium dependent intercellular
adhesion molecule, is important in cell growth and differentiation.
Adhesion between cells is thought to decrease as cancers develop and
disseminate. Therefore, E-cadherin is an important cellular adhesion
molecule for the development and metastasis of malignancies.
Objective: To compare E-cadherin expression in CIN 3 and SCC of
the cervix.
Material and Method: E-cad expression was analysed in surgically
treated stage IB women with SCC and outpatients treated women
with CIN 3, using commercially available polyclonal antibodies on
Formalin-fixed, paraffin-embedded tissues. Patients were divided
into two groups arbitrarily Group1: E-cad expression , 50%, Group
2: E-cad expression .50%. Statistical analysis was performed using
Chi-square test and t test. Survival of the patients was compared
by Kaplan-Meier analysis. Multivariant analysis was performed by
Logistic Regression analysis. P , 0.05 was considered statistically
significant.
Results: There were 40 patients in SCC group while there were 18
patients in CIN3 group. There was no significant differences with re-
spect to age of both groups (p . 0.05). Other clinical variables were
not significantly different among groups. Significantly lower expres-
sion of E-cad was observed in SCC group when compared with CIN
group (62.5% vs. 22.2%, p = 0.005). Furthermore, intensity of E-cad
staining was significantly lower in SCC group compared with CIN3
(59.5% vs. 16.7%, p = 0.003).
Conclusion: Loss of E-cadherin expression may have an important
role in development of invasive SCC from preinvasive cervical neo-
plasias. Reduced E-cad expression may be incorporated into man-
agement and follow-up of preinvasive cervical neoplasias.
000159
THE ASSOCIATION OF CATHEPSIN D EXPRESSION AND
CLINICAL PROGNOSTIC FACTORS IN ENDOMETRIAL ADE-
NOCARCINOMA
I. Dvalishvili, L. Charkviani, T. Charkviani, G. Burkadze
Georgian National Oncology Center Named After Gvamichava A. Gy-
naecological Clinic, Tbilisi, Georgia
Background: Cathepsin D (CathD) is a lysosomal aspartyl protease
secreted by normal and malignant cells. It is considered to be in-
volved in breakdown of the extracellular matrix. Overexpression of
CathD in several types of carcinoma in women appears to be associ-
ated with a poor clinical course. The expression of CathD has not
been studied widely in endometrial adenocarcinoma. The aim of the
present study was to determine the association of CathD expression
and established prognostic factors in endometrial carcinoma.
Materials and Methods: The immunohistochemical expression of
CathD was performed in paraffin embedded tissue from the patients
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with endometrial carcinoma grade I (n = 35), grade II (n = 44), grade
III (n = 25). The association between CathD and established prognos-
tic factors was investigated.
Results: Of 84 tissue specimens, 51 (60.7%) showed a positive reac-
tion for CathD. A significant correlation between CathD and histo-
logical grade was found (P , 0.05). The expression of CathD-
positive increased with the size and myometrial invasiveness of the
primary tumor (p , 0.01). Patients with vessel invasion and pelvic
lymph-node metastasis had a higher incidence of CathD-positive
staining than patients without these findings (p , 0.05). A favorable
prognosis was obtained in CathD-negative cases in comparison with
positive cases (p , 0.01). The expression of CathD in stromal cells
was associated with lymph node positivity (p , 0,05).
Conclusion: The association of CathD expression with tumor differ-
entiation and myometrial invasiveness may show promise as a clini-
cally useful adjunct to prognosis assessment and the planning of
therapy in the patients with endometrial adenocarcinoma.
000160
CA125 LOCALIZES TO DIFFERENT INTRACELLULAR OR-
GANELLES IN DIFFERENT OVARIAN CANCER CELL LINES
R. Eitan1,2,3, G. Springett1, C.S. Awtrey2, D. Thapi1, N. Rosales1,
U. Beller3, D.S. Spriggs1
1Developmental Chemotherapy Service; 2Gynecology Service, Memorial
Sloan-Kettering Cancer Center, New York, NY, USA; 3Department of
Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel
Objectives: MUC16, the gene coding for the CA125 glycoprotein
has been identified, and the intra-cytoplasmic domain of MUC16 is
thought to have a role in cell signaling. It has been shown that
MUC1 localizes to the mitochondria in colon cancer cells and has
a role in resistance to chemotherapy. We set out to define the locali-
zation pattern of MUC16 in ovarian cancer cells.
Methods: Two ovarian cancer cell lines were used, OVCAR3, which
secretes CA125, and SKOV3, which does not. The carboxy-terminal
domain of MUC16 tagged to GFP was transfected into both cell lines
using an expression vector. Both cell lines were also tested for mito-
chondria using Mitotracker. Confocal microscopy was used to deter-
mine localization of the GFP tagged MUC16 relative to the
distribution of mitochondria in SKOV3 and OVCAR3 cells.
Results: In the OVCAR3 cell line, GFP tagged MUC16 localized
preferentially to the mitochondria and to the cell membrane, where-
as in the SKOV3 cells GFP tagged MUC16 was found to distribute
diffusely in the cytoplasm and did not localize to either mitochon-
dria or membrane.
Conclusion: Different ovarian cancer cell lines express CA125 in
a different manner and process the glyco-protein differently. These
differences may account for the differing sensitivity to chemo-
therapy among ovarian cancer cell lines in-vitro and might be rele-
vant for in-vivo sensitivities also.
000161
HPV AND P53 EXPRESSION IN OVARIAN CARCINOMA
E. Kuscu1, B.H. Ozdemir2, S. Erkanli1, A. Haberal1
1Obstetrics & Gynecology; 2Pathology, Baskent University School of
Medicine, Ankara, Turkey
Objectives: Human papillomavirus is the causal factor for cervical
cancer. However, the role of HPV infection in ovarian cancer is un-
clear. This study aimed to determine the presence of human papillo-
mavirus (HPV) in ovarian cancer tissues along with the expression
of tumor suppressor gene p53. We also investigated any possible as-
sociation of HPV with p53 gene mutations in ovarian carcinoma.
Methods: Archived human ovarian cancer tissues (n = 40 cases of
epithelial ovarian cancer) embedded in paraffin blocks were used.
Controls are 32 non-malignant ovarian tumor tissue blocks. In situ
hybridisation (ISH) and immunohistochemistry (IHC) were used to
detect the presence of HPVand p53 expression respectively.
Results: Of the total, 37.5% (n = 15) of malignant and 28.1% (n = 9)
of benign ovarian tumors were positive for HPV (OR: 1.5 CI: 0.5-4.1,
p = 0.4). The difference was not statistically significant. However,
p53 was detected in 72.5% (n = 29) of malignant cases compared to
37.5% (n = 12) of benign cases (OR: 4.3 CI: 1.6-11.9, p = 0.003). Fur-
thermore, a positive correlation between HPV and p53 expressions
in ovarian cancer tissue samples was detected (r = 0.47, p = 0.001).
Conclusions: HPV seems to be not a major component in the devel-
opment of ovarian carcinoma, nevertheless HPV positivity seems to
contribute to the pathogenesis in at least some ovarian carcinoma
cases by way of interaction with tumor suppressor p53.
000162
ABNORMAL UTERINE BLEEDING IN EPITHELIAL OVARIAN
CARCINOMA: A CASE CONTROL STUDY
N. Behtash1, F. Fakor2, M. Hasanzadeh1, E. Rezayof1
1Gynecology Oncology Department, Tehran University of Medical
Sciences/Vali-Asr Hospital, Tehran; 2Obstetric & Gynecology Department,
Guilan University of Medical Science/Azzahra Hospital, Rasht, Iran
Objective: The goals of this study are collecting the data about ab-
normal bleeding in patients with Epithelial Ovarian Carcinoma
[EOC] at diagnosis and the previous 12 months and comparing the
data to menstrual pattern in women referring to primary care clinic.
Methods: This is a case-control study in Vali-Asr hospital from 1995-
2004.The epidemiologic data and menstrual pattern of 254 patients
with EOC compared with 297 healthy women from primary care
clinic in control group.
Results: Of 254 EOC, 30 had borderline tumors, 90 had early stage
(I, II) and 164 had advanced (III, IV) invasive disease. Twenty seven
percent of cases had some type of abnormal bleeding compared with
16% in control group. Time interval between first episodes of abnor-
mal bleeding to diagnosis ranged from 2-5 months. Post menopausal
bleeding in EOC patients was 2 times more than control group.
Conclusion: Earlier diagnosis of EOC may be possible if women
and physicians recognize the importance of vague long-standing
symptoms including abnormal bleeding in this group of patients.
000163
AGE AND RESULTS OF TREATMENT OF ATYPICAL GLAN-
DULAR CELLS
E.M.A. Figueiredo, R. Giorgi, C.M.G. Magalha˜es, G.M. Moralez
Gynecology Oncology, Brazilian National Cancer Institute, Rio De Janeiro,
Brazil
Glandular atypia in Papanicolaou smears from postmenopausal
women can be the result of artifactual alterations such as drying arti-
facts and inflammatory changes or may represent a squamous or
glandular, preneoplastic or neoplastic process. We studied 989
patients treated by large loop excision procedure (LLEP) for abnor-
mal cervix smears at Brazilian National Cancer Institute between Jan-
uary 1999 and September 2003. Eighty six patients having atypical
glandular cells (8.7%) were reviewed and corresponding final histo-
logical diagnoses were further evaluated, the mean age of the patients
was 38.9 (15 to 65 years). The results of hystopatological findings
were: to patients under 40 years old, the hystopatological finding
confirmed cervicitis to 18% of patients, LSIL 18%, HSIL 46%, adeno-
carcinoma 6% and squamous cell carcinoma 12%. Comparably, forty
aged and older patients had hystopatological finding: cervicitis to
19% of patiens, LSIL 17%, HSIL 50%, adenocarcinoma 8% and squa-
mous cell carcinoma 6%. Differing of literature, there were no signifi-
cant differences of hystopatological findings for age adjustment.
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000164
USEFULNESS OF HUMAN PAPILLOMAVIRUS TESTING IN
THE FOLLOW-UP OF PATIENTS WITH HIGH GRADE SIL
AFTER CONIZATION
P. Fuste´1, G. Mancebo1, M. Lo´pez-Yarto1, F. Alameda2, L. Marin˜oso2,
T. Baro´2, S. Serrano2, R. Carreras1
1Gynecologic Oncology, Obstetrics and Gynecology Department; 2Pathol-
ogy Department, Hospital Del Mar, Barcelona, Spain
Objective: To analyse if HPV determination is useful as a predictor
factor of SIL persistence/relapse after conization.
Method: We analyzed a consecutive serie of 92 patients who under-
went conization after HSIL diagnostic, between january 2001 and
june 2004. The high risk HPV-DNA testing was done using PCR de-
termination between 6 weeks and 6 months after treatment. Minimal
follow-up period was 12 months, monitored by Pap smears and col-
poscopy. The results were correlated with other prognostic factors
for recurrent HSIL, as CIN at cone margin or endocervix, high risk
HPV, menopausal status.
Results: 17 cases of HSIL relapse were detected (18,5%). Whereas
the PPV of HPV-DNA presence was low, only 2 patients with nega-
tive HPV-DNA recurred, then determination of HPV-DNAwas more
useful in predict the absence of a second lesion.
Conclusions: The use of HPV testing in the follow-up of treated
HSIL, provides additional information about the risk of relapse in
negative HPV-DNA cases. Just in positive cases for high risk HPV, it
would be necessary an strict cytologic and colposcopic examination
during follow-up after conization.
000165
PREDICTIVE VALUE OF FOCAL ADHESION KINASE IN CER-
VICAL CANCER STAGE I AND II: A CLINICO-PATHOLOGIC
STUDY
B. Gabriel1, A. zur Hausen2, C. Dietz1, M. Klar1, C. Tempfer3
G. Gitsch1, A. Hasenburg1
1Department of Obstetrics and Gynecology; 2Department of Pathology,
University of Freiburg, Freiburg, Germany; 3Department of Obstetrics
and Gynecology, University of Vienna, Vienna, Austria
Introduction: Focal Adhesion Kinase (FAK) is a protein tyrosine ki-
nase that is a critical mediator of signaling events between cells and
their extracellular matrix. FAK is overexpressed in a variety of hu-
man solid tumors and its expression has been correlated with early
tumor cell invasion and metastasis, but data on cervical cancer are
inconclusive. We analyzed FAK protein expression and correlated
these findings with patients survival.
Materials and Methods: In this retrospective study FAK protein
was evaluated by immunohistochemistry in formalin-fixed paraffin-
embedded tissue from 162 samples of cervical cancer, collected
between 1988 and 1995. FAK expression was correlated with clinico-
pathological parameters to analyze its prognostic impact.
Results: The expresssion of FAK was confined to the cytoplasm and
the cell membrane of the tumor cells. Normal epithelium showed bare-
ly any FAK expression. Of 162 cervical cancer samples, 55 (34%)
showed weak expression of FAK, whereas moderate and high expres-
sion was found in 63 and 44 tumors (66%), respectively. Patients with
tumors expressing weak amounts of FAK were characterized by a sig-
nificantly poorer survival compared to those with moderate or high in-
tratumoral FAK expression (p = 0.007, log rank test). Weak expression
of FAK correlated with lymph node involvement (p = 0.02) and tumor
recurrence (p = 0.04). Multivariate Cox regression analysis revealed that
FAK expression was a significant independent predictor for survival.
Conclusion: The specific expression in tumor tissue indicates an im-
portant functional role of FAK in cervical cancer. The survival data
strongly indicate that FAK protein expression in cervical cancer tis-
sue is an independent prognostic factor.
000166
AGGRESSIVE PLACENTAL SITE TROPHOBLASTIC TUMORS.
REPORT OF TWO CASES
C. Galant1, S. Ploteau2, M.C. Nolleveaux3, I. Leconte4, J. Squifflet2,
J. Donnez2, M. Berliere2
1Department of Pathology; 2Department of Gynaecology, Saint Luc Uni-
versity Clinics, Brussels; 3Department of Pathology, Mont-Godinne Clin-
ics, Yvoir; 4Department of Radiology, Saint Luc University Clinics,
Brussels, Belgium
Placental site trophoblastic tumor (PSTT) is a rare trophoblastic le-
sion, derived from the implantation site intermediate trophoblast.
We report two cases, occurring in young women of 25 and 33 years
old. Clinically, the first patient presented vaginal discharge. An uter-
ine resection was performed for a fibroma, showing, at histological
examination, an infiltration of the myometrium by isolated enlarged
cells, corresponding to a PSTT. The other patient went to hospital for
a curettage after a spontaneous abortion and the diagnosis of PSTT
was performed on the endometrial biospy. An uterine perforation at
the time of curettage occurred. In both cases, HCG beta levels re-
mains high, and MRI showed the presence of residual tumor. An
hysterectomy was performed. On hysterectomy specimens, PSTT
was still present, and infiltrated more than on half of the myometrial
depth. The tumoral cells were positive for inhibin alpha, HPL, HCG
beta, whereas ER and PR were negative. Some of the tumor cells
were immunolabelled for p53. The proliferation index, assessed by
the detection of Ki67 in both cases was at 10%, and areas of necrosis
were present in the biopsies as well as in the surgical specimens.
These criteria are linked to a more aggressive behavior of the tumor
and the detection of p53 could play a role in the tumoral potential of
the trophoblastic cells.
000167
UNITED KINGDOM COLLABORATIVE TRIAL OF OVARIAN
CANCER SCREENING (UKCTOCS): OUTCOME REVIEW
PROCESS
The UKCTOCS Group, A. Gentry-Maharaj
Gynaecological Cancer Research Centre, Institute of Women’s Health,
University College London, London, UK
UKCTOCS is a randomised control trial of ovarian cancer screening.
200,000 postmenopausal women aged 50 to 74 are randomised to ul-
trasound, serum CA125 or control in 1:1:2 ratio. The primary out-
come is ovarian cancer mortality. The objective of this report is to
describe the outcomes review process aimed at ensuring unbiased
classification of ovarian cancer diagnoses and deaths. The coordinat-
ing centre is notified of all cancers and deaths through the Office of
National Statistics via a ‘flagging’ study. In addition, information is
obtained directly from collaborating centres and participants via
postal questionnaire. An independent outcomes committee, consist-
ing of epidemiologist (chair), gynaecological oncologist and patholo-
gist, reviews all data (death certificates, ONS cancer registration;
histology reports; operative notes and discharge summaries) on can-
cers and deaths with specified ICD codes. These are chosen to en-
compass all possible ovarian pathology and in addition to C56
(primary malignant ovarian neoplasm), include others like C76 (ma-
lignant neoplasm of abdomen and pelvis), C80 (malignant neoplasm
without specification of site), D39.1 (neoplasm of uncertain behav-
iour of ovary) etc. The committee is blinded to the randomisation
group. Outcomes are classified as definitely ovarian cancer or proba-
ble, possible or uncertain. Difficult cases identified by the outcomes
committee will be reviewed by multidisciplinary input from inde-
pendent gynaecological oncology experts. A pilot pathology review
of slides is planned to evaluate the impact on final ovarian cancer di-
agnosis. It is inevitable that there will be better documentation for
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screen-detected cancers. It is therefore essential that there is well-es-
tablished protocol aimed at minimising bias.
000168
THE ROLE OF CYCLIN-A, CYCLIN-E AND P-27 IN NORMAL
ENDOMETRIUM AND ENDOMETRIAL PATHOLOGIES
S.T. Gezgincx1, K. Gezgincx1, H. Toy2, C¸. C¸elik1, M.C. C¸olakog˘lu1,
C. Akyu¨rek1
1Gynecology and Obstetrics; 2Pathology, Selcuk University Faculty of
Meram Medicine, Konya, Turkey
Objective: To demonstrate the role of cyclins (Cyclin-A, Cyclin-E)
that play role in cell proliferation cycle and the role of P27 gene that
is known as tumour supressor gene in endometrial cancer, endome-
trial hyperplasia and proliferative endometrium by immunohisto-
chemical methods.
Material and Methods: This study is carried out among 75 patients;
in the first group there were 25 stage I endometrioid type endo-
metrial cancer patients, in the second group there were 25 simple en-
dometrial hyperplasia cases, and in the third group 25 proliferative
endometrium cases were included.
Results: When groups were compared for Cyclin-E immunoreac-
tivity; there were statistically significant differences between the first
group and second group, the first and the third group (P , 0.05).
When groups were compared for Cyclin-A immunoreactivity; no
statistically significant differences were found among the groups (P
. 0.05). When the groups were compared for P27 immunoreactivity;
a statistically significant differences were detected among the groups
(P , 0.05).
Conclusion: As a result, Cyclin-E was found probably to play role in
the development of endometrial cancer. P27 was found to be effec-
tive at the progression of endometrial hyperplasia and endometrial
cancer. It may be proposed that the histopathologic evaluation of
Cyclin-E and P27 in patients with endometrial hyperplasia who
were planned to be treated medically; these may be important for
the evaluation of future development of the endometrial cancer.
000169
ANTISENSE CHEMORADIOIMMUNOTHERAPY COMPOSED
OF ANTICYCLIND1SCFV LINKED ONTO RADIOISOTOPES,
VINORELBINE, PROCAINAMIDE & 21NUCLEOTIDE DOUBLE-
STRANDED SIRNA TARGETED TO IRF9 INDUCE ANOIKIS &
APOPTOSIS IN METASTATIC BREAST CANCER
J. Giannios1, G. Kanellopoulos1, P. Lambrinos2, N. Alexandropoulos3
1Dept. of Oncology, GSHA and Dept. of Radiation Oncology, IASO;
2Dept. of Oncology, PF; 3Dept. of Clinical Biochemistry, IH, Greece,
Metastatic breast Ca is resistant to cytotoxic drugs and radiation
making it one of the most aggressive malignancies. We obtained sur-
gically 137 metastatic breast Ca specimens from patients. Genomic
DNA of tumours was analysed for CpG island hypermethylation by
using MS-PCR. All of the tumours showed hypermethylation of tu-
mour suppressor genes with the following frequencies: E-cadherin
92%, p16 89%, RASSF1A 84%, RARb2 78%, hMLH1 60%, BRCA2
54% and p53 51%. IHC,WB,SB and RT-PCR exhibited overex-
pression of DNMT1, IRF9/p48/ISGF3g, cyclinD1, bcl-2, Raf1 and
cdc25c. We treated the MBC with anticyclinD1scFv attached onto
high energy radioisotopes, vinorelbine, procainamide and 21 nucleo-
tide double stranded siRNA segment generated against IRF9. Post-
treatment, we detected re-expression of tumour suppressor genes af-
ter inhibition of DNMT1 by demethylating procainamide. There was
downregulation of cyclinD1 due to targeted scFv and inactivation of
bcl-2, Raf1 and cdc25c due to phosphorylation by vinorelbine. We
detected upregulation of p21Waf1, p27Kip, Bid and Bak. The 21nu-
cleotide double stranded siRNA targeted to IRF9 inhibited its
mRNA. The high energy radioisotopes induced DNA double strand
breaks in MBC cells arresting synergistically with MT depolymeriz-
ing vinorelbine their growth at the G2/M transition according to
flow cytometry analysis. We detected externalization of PS, depolar-
ization of mitochondrial transmembrane potential, activation of cas-
pase-3,7,8,9 and bax, cleavage of poly (ADP-ribose) polymerase and
DNA fragmentation. TEM exhibited D2 apoptotic signs forming ap-
optotic bodies which were phagocytosed by adjacent tumour cells
leading to an autophagocytic bystander killing effect associated with
overexpression of typeII LC3. TEM exhibited signs of anoikis. BrdU
and MTT exhibited inhibition of DNA synthesis and metabolic activ-
ity of treated MBC cells compared to untreated controls. We have
achieved to eradicate MBC cells chemoresistant to taxanes with com-
bined chemoradioimmunotherapy after circumvention of chemo
and radioresistant mechanisms.
000170
ANASTROZOLE, HYDRALAZINE AND VINORELBINE IN-
DUCE APOPTOSIS IN BREAST INFILTRATING DUCTAL CA
OF A POSTMENOPAUSAL PATIENT WITH HYPERMETHYLA-
TION OF AROMATASE (CYP19) GENE AND ER
J. Giannios1, G. Kanellopoulos1, P. Lambrinos2, N. Alexan-
dropoulos3
1Dept. of Oncology, GSHA and Dept. of Radiation Oncology and Radio-
genomics, IASO; 2Dept. of Oncology, PF; 3Dept. of Clinical Bio-
chemistry, IH, Greece
Postmenopausal women produce estrogens through the aromatase
(CYP19) gene which is present in high concentrations in breast can-
cer or its stroma. Although breast Ca is sensitive to endocrine inter-
vention in sequence, eventually resistance will occur. We obtain
cancer cells from a resistant to treatment postmenopausal patient
with advanced infiltrating or invasive ductal carcinoma (IDC). MSP
detected coincident aberrant 59CpG island hypermethylation of aro-
matase (CYP19) and ER which caused their transcriptional silencing.
Loss of ER and CYP19 expression was associated with poor histolog-
ical differentiation, high growth fraction and poor clinical outcome.
PCR exhibited overexpression of antiapoptotic oncogene bcl-2 which
causes chemoresistance. After combined administration with aroma-
tase inhibitor with anastrozole, DNA methyltransferase inhibitor
hydralazine and vinorelbine, we observed phosphorylation and
downregulation of bcl-2, CpG island demethylation and re-expres-
sion of CYP19 and ER protein and inhibition of the metabolic trans-
formation of androgenic precursors into estrogens. All these induced
apoptosis in tumour cells according to TUNEL. TEM exhibited irre-
versible D2 apoptotic signs such as disintegration of tumour cells to
membrane bound apoptotic small bodies which were phagocytosed
by adjacent tumour cells leading to a bystander killing effect. Con-
cluding, this therapeutic approach may revolutionize treatment
against advanced breast infiltrating ductal carcinoma resistant to
treatment due to potential advantages offered in comparison to con-
ventional therapy such as well defined mode of action, selectivity
and mainly circumvention of resistance to treatment by causing
DNA demethylation reactivating transcriptionally silenced genes
such as CYP19 and ER downregulating by phosphorylation antia-
poptotic oncogene bcl-2.
000171
CLINICAL OUTCOMES OF PRIMARY AND INTERVAL DE-
BULKING SURGERY IN ADVANCED OVARIAN CANCER
T. Giannopoulos1, N. Ngeh2, H. Thomas3, A. Tailor4, S. Butler-
Manuel5
1Gynaecogical Oncolog, Royal Surrey County Hospital, Guildford; 2Gy-
naecogy, East Surrey Hospital, Redhill; 3Medical Oncology; 4Gynaeco-
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gical Oncology; 5Gynaecogical Oncology, Royal Surrey County Hospital,
Guildford, UK
Background: Primary Debulking Surgery (PDS) followed by chemo-
therapy is still considered the optimal treatment for advanced Epi-
thelial Ovarian Cancer. Unfortunately, it is associated with a high
risk of morbidity and intraoperative complications. We examined
the impact of Interval Debulking Surgery (IDS) on clinical outcomes
of patients considered unsuitable for PDS (as optimal cytoreduction
was not anticipated) and compared them with outcomes of women
that had PDS followed by chemotherapy.
Patients and Methods: Non-randomised prospective study of 35
patients who underwent IDS and 29 patients treated with PDS. All
patients had stage IIIC or IV disease and were treated by the same
two surgeons. The IDS patients were considered unresectable based
either on pre-operative CT or laparoscopy findings. All patients re-
ceived the same regimen of chemotherapy.
Results: There was no significant difference regarding patients’ age
and tumour stage. Optimal cytoreduction rate was similar in both
groups. The mean blood loss and the possibility of admission in the
Intensive Treatment Unit (ITU) were significantly less in the IDS
group. The risk of postoperative complications (chest, wound and
urinary infection) and duration of hospitalization were also less in
the IDS group but did not reach statistical significance.
Conclusions: IDS in patients with ‘unresectable’ disease seems to
achieve similar rates of optimal debulking as PDS, with reduced
need for blood transfusion and ITU care. In the absence of any evi-
dence of adverse effects on progression free and overall survival,
IDS could evolve as treatment of choice for selected patients with
advanced ovarian cancer.
000172
ENDOMETRIAL CANCERS IN WOMEN UNDER 40 YEARS:
INSIGHTS FROM THE MCGILL EXPERIENCE
R.M. Gilbert1, L. Tan1, A. Kerim-Dikeni1, P.G. Gillett1, L. Souhami2,
L. Portelance2, S. Patel2, L. Gilbert1
1Department of Obstetrics & Gynecology; 2Department of Radiation
Oncology, McGill University Health Centre, Montreal General Hospital,
Montreal, Canada
Objective: To determine the optimum management of endometrial
cancer (EC) in women below 40 years.
Results: 31 of the 1194 women with EC treated surgically at our in-
stitution between 1989 and 2003 were below 40 years. 58% were nul-
liparous. Although the preoperative assessment suggested low risk
pathology in 93.5% of patients, the final pathology was high-risk in
19%. Positive lymph node metastases were found in 20% of the
patients who had full surgical staging despite low-risk pathology. Of
the patients who had a bilateral salphingo-oohorectomy despite the
preoperative low-risk pathology, 13% had unexpected synchronous
ovarian primaries and one had a fallopian tube metastasis. One
patient with grade II endometrioid adenocarcinoma, who had not
had full surgical staging, developed inguinal metastatic disease 15
months later. Assessment of sexual functioning or menopausal
symptoms did not form part of the routine follow-up evaluation.
Apart from the patient with recurrence in the inguinal nodes, one
patient with Stage IV disease died at 13 months, one Stage I patient
died of recurrent breast cancer. The remaining patients are alive and
free of disease -median follow-up 69.86 months.
Conclusion: In our experience, dispensing with surgical staging or
retaining the ovaries on account of the young age and low risk pre-
operative pathology is unsafe and counterproductive as it may ne-
cessitate the use or pelvic radiotherapy to reduce the risk of
recurrent disease. Menopausal symptoms and sexual dysfunction in-
duced by surgical castration and adjuvant treatment should be ad-
dressed during follow-up of these young women.
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CONSERVATIVE TREATMENT FOR VIN-III WITH TOPICAL
IMIQUIMOD CREAM 5%
F. Goffin1, M.C. Renaud2, M. Plante2, M. Roy2
1Gynecological Oncology, University of Lie`ge, Lie`ge, Belgium; 2Gyneco-
logical Oncology, University of Laval, Laval, QC, Canada
Objective: To evaluate the efficacy, tolerance and recurrence rate af-
ter self-treatment with Imiquimod 5% of patients presenting VIN-III.
Material and Methods: Between September 1999 et April 2004, 45
patients with biopsy-proven VIN-III were prospectively offered con-
servative treatment with imiquimod 5%, twice weekly. Patients were
followed every 6 weeks, photographs were recorded. Epidemiologic
factors linked to VIN-III, response to treatment, side effects and re-
currence rate were recorded.
Results: Mean age was 45 years (23-74). Thirty-eight patients
(85%) were smokers, 2 were immuno-suppressed. Twenty-two (52%)
were referred with recurrent VIN-III. Multifocal, polymorphic and
cutaneo-muquous lesions were obeserved in 71%, 50% and 57% of
the cases, respectively. Thirty-eight women completed at least 8
weeks of treatment. Complete responses (CR) occured in 24 patients
(56.4%), partial response (PR) of at least 50% in 18 others (38.4%).
Failure to treatment were observed in 1 immuno-depressed woman.
The mean treatment time was 15 weeks (5-28) and besides local irri-
tation and burning, no serious side effects were noted. Median
follow-up was 18 months (2-52). Among CR, after a median follow-
up of 24 months, only one patient (2.3%) recurred. Among PR, 5
patients recurred after a median follow-up of 15 months.
Conclusions: Self-application of imiquimod 5% is efficious and safe
for VIN-III treatment. It may replace (for CR) or reduce (for PR) the
surgical extent of VIN-III resection or ablation. Longer follow-up is
necessary to confirm the low recurrence rate that might be the most
important advantage of this conservative treatment.
000174
HYPOXIA-INDUCIBLE FACTOR-1a AND GLUT-1 EXPRES-
SION IN HYPERPLASIA AND ENDOMETRIAL CANCER
N. Horree1, P.J. van Diest2, P. van der Groep2, D.S. Sie-Go2, A.P.M.
Heintz1
1Gynecology; 2Pathology, UMCU, Utrecht, The Netherlands
Introduction: Hypoxia-inducible-factor-1a (HIF-1a) plays an essen-
tial role in the adaptive response to hypoxia. The activated HIF-1a
pathway triggers biologic events that are associated with aggressive
tumor behavior. Glut-1 is a HIF-1a regulated facilitative glucose
transporter allowing hypoxic tumor cells distant from stromal blood
vessels to survive through glycolysis. We analyzed HIF-1a and Glut-
1 in an endometrial carcinogenesis model.
Methods: Paraffin-embedded clinical specimens from inactive endo-
metrium (IE, N = 19), endometrial hyperplasia (EH, N = 23) and en-
dometrioid carcinoma (EC, N = 33) were used. HIF-1a nuclear and
Glut-1 membrane expression were identified immunohistochemi-
cally.
Results: HIF-1a was seen in 5/19 IE cases, always in a diffuse, non-
necrosis related expression pattern. EH showed diffuse HIF-1a in
12/23 cases, one of these also showing a perinecrotic pattern. EC
showed a diffuse HIF-1a pattern in 26/33 cases, 7 of which also had
a perinecrotic pattern (p = 0.00 v2-test), 2/33 showed an exclusively
perinecrotic pattern. Mean percentages of HIF-1a positive cells in IE,
EH and EC were respectively 0.6 (0-5)%, 4.7 (0-20)% and 25.7
(0-90)%. There was no membranous expression of Glut-1 in IE and
EH in contrast to 30/32 (93.8%) of EC, always in a perinecrotic fash-
ion. In EC, perinecrotic HIF-1a and Glut-1 were strongly correlated
(v2-test; p = 0.00).
Conclusion: HIF-1a shows increasing overexpression from IE
through EH to EC, whereas perinecrotic, hypoxia associated HIF-1a
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overexpression is absent in IE, rare in EH and frequent in EC. The
association between perinecrotic HIF-1a and Glut-1 expression
points to functional HIF-1a. We postulate that HIF-1a plays an im-
portant role in carcinogenesis of endometrial cancer.
000175
MICROSATELLITE ALTERATION IN BENIGN, BORDERLINE
AND MALIGNANT EPITHELIAL TUMORS OF THE OVARY
I.S. Park, H.J. Lee, S.S. Kim
Department of OB/GYN, Kyungpook National University Hospital,
Daegu, Korea
Some genetic alterations are involved in ovarian carcinogenesis.
Since some benign and borderline tumors may represent early steps
in ovarian carcinogenesis, analysis of precursor lesions could pro-
vide evidence that an accumulation of genetic events is required in
order for normal ovarian epithelium to generate benign, borderline,
malignant tumors. Few pre-invasive ovarian tumors have so far
been studied. 60 cases of ovarian epithelial tumor, including benign,
borderline, and malignant tumors, were analyzed for microsatellite
instability (MSI) by gel analysis of paired germ line and tumor
DNA. PCR amplification was performed using the panel of 5 micro-
satellite markers recommended by the NCI (BAT25, BAT26, D2S123,
D5S346, D17S250) and 6 additional markers (D1S160, D1S162,
D7S522, D11S860, D17S855, D17S932). In this study, D2S123 and
D5S346 were the most frequently altered markers in malignant ovar-
ian tumors and D11S860 locus showed MSI in 4 adenomas, 4 border-
line tumors, and 12 malignant tumors. Other markers displayed
instability with only one or two tumors showing MSI. On the basis
of NCI criteria, most benign tumors demonstrated microsatellite sta-
ble (MSS). In the borderline tumors, 10 tumors revealed MSS, 8 tu-
mors had low-frequency MSI (MSI-L), and two tumor had high
frequency MSI (MSI-H). In the malignant tumors, 6 tumors revealed
MSS, 2 tumor had MSI-L, and 12 tumors had high MSI-H. According
to the result, MSL-H is more frequently seen in the malignant tu-
mors. D2S123 and D5S346 were the most frequently altered markers
in the malignant tumors, and D11S860 locus may be involved in the
early step of carcinogenesis.
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OVARIAN CANCERS: EPIDEMIOLOGY, MANAGEMENT AND
PROGNOSIS. SHEFFIELD CASE SERIES OF 871 PATIENTS
S. Abdul, M.E.L. Paterson, J.A. Tidy
Sheffield Gynaecological Cancer Centre, Gynaecological Oncological Sur-
gery, Royal Hallamshire Hospital, Sheffield, UK
Objective: To determine epidemiology, management and outcome
of ovarian cancers managed in Sheffield.
Methods: Prospective case series of 871 patients.
Results: Age = 6-93 yrs, mean = 59. 34% had medical problems: Hy-
pertension = 27%; Ischaemic heart disease = 16%; Diabetes = 6%.
Speciality first referred to: Gynaecology = 45%; Surgery = 35%, Med-
icine = 12% and others = 8%. Symptoms: Abdominal distension =
43%, Pain = 37%, Bloatedness = 16%, Bowel disturbance = 10%,
PMB = 9%, Mass = 3%, Urinary = 1.5% and others , 1%. 42% had .
1 symptom. Symptom duration = 0-48 months. Investigations: USS
= 90%, CT = 34% and MRI = 5%. Ca125 levels raised (.35IU) in: All
ovarian cancers = 85%, Epithelial ovarian cancers (EOC) = 89%, pri-
mary peritoneal tumours (PPT) = 100% and Borderline tumours =
60%. Surgery performed in 95%. Operation was: 1st = 85.6%; 2nd =
13.7% and 3rd = 0.7%. Procedure performed: BSO = 70%, hysterec-
tomy = 68% of those with a uterus, Omentectomy = 68%, Appendec-
tomy = 6%, small bowel resection = 2.5%, Large bowel resection =
5.7%, Omental biopsy = 1.7%, LSO = 6%, RSO = 9% and debulking
= 8%. Incision: Vertical = 93%; Transverse = 7%. Ascites present =
61% and positive of malignant cells = 80%. If Ascites absent, wash-
ing taken in 93% & positive of malignant cells in 23%. Residual dis-
ease range = 0-20 cm: 0cm = 50%; 0-2cm = 27%; .2cm = 23%.
Histology: Borderline = 16%; Epithelial = 74%; PPT = 3%; Germ cell
= 1.2%; Sex cord stromal = 2%; Mixed mullerian = 0.5%; Non-epithe-
lial = 1%; Metastatic = 2.5%. EOC type: Serous = 50%; Endometrioid
= 20%; Mucinous = 11%; Clear cell = 8%; Serous papillary = 5%:
Mixed pattern = 5%. FIGO staging for: All tumours: I = 30%, II =
9%, III = 51% & IV = 10%; Epithelial ovarian carcinomas I = 24%, II
= 9.8%, III = 57% and IV = 9.8%. Chemotherapy: 1: In all tumours
Adjuvant = 60% and Neoadjuvant = 3.3%. 2: EOC = 80%; 3: PPT =
95% 4: Germ cell = 56%. 5-year survival: All ovarian cancers = 41%;
EOC = 38.5%; Borderline = 83%; PPT = 33%; Sex cord = 66%. EOC
stage I = 80%, II = 77%, III = 24% and IV = 28%.
Conclusions: The study highlights the epidemiology, management
and outcome of ovarian cancers
000177
TRENDS IN THE EPIDEMIOLOGY, MANAGEMENT AND
OUTCOMES OF VULVAR CANCERS
S. Abdul1, M.E.L. Paterson1, J.A. Tidy1
1Sheffield Gynaecological Cancer Centre, Gynaecological Oncological
Surgery, Royal Hallamshire Hospital, Sheffield, UK
Aim: To assess trends in epidemiology, management and outcomes
of vulvar cancers.
Methods: Analysis of 230 vulvar cancers managed between 1981
and 2002.
Results: 92% of patients were managed surgically. 6% had primary
radiotherapy. Surgical management, epidemiology and outcomes in
cases managed between 1981 and 2002 are shown in Table 1. Man-
agement has evolved from ‘en block’ radical vulvectomy (13%), to
triple incision (TI) vulvectomy (28%) and then radical wide local ex-
cision (WLE) with inguino-femoral lymphadenectomy (24%), with
no significant change in survival. This has resulted in a reduction in
need for plastic reconstruction (from 40% to 4%), post-operative
morbidity and hospital stay (from 40 to 21 days). Adjuvant radio-
therapy was given in 12%. 5-year all cause survival for SCC was
57%. The mean age has increased from 59 to 72 and this may explain
the small non-significant reduction in all 5-year survival. FIGO
stage, tumour size, grade and lymph node status were prognostic
factors. Age, symptoms, duration of symptoms, tumour histology,
FIGO stage, adjacent skin histology, tumour site, number of nodes
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harvested, hospital stay, recurrence rate, medical co-morbidity were
consistent with previous reports.
Conclusions: Management has evolved towards less radical surgery
with reduced morbidity and hospital stay. Epidemiology and out-
comes are comparable to previous reports.
000178
PREDICTORS OF INGUINO-FEMORAL LYMPH NODE ME-
TASTASES IN VULVAL SQUAMOUS CELL CARCINOMA.
CAN CONTRALATERAL LYMHADENECTOMY BE OMMIT-
TED IN TUMOURS WITH 5 MM DEPTH OF INVASION?
S. Abdul, M.E.L. Paterson, J.A. Tidy
Sheffield Gynaecological Cancer Centre, Gynaecological Oncological Sur-
gery, Royal Hallamshire Hospital, Sheffield, UK
Objective: To assess risk of inguino-femoral lymph node metastases
in vulval tumours with cellular differentiation, tumour size and
depth of invasion as predictors of lymph node metastases.
Methods: Prospective analysis of 90 vulval squamous cell carcino-
mas managed by radical tumour excision and inguino-femoral lym-
phadenectomy, between 1981 and 2002.
Results: Proportion of patients with inguino-femoral lymph node
metastases according to tumour size, tumour differentiation and
depth of tumour invasion in squamous cell carcinoma of the vulva
are shown in table 1. Risk of ipsilateral and contralateral lymph no-
des metastases increases with increasing tumour size, increasing
depth of tumour invasion and worsening cellular differentiation. Of
significance (p = 0.05 Chi squared test), no contralateral lymph node
metastases occurred in the 39 tumours with a depth of invasion of
5 mm, compared to the 17% contralateral lymph node metastases
in tumours with depth of invasion .5 mm.
Conclusions: Tumour size, depth of invasion and cellular differenti-
ation are related to risk of lymph node metastases. No contralateral
lymph node metastases occurred when tumour depth of invasion
was 5 mm. This suggests that contra-lateral lymphadenectomy
may potentially be omitted in patients with tumour depth of inva-
sion 5 mm but further work is needed to validate these findings.
000179
ANALYSIS OF THE OUTCOME OF PATIENTS REFERRED
FOR COLPOSCOPY AFTER ONE SMEAR SHOWING MILD
DYSKARYOSIS
A.S. Ahmed1, G. Goumalatsos2, N. Akbar3, F.G. Lawton1,
M. Savvas2
1Gynaecological Oncology Dept, Guy’s and St Thomas’ Hospital; 2Gynae-
cology Dept; 3Histopathology Dept, King’s College Hospital, London, UK
Objective: To assess the outcome of patients referred for colposcopy
after one smear showing mild dyskaryosis.
Methods: Retrospective analysis of patients referred for colposcopy
after one mildly dyskaryotic smear with a follow up period of 48
months. These women have never had any previous abnormal
smears.
Settings: Colposcopy clinic, King’s College Hospital, London.
Results: We identified 101 patients who were seen in the colposcopy
clinic following one mild dyskaryotic smear. At 6 month, 69 (69%)
patients had repeat smears; 37 (37%) had a normal smear, 16 (16%)
borderline, 11 (11%) had persistent mild dyskaryosis, 3 (3%) inade-
quate smear, and only 2 (2%) showed moderate dyskaryosis. Of the
remaining 32, nine patients (9%) failed to attend and 23 (23%) had
their smears performed after 6 months; of these, 16 (16%) were nor-
mal, 4 (4%) borderline, 2 mild and one was inadequate. Over the
four year period, only 14 patients (14%) required treatment with
loop cone biopsy. Histology confirmed CIN I in one case (1%), CIN
II in 6 patients (6%), CIN III in 3 (3%) and no evidence of CIN in 4
(4%)
Conclusion: 53% of patients who presented with one smear show-
ing mild dyskaryosis subsequently had a normal smear; high grade
CIN occurred in only 9% of patients. The results are reassuring and
reveal a lower prevalence of high grade CIN in such women than
has been previously reported. Our results suggest that colposcopic
referral may not be necessary after only one mildly dyskaryotic
smear.
000180
THE EXPRESSION OF KI-67, P53, ESTROGEN AND PRO-
GESTERONE RECEPTORS AFFECTING SURVIVAL IN
UTERINE LEIOMYOSARCOMAS. A CLINICOPATHOLOGIC
STUDY
S.E. Akhan1, E. Yavuz2, A. Tecer1, A.C. Iyibozkurt1, S. Topuz1,
S. Tuzlalı2, E. Bengisu1, S. Berkman1
1Department of Obstetrics and Gynecology, Division of Gynecologic On-
cology; 2Department of Pathology, Istanbul Medical School, Istanbul,
Turkey
Objectives: To evaluate the level of expression of estrogen receptor
(ER), progesterone receptor (PR), p53 and Ki-67 in patients with leio-
myosarcoma and to investigate the effect of these and to identify the
clinical parameters on prognosis.
Materials and Methods: Twenty-four patients operated for LMS of
uterine origin between 1994 – 2003 at Istanbul Medical School, De-
partment of Obstetrics and Gynecology and Division of Gynecologic
Oncology constituted our study group. The effects of stage, grade,
chemotherapy, radiotherapy, number of mitoses, presence of necro-
sis, Ki-67 and p53 expression, presence of estrogen and progesterone
receptors on survival were evaluated.
Results: The mean follow-up period of patients is 30.42 
25.15 months. The mean overall survival for all LMS patients
was estimated to be 48.4  10.38 months. The cumulative sur-
vival ratio in the 33rd month was 33.08. Age, menopausal sta-
tus, history of prior radiotherapy, number of mitoses had no
statistically significant effect on overall survival in our study al-
though stage had a significant effect. Finding of greater than
10% steroid receptor expression has a positive effect on survival
([ER p = 0.019; log rank = 5.49] and [PR p = 0.023; log rank =
5.14]). There was a survival advantage in patients with Ki-67
expression (p = 0.034; log rank = 4.49) below the median
value.
Conclusion: Surgical staging is an important prognostic factor in
LMS patients. Contrary to the current literature, our findings sug-
gest that estrogen and progesterone receptor positivity greater than
10% may be associated with a better prognosis.
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000181
BRCA1/BRCA2 MUTATIONS IN PRIMARY OVARIAN CAN-
CER PATIENTS
D. Aktas1, M. Gultekin2, G. Aksan2, G. Tulunay3, A.K. Ilhan3,
M. Alikasifoglu1, F. Kose3, K. Yuce2, E. Tuncbilek1, A. Ayhan2
1Department of Genetics; 2Department of Obstetrics and Gynecology,
Hacettepe University, Ankara; 3Department of Obstetrics and Gyne-
cology, Ministry of Health Women and Maternity Teaching Hospital,
Ankara, Turkey
Objective: Individuals carrying inactivating germline mutations in the
breast and ovarian cancer susceptibility gene BRCA1 and BRCA2 have
an increased risk of developing cancer. Germline mutations of the two
genes are transmitted in the autosomal dominant fachion and predis-
pose carriers to the development of ovarian and/or breast cancer.
Methods: We have screened 176 women with primary ovarian can-
cer for mutations in BRCA1 (185delAG and 5382insC) and BRCA2
(6174delT) gene in using mutagenically separated PCR, single strand
confirmation polymorphism (SSCP) analysis followed by sequencing
of variant bands.
Results: Three germlime alterations were identified: A frameshift
mutation (5382insC) was observed in two ovarian cancer patients
with familial cancer history. A unique amino acid substitution in ex-
on 20 (G1748S) was seen in two patients and a splice site variant
(IVS20 1 5 A.T) was deteceted in a patient with ovarian cancer.
Moreover, a complex alteration (IVS20 1 5 A.T and G1748S) was
also noted in two patients. However, 185delAG and 6174delT muta-
tions were not observed in ovarian cancer subjects.
Conclusion: Our preliminary results indicate that BRCA1 gene are
involved in some ovarian cancer patients, both with and without
a family history, demonstrating the importance of BRCA1/BRCA2
in the development of ovarian cancer patients in Turkish population.
000182
CYP1A1 GENE POLYMORPHISM AND RISK OF GYNECO-
LOGIC MALIGNANCIES
D. Aktas1, M. Gultekin2, I. Esinler2, C. Taskiran2, M. Alikasifoglu1,
E. Tuncbilek1, A. Ayhan2
1Department of Genetics, Hacettepe University Faculty of Medicine, An-
kara; 2Department of Obstetrics and Gynecology, Hacettepe University,
Ankara, Turkey
CYP1A1 is involved in xenobiotic metabolism, classified as phase I
cytochrome P-450 enzymes that converts environmental procarcino-
gens to reactive intermediates with carcinogenic effects. To determine
distribution of the CYP1A1*3 polymorphism (in exon 7 of the gene),
we assessed the association of CYP1A1 gene polymorphism in 117
patients with epithelial ovarian cancer, 59 patients with endometrial
hyperplasia, 94 patients with endometrial cancer, 61 patients with
cervical intraepithelial neoplasia (CIN), 85 patients with cervical can-
cer and 202 control subjects. The CYP1A1 Ile/Val genotype signifi-
cantly increase the risk of patients with epithelial ovarian neoplasm
(O.R:5.7, 95%CI: 3.34-9.76). There were significantly differences in the
distribution of Val/Val genotype among all patients (O.R:5.85,
95%CI: 2.4-14.25). Among endometrial hyperplasia, the higher fre-
quency of patients with Ile/Val and Val/Val genotype (O.R: 5.0,
95%CI: 2.6-9.5 and O.R: 4.25, 95%CI: 2.3-7.84), respectively. Further-
more, there was statistical significant increase in relative risk associa-
tion with Ile/Val and any Val genotype between endometrial cancer
patients and controls (O.R: 3.0, 95%CI: 1.74-5.28 and O.R: 2.54,
95%CI: 1.5-4.32), respectively. Among CIN patients, there were signif-
icantly differences in the distribution of Ile/Val and any Val genotype
(O.R: 4.5, 95%CI: 2.41-8.43 and O.R: 3.7, 95%CI: 2.03-6.78). Moreover,
there was significantly differences in the distribution of Ile/Val and
any Val genotype among cervical cancer patients (O.R: 6.4, 95%CI:
3.6-11.4 and O.R: 5.65, 95%CI: 3.2-9.8). Our results indicate that CY-
P1A1 gene polymorphism should be considered as an important risk
modifier in the development of gynecologic malignancies and might
be used as a predictive marker for gynecological carcinogenesis.
000183
USE OF GNRH FOR TREATMENT OF SERTOLI-LEYDING-
CELL TUMER
G.H. Alavi, H. Fattahi, A.S. Fattahi
Ghaem Hospital Medical School,Mashad University of Medical Sciences,
Mashad, Iran
Object: To evaluate the effect of GnRH on sertoli-leydig-cell tumor
in a 45-year old woman. Design: Case report Setting: A university
hospital Patient: A 45-year old woman exhibited persistent elevation
of testosterone (.2ng/ml) four months after surgery for sertoil-ley-
dig-cell tumor of the ovary that suggested the presence of some re-
sidual active tumor.
Result: The serum testosterone levels returned to normal limits after
3 dose of GnRh and all tumor evaluation were negative. The patient
was alive and free of disease 30 months of the treatment with GnRh.
Conclusion: GnRH may be an alternative choice for treatment a per-
sistent or recurrent hormone-producing tumor of ovary.
000184
PERITONEAL TUBERCULOSIS MIMICKING ADVANCED
OVARIAN CARCINOMA: A CASE REPORT
V. Vandenbroucke1, P.H. Moerman2, F. Ulens3, I. Vergote1,
F. Amant1
1Gynaecological Oncology; 2Dep Pathology, UZ Gasthuisberg, Katholieke
Universiteit, Leuven; 3Dep Obstetrics and Gynaecology, M Middelares,
Lommel, Belgium
Background: Mycobacterium Tuberculosis is worldwide the most
frekwent cause of tuberculosis. The disease affects mainly the lungs,
but in one third of patients other organs are also affected. Tubercu-
lous perotonitis is an uncommon manifestation of extra-pulmonary
infection. This can mimic a malignant abdominal proces.
Case: A 62-year-old female patient presented with abdominal swell-
ing, thoracal pain and general malaise. Transvaginal ultrasound re-
vealed ascites with adhesions and an omental cake. CT scan showed
extensive omental and mesenterial implants. A CA-125 level of 538
kU/L was noted. We performed a diagnostic laparoscopy: ovarian
cancer with extensive metastatic disease was suspected. The pathol-
ogy report described necrotic granulomatous nodules. Mycobacteria
could not be demonstrated on direct preparations. A new laparosco-
py was performed to take new peritoneal biopsies for culture. These
were positive for Mycobacterium Tuberculosis, sensitive for all tu-
berculostatics. This resulted in the final diagnosis of tuberculous
peritonitis. Culture of urine and sputae remained negative. Anti-
tuberculosis treatment was started. Radiologic and laparoscopic pic-
tures of peritoneal tuberculosis will be presented.
Conclusion: Tuberculous peritonitis and peritoneal carcinomatosis
might share a similar clinical presentation, radiologic findings and
elevated tumormarker. The potential for tuberculous peritonitis
needs to be taken into account, especially in immigrants from coun-
tries with a high prevalence of tuberculosis. Laparoscopy with biop-
sies is an effective and safe method to make the diagnosis and to test
the sensitivity to the tuberculostatics.
000185
LYMPHOBLASTIC LYMPHOMA PRESENTING AS BILAT-
ERAL GIGANTOMASTIA IN PREGNANCY
G. Vandenberghe1, F. Amant2, F. Claerhout1, D. Selleslag3,
N. Schockaert1
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1Department of Obstetrics and Gynecology, St-Lucasziekenhuis, Asse-
broek; 2Department of Gynecological Oncology, Gasthuisberg, Leuven;
3Department of Hematology, St-Janziekenhuis, Brugge, Belgium
Gigantomastia is a rare condition of excessive and generalized en-
largement of the breasts, presenting in puberty and pregnancy. In
most cases it is related to a benign cause, associated with an excess
of circulating hormones or a target-organ hypersensitivity of mam-
mary tissue to normal hormone stimulation. We present a case of
bilateral gigantomastia in pregnancy as the primary presentation
of a T-cell lymphoblastic lymphoma. Case report. A 29-year-old
woman presented with extreme enlargement of the breasts at 30
weeks of twin-gestation. An excessive physiologic stimulation was
hypothesised and a caesarean section was performed at 33 weeks be-
cause of preterm labor. After delivery magnetic resonance imaging of
the breasts and thorax revealed bilaterally nodulated breasts and a 10
cm diameter mass in the anterior mediastinum. Biopsy of the medias-
tinal mass and the breasts revealed a T-lymphoblastic lymphoma.
Treatment with multi-drug chemotherapy (according to the GMALL
93 protocol) was initiated and after 9 months the disease is in com-
plete remission. Comment. Non Hodgkin’s lymphoma presenting as
bilateral gigantomastia during pregnancy is very rare. A literature
search only revealed two reports where gigantomastia during preg-
nancy was due to a lymphoma. Pregnancy is likely to delay the diag-
nosis of malignancy that provokes gigantomastia, probably resulting
in a higher stage and poor prognosis. Gigantomastia occuring during
pregnancy therefore should alarm the clinician.
000186
ENDOMETRIAL STROMAL SARCOMA COMPLICATING A
24 WEEKS TWIN PREGNANCY
S. Anderman1, M. Moiseyev1, G. Groisman2, S. Ballas1
1Obstetrics and Gynecology; 2Pathology, Hillel Yaffe Medical Center,
Hadera, Israel
Objective: A case of Uterine Endometrial Stromal Sarcoma diagnosed
in pregnancy, which was initially diagnosed as leiomyoma is pre-
sented. This is the first reported case of midtrimester twin pregnancy-
IVF with egg & sperm donation induced, in a 49-years-old woman.
Case: A 49-year-old single woman G2P0 post IVF with a presumed
uterine subserous leiomyoma, was hospitalized on several occasions
for vaginal bleeding that was first noted in the 13-th week of twin
pregnancy. Serial ultrasound examinations revealed a fastly growing
mass on the right side of the uterine fundus. She also developed a se-
vere leukemoid reaction with WBC counts rising from 22,000/ml to
160,000/ml. She delivered spontaneously at the 24-th week 2 prema-
ture newborns. Several hours later she developed hemorrhagic shock
due to intraabdominal bleeding. On emergency laparotomy a rup-
tured malignant mass originating in the uterine fundus with massive
intraabdominal spread was discovered. Total abdominal hysterecto-
my,bilateral salpingooophorectomy and resection of transverse colon
with end to end anastomosis were performed. The pathologic diag-
nosis was: Low and high grade endometrial stromal sarcoma. She
died three weeks after delivery, and none of the newborns survived.
Conclusion: A strong desire to bear children should be carefully as-
sessed in old women. Special attention should always be paid to
rapidly growing uterine masses during pregnancy.
000187
LAPAROSCOPIC BIOPSY VERSUS IMAGE GUIDED BIOPSY
IN DIAGNOSIS OF SUSPECTED OVARIAN CANCER
A. Anwer, R. Naik, R. Athavale, A.D. Lopes, K.A. Godfrey, M.H.
Hatem
Northern Gynaecological Oncology Centre, Queen Elizabeth Hospital,
Gateshead, UK
Background: Laparoscopic and image guided biopsy techniques
have been used for a long time but to our knowledge have
never been evaluated or compared in the management of ovarian
cancer.
Aims: To compare laparoscopic with image guided biopsies for
diagnosis of suspected ovarian cancer with respect to accuracy,
safety and guiding patient management. Materials and Methods:
A retrospective case note study was performed for all biopsies
taken for suspected ovarian cancer over 4 years from 31/6/2000
to 1/7/2004.
Results: 47 image guided biopsies (Group I) and 41 laparoscopic
biopsies (Group II) were evaluated. The mean age in years was
68.2 in groupI and 60.3 in group II. WHO performance status was
.2 in 35 of group I and 7 of group II patients. Tissue sample
was inadequate in 3 group I cases, while all group II samples were
adequate. There were no complications in group I but group II had
1 port site haematoma, 1uterine perforation and 1 anaesthetic com-
plication. There were 4 inconclusive and 2 false negative reports in
group I. Group II had 3 false negative reports. Overall procedure
cost for group I was £290 and £ 2101 for gp II. Cases in groupI
were older (p , 0.01) and had a poorer performance status as com-
pared to group II (p , 0.001) but adequate tissue biopsy (p=ns)
was obtained with no complications (p =ns). Cost ratio was 1:7.2.
Both modalities were found equally useful in guiding patient
management.
Conclusion: Image guided biopsy is an accurate, safe and a cost ef-
fective alternative to laparoscopic biopsy in medically compromised
cases of ovarian cancer.
000188
DETERMINANT FACTORS FOR OMENTAL METASTASES IN
ENDOMETRIAL CANCER
M. Api, P. C¸ilesiz, H. Go¨rgen, N. Ergin, A. C¸etin, M. Yayla
Department of Ob&Gyn, Haseki Education and Research Hospital,
Istanbul, Turkey
Objective: To evaluate the factors in endometrial cancer which may
predict the endometrial spread of the disease to omental tissue
Material and Methods: Data of 47 endometrial cancer patients have
been retrospectively reviewed and analyzed.
Results: Twenty-nine omentum sampled and 18 not sampled endo-
metrial cancer patients (n = 47, mean age: 62,7 9,8) were investi-
gated for omental specimen positivity (3,4%), recurrence (2,1% in
median follow-up of 12 months), lymphovascular space invasion
(LVSI, 20% positive), stage of disease (72,3% stage I), grade of dis-
ease (57,5% grade I, 25,5% grade II and 17% grade III), histologic
type (85,1% endometrioid type adenocarcinoma), CA-125 level
(,35 IU/ml in 85,4%) and adjuvant therapy (36,2% only followed,
53,2% given radiotherapy and 10,6% had chemotherapy). There
was no significant difference in terms of recurrence in omentum
sampled and not sampled patients (p. 0,05). In omental specimen
available subjects there was no statistically significant difference
found for LVSI (p = 0,18, OR = 1,25 95% CI: 0,8-1,9), age (p = 0,62)
and number of lymph nodes sampled (p = 0,35) but statistically
significant difference was detected for CA-125 (p , 0,001), stage
(p = 0,034) and histologic type (p = 0,001) for omental specimen
positivity.
Conclusion: Eventhough the spread, type and agressivity of
tumor seems to be positively correlated with the omental posi-
tivity in the endometrial cancer patients, our results suggest that
none of these factors are reliable to determine the state of
omental metastasis. Omentectomy should still be a part of en-
dometrial cancer surgery since these predeterminant factors
are weakly associated with the decision that it should be
abondoned.
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000189
DETECTION OF HUMAN PAPILLOMAVIRUSES IN OVARIAN
MALIGNANCY BY POLYMERASE CHAIN REACTION
L.A. Ashrafian, S.V. Mukhtarulina, V.I. Voznesenskii
Russian Science Center of Rentgenoradiology, Moscow, Russia
Objective: The role of HPV infection in ovarian cancer is unclear.
The aim of this study was to investigate association between HPV
and epithelial ovarian cancer.
Materials and Methods: The patients group consisted of 67 epithe-
lial ovarian carcinomas (52 serous adenocarcinomas, 15 mucinous
adenocarcinomas). The control group - of 25 nonmalignant ovarian
tissues collected from women with uterine pathology undergoing
pelvic surgery. DNA was isolated from snap-frozen ovarian tumor
tissues and polymerase chain reaction (PCR) kits were used to detect
the presence of HPV in tumor DNA samples.
Results: HPV DNAwas detected in 76% of tumor samples. Only 8%
of normal ovarian tissue samples were positive determined by PCR
(p , 0,001). There was no correlation between HPV infection and
histological type of ovarian cancer. The positive rate is 75% of serous
adenocarcinomas and 80% mucinous adenocarcinomas (p . 0,05).
Among samples of epithelial ovarian carcinomas more frequently
were revealed HPV-18-30%, 52-30%, 55-27%, 83-18%, 39-16% types.
HPV-18 type was significantly higher in mucinous adenocarcinomas
(80%) compared to serous cancer (15%) (p , 0,001); HPV-52 (36,5%),
55 (32,7%) types - in serous adenocarcinomas compared to mucinous
cancer (7% and 7% respectively) (p , 0,01).
Conclusions: Our results support an association between HPV-18,
52, 55, 83 and 39 types and epithelial ovarian malignancy. The prev-
alence of HPV infection in ovarian cancer is much higher than nor-
mal ovarian tissues, suggesting that HPV may play a role in the
development of ovarian cancer.
000190
DETECTION OF HUMAN PAPILLOMAVIRUS DNA IN
OVARIAN CARCINOMA
F. Atalay1, M.Z. Taner2, C¸. Taskiran2, I. Pak3, M. Or4, S. Tuncer4
1Department of Gynecologic Oncology, Ankara Oncology Research And
Educational Hospital, Ankara; 2Gazi University, Faculty of Medicine,
Department of Obstetrics Gynecology, Ankara; 3Department of Pathol-
ogy, Ankara Oncology Research And Educational Hospital, Ankara;
4Metis Biothecnology Laboratory, Ankara, Turkey
Objective: The aim of this study was to examine the presence of
human papillomavirus (HPV) DNA and genotyping in ovarian
carcinomas.
Materials and Methods: The presence of HPV DNA in 100 cases of
primary ovarian cancers was detected in paraffin embedded sam-
ples by polymerase chain reaction (PCR). PCR amplifications were
done by MY09/11 primer set after digestion and phenol-chloroform
extraction of the DNA. HPV PCR positive samples were analyzed
and genotyped by OpenGene automated DNA sequencing system
(Visible Genetics, Canada).
Results: HPV DNA was detected in 9 (9%) samples. HPV-16 DNA
sequences were identified in 7 (7%) while HPV-33 were found in 2
(2%) of the 100 studied ovarian carcinoma samples. Histology of
the 7 HPV-16 positive cases showed that there were 1 granulosa
cell tumor, 6 serous papillary cystadenocarcinoma. HPV-33 were
found positive in 2 (2%) of the studied samples. Histology of the 2
HPV-33 positive cases were serous papillary cystadenocarcinoma.
No other HPV types were detected in the tested samples. So, in
HPV positive cases the histologic dominance was 8 (88,8%) serous
papillary. In studied cervical samples 2 of 5 cases were found po-
sitive, in one HPV 16 and the other case was HPV 33 positive,
while in ovarian tissue of these two cases HPV 33 positivity was
detected.
Conclusion: The HPV posititivity is well known etiologic factor in
cervical cancer, but it is role in ovarian cancer pathogenesis is not
clear with 8% positivity, and if present may plays a minor role.
000191
RADICAL PARAMETRECTOMY IN THE TREATMENT OF
INVASIVE CERVICAL CANCER AFTER SIMPLE HYSTEREC-
TOMY
N. Behtash, H. Ayatollahi, F. Ghaemmaghami, M. Modares Gilani,
A. Mousavi, F. Esfehani
Gynecology Oncology Department,Tehran University of Medical Sciences/
Vali-E-Asr Hospital, Tehran, Iran
Objective: To assess the morbidity and efficacy of Radical Parame-
trectomy (RP) performed following simple hysterectomy in patients
with invasive cervical carcinoma.
Methods: Seven year retrospective chart review identified 5 patients
that underwent RP with pelvic and paraaortic lymphadenectomy
and upper vaginectomy. Data were collected on demographics, tu-
mor stage, histology and survival.
Result: One patient had stage IA lesion, one stage IB1, 2 patients
had stage IIA, and one with unknown stage. One of these patients
had adenocarcinoma. Median age was 41.6 years. The most indica-
tion for hysterectomy was abnormal vaginal bleeding (3 out of 5,
60%). Two patients had pelvic node metastases. Surgical margins in
all 5 patients were tumor free at the time of RP. Two patients with
positive pelvic nodes received adjuvant radiotherapy. Mean follow
up time was 48.8 months. Four patients are alive without disease,
and one patient who had been node positive, died 12 months after
receiving radiation.
Conclusion: RP is an acceptable option for patients diagnosed with
incidental finding of invasive cervical cancer at the time of simple
hysterectomy. Careful selection of RP for patients not having resid-
ual tumor, will obviate adjuvant radiotherapy in most cases.
000192
CANCER OF THE VAGINA AT THE LOWER THIRD TREATED
WITH WIDE LOCAL EXCISION, MODIFIED MARTIUS
FLAP INTERPOSITION AND BILATERAL INGUINAL-PELVIC
LYMPHADENECTOMY
A. Basxaran, M.C. Salman, O¨.T. Gu¨ler, Z. Gu¨ler, D. Katlan,
A. Ayhan
Obstetrics & Gynecology Department, Hacettepe University Faculty of
Medicine, Ankara, Turkey
Background: Vaginal cancer is uncommon and occurring in less
than 2% of the patients with gynecologic malignancies. And approx-
imately 30% of the vaginal carcinoma lesions occur in the lower
third of the anterior wall
Case: Sixty-four year old woman admitted with postmenopausal
bleeding; during pelvic examination suburethral ulcerative 4x3cm
mass was detected. The magnetic resonance imaging of the pelvis re-
vealed mass lesion on the anterior wall of the vagina that is not dis-
cernible from the urethra. Biopsy result of the suburethral mass was
squamous cell carcinoma. Mass was excised till negative borders are
obtained, due to this external 3rd of urethra was also resected. And
modified Martius flap interposition was added to the surgical pro-
cedure to support urethra. Inguinal and pelvic lymphadenectomy
revealed 2 cm left inguinal and 1,5 cm right obturator lymphadenop-
athy, and obturator lymph node was metastatic. Post-operative adju-
vant radiotherapy was also given.
Conclusion: Martius flap interposition is one of the surgical proce-
dures that tend to be forgotten. In homology with use of forceps the
state of art in surgery should not be left to the books on the dusty
shelves of the library in gynecologic oncology.
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000193
DNA PLOIDY ANALYSIS AND THINPREP CYTOLOGY ARE
METHODS OF COMBINED CORRELATION OF THE FINAL
DIAGNOSIS IN A CASE OF EPITHELIAL OVARIAN CANCER
S.R. Babloyan1, Z.G. Voulgaris1, M. Papaethimiou2, A.D. Kyr-
oudes3, P. Karakitsos3
11st Department of Obstetrics and Gynecology, National University of
Athens, ‘‘Alexandra’’ Hospital, Athens; 2Cytological Department ‘‘Alex-
andra’’ Hospital, Athens; 3Department of Histology and Embryology,
Medical School, National University of Athens, Athens, Greece
Objective: The aim of our study is combined correlation of the final di-
agnosis with DNA ploidy and ThinPrep method and amelioration of
thediagnostic accuracy in a caseofmalignant epithelial ovarian tumors.
Methods: Our study was carried out on 105 patients with malignant
epithelial tumors of the ovary. The age of our patients ranged from
22 to 70 years. (Mean value 45.2, SD = 18, 35). For ThinPrep cytology
two smears (1 stained by Papanikolaou and 1 by Feulgen) were pre-
pared. In the Feulgan stained smears DNA ploidy measurements
were performed using SAMBA 2004 image analyzer.
Results: The 60, 95% of the cases of our materials were aneuploid
and the remaining 39, 04% euploid. The results detect diploid DNA
in 20 from 84 cases of IIC-IV stage (23, 80%). In 4 cases with false
negative cytological results aneuploid DNAwas detected in the his-
togram of static cytometry. A statistically significant difference was
observed between the final cytological diagnosis and the ploidy sta-
tus for discrimination of malignant from mesothelial cell (x2 = 11,
25, p , 0,001). The sensitivity, specificity, predictive value of positive
result, predictive value of negative result and the diagnostic accura-
cy of the final cytological diagnosis and DNA ploidy analysis were
97,62%, 100%,100%,91,3% and 98,09% respectively
Conclusion: DNA ploidy can not be use as independent diagnostic
criteria and only combined DNA ploidy analysis and ThinPrep
methods show effective increase of diagnostic accuracy, can be use
for the final diagnosis correlation and determinate of prognosis.
000194
RADICAL VAGINAL TRACHELECTOMY AND LAPAROS-
COPICALLY PELVIC LYMPHADENECTOMY FOR PRESERVA-
TION OF FERTILITY IN EARLY CERVICAL CARCINOMA - A
CASE REPORT
N. Badzakov, N. Pancevski, S. Timceva, B. Sardzovski, A. Krstevski,
B. Velkovski
Special Hospital for Obstetrics/Gynecology, ’Mala Bogorodica’, Minimally
Invasive Surgery, Skopje, Macedonia
Objective: Radical trachelectomy was developed by Dargent as an
alternative surgical treatment for cervical cancer. The techique was
performed by laparoscopic approach and vaginal route, in the same
way as vaginal radical hysterectomy, but the cervix is removed,
only.
Case report: A 32 year old woman presented microinvasive carci-
noma of the cervix after conization without patologic free mar-
gines. The patient desire fertility-sparing menagement. A radical
trachelectomy was performed using the laparoscopico-vaginal ap-
proach. The procedure started with laparoscopic pelvic transperi-
toneal lymphadenectomy, the radical trachelectomy was carried
by the quantity of suctioned fluids and weighed sponges. Opera-
tive time was measured from the time of troacar instillation to
closure of the vaginal skin. Bladder function was assessed objec-
tively after 3 dt day removal of the urinary catheter by perform-
ing ultrasound postvoiding residual urine. The patient was
carefully followed up 1, 3, 6, 12 months with clinical examination,
pap smear and routine ultrasound assessment. As complete clini-
cal, cytological, ultrasound remission was confirmed to one year
after surgical procedure, we accepted that the patient try to be-
come pregnant.
Discussion: In early stage cervical carcinoma, the most important
prognostic factors are tumor size and presence of lympho-vascular
spaces invasion. When tumors are small and there is no invasion of
the lymphatic space, the likelihood of lymph node involvement of
later recurrence of carcinoma is low. In young women with cervical
cancer with low risk factors for recurrence, preservation of fertility
become an option.
000195
A STUDY ON THE EXPRESSION OF P16 GENE, METHYLA-
TION OF P16 GENE PROMOTOR AND HPV TYPING IN
UTERINE CERVICAL NEOPLASIA
D.H. Bae1, S. Jeon1, G.H. Nam2, S.D. Choi1, J.S. Kim1, Y.S. Kim1
1Soonchunhyang University Chunan Hospital OB & GYN, Chunan;
2Soonchunhyang University Bucheon Hospital OB & GYN, Chunan,
South Korea
In cervical carcinogenesis, abnormality of p16 gene such as meth-
ylation of p16 gene promotor was investigated as an important
factor like HPV (human papilloma virus). The aims of our study
are to investigate the expression of p16 gene, methylation of p16
gene promotor, and HPV typing in uterine cervical neoplasia
and to evaluate relationship between them in uterine cervical
carcinogenesis. We investigated the expression of p16 gene with
immunohistochemical method, methylation of p16 gene promotor
with methylation specific polymerase chain reaction (MSP) and
HPV typing with HPV DNA microarray. A total of 140 samples(-
normal 10, CIN1, 31 CIN2, 3 62, invasive cancer, 37) were in-
cluded. All cases were divided into two groups according to
HPV DNA test.
Result: 1. In positive HPV group, P16 gene expression was ob-
served in CIN1 (30.8%), CIN 2,3 (60%) and in invasive cancer
(81%), p16 immunoreactivity was increased during carcinogenesis
and there was increasing tendency of p16 gene expression in
positive HPV group 2. Methylation of p16 gene promotor tended
to be more frequent in negative HPV group especially during
carcinogenesis.
Conclusion: 1. p16 gene expression that tended to be more
frequent in positive HPV cases appears to reflect HPV in-
duced cell cycle dysregulation 2. Methylation of p16 gene pro-
motor may be one of the important mechanism for uterine
cervical carcinogenesis especially in negative HPV cases. 3
The expression and promotor methylation of p16 gene may
be molecular marker for early detection of uterine cervical
cancer.
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EIF-4E EXPRESSION IN THE PROGRESSION OF CERVICAL
NEOPLASIA
J.W. Lee1, S.Y. Song2, J.J. Choi1, C.H. Choi1, J.H. Lee1 B.G. Kim1,
D.S. Bae1
1Department of Obstetrics & Gynecology; 2Department of Pathology,
Samsung Medical Center, Sungkyunkwan University School of Medi-
cine, Seoul, South Korea
eIF4E controls the translation of various malignancy-associated
mRNAs which are involved in polyamine synthesis, cell cycle pro-
gression, activation of proto-oncogenes, angiogenesis, autocrine
growth stimulation, cell survival, invasion and communication with
the extracellular environment. We investigated whether the expres-
sion of eIF-4E is associated with the progression of cervical neopla-
sia. The eIF-4E expression was evaluated by immunohistochemistry
in 89 formalin-fixed paraffin-embedded cervical tissues: 10 normal
cervical specimens, 19 low-grade squamous intraepithelial lesions
(LSILs), 20 high-grade squamous intraepithelial lesions (HSILs), and
40 invasive squamous cell carcinomas (ISCCs). The expression of
eIF-4E was undetectable in normal cervical squamous epithelium,
but had variable staining in the basal layer of normal endocervical
glands. The expression gradually increased in accordance with the
progression from LSIL to HSIL and ISCC (P , 0.001) and was de-
tected in all cases of HSIL and ISCC. These results suggest that eIF-
4E may play a significant role in tumor progression of cervical neo-
plasia and may represent useful markers for malignant transforma-
tion of cervical squamous cells. Further studies would likely result
in the development of novel approaches for early detection and ther-
apy for this disease.
000197
THE ANTI-IDIOTYPIC MONOCLONAL ANTIBODY ACA125
IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN,
FALLOPIAN TUBE OR PERITONEAL CANCER. A PHASE II
TRIAL OF THE AGO-OVAR
A.K. Belau1, R. Kimmig2, K. Wollschla¨ger3, V. Heilmann4,
P. Harter5, F. Hilpert6, J. Sehouli7, S. Loibl8, U. Canzler9,
J. Pfisterer6
1Department of Gynecology and Obstetrics, University Greifswald,
Greifswald; 2Department of Gynecology and Obstetrics, University Es-
sen, Essen; 3Department of Gynecology and Obstetrics, University Mag-
deburg, Magdeburg; 4Department of Gynecology and Obstetrics,
University Ulm, Ulm; 5Department of Gynecology and Obstetrics, HSK
Wiesbaden, Wiesbaden; 6Department of Gynecology and Obstetrics, Uni-
versity Kiel, Kiel; 7Department of Gynecology and Obstetrics, Charite´
Berlin, Berlin; 8Department of Gynecology and Obstetrics, University
Frankfurt, Frankfurt; 9Department of Gynecology and Obstetrics, Uni-
versity Dresden, Dresden, Germany
Background: The majority of patients with advanced ovarian cancer
will recur despite platinum-taxane first line therapy. ACA125 is
a murine anti-idiotypic antibody of the tumor-associated antigen
CA-125 and can lead to the generation of anti-anti-idiotypic antibod-
ies (Ab3).
Methods: This multicenter phase I/II trial included 36 pts. with re-
current OC comparing two vaccination schedules: 9 (group A) vs. 6
injections (group B), 18 pts. in each group. Four sc injections at 2.0
mg were administered every two weeks and then monthly for 2 or 5
additional doses. Primary objective was safety, secondary objective
immunological response.
Results: Treatment was completed as planned in 8 (44%) and 16
(89%) pts. in group A/B. No treatment limiting toxicities occurred in
either group. The most common toxicity related to the vaccine was
Grade 1/2 local injection site reaction. Other toxicities seemed to be
related to the pts. disease and/or the prior chemotherapy. Induction
of Ab3 was observed in all pts. except in two (A) and one (B) pts.
who progressed prior to Ab3 evaluation (median titer 6 weeks after
last vaccination, group A vs B: 359.6 lg/ml (range: 98.9-988.7) vs
209.6 lg/ml (range: 8.6-618.9), p = 0.0556). Both schedules showed
no differences with regard to induction of HAMA (median titer
6 weeks after last vaccination, group A vs B: 8.1 lg/ml (range:
1.4-184.9) vs. 2.0 lg/ml (range: 0.017-13.2), p = 0.100) and IFN-c
secretion.
Conclusions: ACA125 vaccination is safe, well tolerated and in-
duced humoral and cellular immune response. Both schedules were
not different with regard to toxicity and immunogenicity.
000198
TOWARDS UNDERSTANDING LOW LIBIDO IN CERVICAL
CANCER SURVIVORS
K. Bergmark1,2, E. A˚vall Lundqvist1, G. Steineck2
1Department of Gynaecological Oncology; 2Clinical Cancer Epidemiol-
ogy, Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden
The effects of radiotherapy and chemoradiation on hormone levels,
with special regard to testosterone, and its effects on libido and
sexual function in women with cervical cancer is by and large un-
known. Sexual dysfunction, decreased sexual arousability, dyspareu-
nia and low libido is well documented in cervical cancer survivors.
In women oophorectomized for benign conditions, sexual dysfunc-
tion has been documented, and attributed to low testosterone levels.
Treatment with testosterone in women (without cancer) with sexual
arousal disorders often results in increased libido. No similar studies
have been done on women with cancer, because of unknown or un-
wanted effects with regard to cancer. We are performing a pilot
study on hormone levels after different kinds of treatment for cervi-
cal cancer. Our results will be correlated to the women’s own reports
of sexual function. The results are being collected, and the results
will be presented at the conference.
000199
LYMPH NODES INVOLVEMENT AND SURGICAL STRATEGY
IN PATIENTS WITH ADVANCED OVARIAN CANCER
A. Berishvili, K. Laktionov, V. Kuznetsov, A. Kedrova,
N. Kerzkovskaia
Depatment of Gynecology, Blokhin’s Cancer Research Center, Moscow,
Russia
Objective: Aim of the study was to establish pelvic and paraaortic
lymph nodes involvement and surgical strategy in patients with ad-
vanced ovarian cancer.
Methods. In this study we included 35 patients with ovarian cancer
stage III and IV in whom total lymphadenectomy or lymph nodes
resection was added to the standard surgery (panhysterectomy with
omentectomy).
Results. Total lymphadenectomy was performed in 24 (68,6%) pa-
tients. 14 (58,3%) patients had clinically involved lymph nodes and
in 10 (41,7%) cases lymphadenectomy was prophylactic procedure.
Metastasis were found in 41,7% (10 patients). Lymph nodes resection
was performed in 11 (31,4%) patients and in all cases there were clin-
ical signs of their tumor involvement. Metastasis were found in
90,9% (10 patients) that was statistically significantly higher then in
patients with total lymphadenectomy (p = 0,04). Resection of intrao-
peratively enlarged lymph nodes allowed us to predict their meta-
static involvement in 84% cases. Prophylactic lymphadenectomy
revealed metastasis in 25% of cases. Lymph nodes metastasis were
found in 57,1% (20 patients). Pelvic lymph nodes were involved
most often - in 31% of cases, paraaortic - in 11,4%, inguinal - in 8,6%
and pelvic-paraaortic - in 5,7% of cases.
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Conclusion. Metastatic lymph nodes involvement was found in
57,1% of patients with advanced ovarian cancer, mostly - in pelvic
lymph nodes. Pelvic-paraaortic lymphadenectomy is indicated in case
of clinical and/or intraoperative signs of lymph nodes involvement.
000200
LYSOPHOSPHATIDIC ACID AS A TUMOR MARKER IN THE
FOLLOW UP OF PATIENTS WITH EPITHELIAL OVARIAN
CANCER
T. Bese1, M. Barbaros1, S. Cengiz2, E. Baykara2, F. Demirkiran1,
M. Arvas1, C. Sanioglu1, D. Kosebay1
1Obstetrics and Gyncecology, Gynecologic Oncology, Cerrahpasa Medical
Faculty, Istanbul University, Istanbul; 2Institution of Forensic Science,
_Istanbul University, Istanbul, Turkey
Objective: The aim of this study is to detect the plasma levels of Ly-
sophosphatidic Acid (LPA) in epithelial ovarian carcinoma patients
and to demonstrate whether it is usefull in the follow up of the dis-
ease as a tumor marker.
Materials and Methods:29epithelial ovarian cancerpatientswhowere
planed to receive chemotheraphywere included into the study. Patients
recieved 6 doses of chemotheraphy with Paclitaxel 1 Carboplatin. Se-
rum CA 125 levels were measured initially and before each chemothe-
raphy administration. Plasma samples of initial and before every
chemotherapy administration were also collected and stored at - 80 C
in deep freezer for LPA analysis. Gas chromotographic method was
used for plasma LPA detection. LPA levels which were below the level
of detection were assumed to be 0,1 mmol/L for statistical analysis.
Results: The mean preoperative plasma LPA level was 7.216.63
mmol/L. The same value was 5.215.32 mmol/L before the sixth che-
motherapy. While means of plasma LPA values were not different
from each other (p = 0,832)., medians of serum CA 125 were signifi-
cantly different (p = 0,000) which were determined before each che-
motherapy administration. Plasma LPA levels decreased slightly with
chemotherapy administration and there was a weak negative correla-
tion. (Spearman, rs = -0.151, p = 0.034). However, serum CA125 values
declined with chemotherapy administration and there was a signifi-
cant good negative correlation (Spearman rs = -0,596 p = 0,000).
Conclusions: In the follow-up of epithelial ovarian cancer patients
that requiried adjuvant chemotherapy, measurement of plasma LPA
levels have no superiority to the serum CA-125 levels.
000201
THE ANALYSIS OF THE TREATMENT OF OVARIAN CANCER
PATIENTS WITH NEO-ADJUVANT CHEMOTHERAPY
M. Bidzin´ski1, A. Dan´ska-Bidzin´ska1, G. Panek1, P. Sobiczewski1,
P. Derlatka1, P. Raczyn´ski2
1Dpt of Gynaecological Oncology Memoral Cancer Centre, Warsaw;
2Institrute of Mother and Child, Warsaw, Poland
Introduction: Primary surgery and adjuvant chemotherapy is the
standard treatment in ovarian cancer patients. Neo-adjuvant chemo-
therapy is one of the treatment modes in patients with poor general
condition or advanced disease, not adjustable for primary surgery.
The purpose of this study was to evaluate if the efficacy of this new
option of therapy is comparable to the standard method.
Materials and Methods: 319 ovarian cancer patients, FIGO stage III
and IV, have been analyzed. Within this group, 50 women were trea-
ted with neo-adjuvant chemotherapy. 18 patients were operated af-
ter 3 cycles of neo-adjuvant chemotherapy, and 32 patients - after 6
cycles. Results of treatment were evaluated, including disease free
survival, and number of complications. Factors that may influence
the treatment results were also analyzed.
Results: The median of disease free survival in the group treated with
adjuvant chemotherapy (group 3), and operated after 3 cycles of neo-
adjuvant chemotherapy (group 1), were 19 and 20 months, respective-
ly. For the group operated on after 6 cycles of neo-adjuvant chemother-
apy (group 2), the median of disease free survival was 15 months (p =
0,27). The following factors have been found to influence the treatment
results: optimal cytoreduction and tumor grading. There was no differ-
ence in complications rate between three analyzed groups.
000202
GENE EXPRESSION PROFILING IN EARLY STAGE CERVICAL
CANCER
P. Biewenga1, M.R. Buist1, P.D. Moerland4, L.A. Gilhuijs-Pederson4,
A.H. van Kampen4, D. Wehkamp4, J.A. Faase4, L.J. Stalpers2, F.J. ten
Kate5, M.S. Schilthuis1, J. van der Velden1, M.P. Burger1, F. Baas3
1Obstetrics and Gynaecology; 2Radiotherapy; 3Neurogenetics; 4Bioinfor-
matics Laboratory; 5Pathology, Academic Medical Center, Amsterdam, The
Netherlands
Introduction and Methods: Specific alterations in gene expression pat-
terns might be used for molecular classification, prediction of disease
outcome and treatment response. We determined the gene expression
profile in tumours of 28 patients with early stage cervical cancer with
(P) and without (N) lymph node metastasis after radical hysterectomy,
using whole human genome oligonucleotide microarrays.
Results: We used an ANOVA based approach with multiple testing
correction to identify signatures of gene expression. A group of 15
differentially expressed genes between the two groups was found,
including genes that have been related in the literature to tumour
growth and metastasis. Using a classifier, with 1000 random splits of
the data in a training set of 20 patients (11N/9P) and a test set of 8
patients (4N/4P), the mean error rate was 36% with a 0-62 95% CI.
Varying the training set size showed that the proportion of misclassi-
fication decreased as the training set size increased.
Conclusion: We found a possible signature of differentially ex-
pressed genes in patients with early stage cervical cancer with and
without lymph node metastases. Our limited group size probably
accounts for the 36% the misclassification rate, but a decreasing
trend is seen when increasing the training set size. More samples are
necessary to build a significant model.
000203
THE ACTIVITY OF ENZYMES OF ESTROGEN METABOLIC
PATHWAY: RELATION WITH STAGE, GRADE AND HISTO-
LOGICAL SUBTYPE
N.V. Bochkareva1, L.A. Kolomiets2, I.V. Kondakova1, A.B. Muntyan2
1Laboratory of Tumor Biochemistry, Tomsk Cancer Research Institute of
RAMS; 2Gynecology Department, Tomsk Cancer Institute of RAMS,
Tomsk, Russia
The purpose of the study is to reveal the correlation between the ac-
tivity of estrogen metabolic enzymes in malignant endometrial tu-
mors and Stage, histological subtype and differentiation Grade. A
total of 57 patients with Stage ‘in situ’, I and II endometrial cancer
were enrolled into the investigation. Activity of aromatase, catechol-
O-methyltransferase (COMT), glutathione -S-transferase (GST) and
total activity of 2- and 4-hydroxylases were assessed by radioenzy-
matic and spectrophotometric techniques. Variations in activity of
estrogen hydroxylases, COMT and GSTwere found to be dependent
on disease Stage and tumor depth invasion into the myometrium.
The dependence of COMT activity on tumor Grade was also re-
vealed. The COMT activity in well-differentiated endometrial can-
cers was significantly lower compared to that of moderately
differentiated endometrial cancers. The relation of the activity of en-
zymes of estrogen metabolic pathway with the tumor histological
subtype was found. The total activity of estrogen 2- and 4-hydroxy-
lases in non-endometrioid endometrial tumors was higher compared
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to that in endometrioid endometrial tumors. The detected correla-
tion between the activity of enzymes of estrogen metabolic pathway
and Stage and tumor depth invasion indicates that estrogen 2/4-hy-
droxylases, COMT and GST play an important role in tumor inva-
sion and growth. The dependence of the activity of enzymes of
estrogen metabolic pathway in endometrial cancers on histological
subtype and differentiation Grade is under discussion.
000204
RESULTS OF ADJUVANT BRACHYTHERAPY OF STAGE IB
ENDOMETRIAL CARCINOMA
K. Cepni, A. Mayadaglı, M. Eren N. Ozturk, S. Gul
Dr. Lu¨tfu¨ Kırdar Kartal Eg˘itim Arasxtırma Hastanesi, Istanbul, Turkey
Objectives: We aimed to evaluate the pelvic control and survival
rates with only high-dose rate brachytherapy in patients with stage
IB endometrial carcinoma according to FIGO staging system.
Materials and Methods: We evaluated 54 patients retrospectively.
The mean age of the patients were 60. All of the patients were stage
IB. The grades of the 3 patients were unknown, 23 patients were
grade 1, 27 of them were grade 2: and one of them was grade 3. The
operational procedures were total abdominal hysterectomy 1 bilat-
eral salpingo-oophorectomy for 29 of the patients and TAH1BSO1
lymphadenectomy in 25 of them. As adjuvant therapy, these patients
had intracavitary treatment by double ovoids and using Curietron
afterloading apparatus. The mean brachytherapy applied was 30 Gy.
Results: During the follow-up period no adverse event was seen in 33
patients, 14 of the patients had incontinence and 7 had proctitis. The
mean follow-up period was 17 months. Pelvic control was achieved
in 51 of the patients. Approximately 16 months following the end of
the treatment 3 patients had pelvic recurrence. The local control rate
was found to be 94.4%. One of these patients had distant metastasis
24 months after the treatment. One of the patients was dead at the
34th month of the follow-up period due to the disease and 3 of them
were dead because of other reasons. General survival rate was 92.5%.
Conclusion: Brachytherapy alone as adjuvant therapy is sufficient for
local control and survival in Stage IB endometrial carcinoma patients.
000205
PROGNOSTIC FACTORS AND SURVIVAL RATE IN PA-
TIENTS WITH EPITHELIAL OVARIAN CANCER TREATED
WITH PACLITAXEL AND CARBOPLATIN
M.S. Cha, I.J. Choi, M.S. Han, H.H. Kim, G.H. Je
OB & GY, Dong-A University Hospital, Busan, South Korea
Objectives: The purpose of this retrospective study is to identify
prognostic factors and survival rate in patients with epithelial
ovarian cancer treated with combination chemotherapy.
Methods: Carboplatin and Cyclophosphamide were used in stage Ic
and Paclitaxel and Carboplatin were used in stabe II to IV after pri-
mary Surgery.
Results: FIGO stage distribution of 98 patients were 38.2% for stage,
5.9% for stage a, 44.1% for stage b, 11.8% for stage v. The histopath-
ologic type distribution were serous type (45.6%), mucinous type
(36.8%), endometriod type (8.8%), clear cell type (7.4%), mixed type
(1.4%). In 18 patients (26.5%, residual tumor size more than 1 cm af-
ter primary cytoreductive surgery. The overall 5-year survival rate
was 55.7%, and 5-year survival rate of each stage were as follow:
95.8% (stage I&II), 28.4% (stage b), 0% (stage v). The overall survival
time of stage /a were 90 months, stage b 39 months, stage v 17
months. In multivariate analysis of prognostic factors, P value of
FIGO stage, residual tumor volume, and ascitic fluid volume were
calculated as follow p = 0.011, p = 0.026, p = 0.031.
Conclusions: Paclitaxel and Carboplatin were effective chemothera-
peutic agents in stage II to IV serous ovarian cancert patients. FIGO
stage, residual volume, ascitic fluid volume were most significant in-
dependent prognostic factors.
000206
STAGE I ENDOMETRIAL CANCER:TREATMENT AND 5, 10
AND 15-YEAR SURVIVAL
G.B. Chakalova
Department of Gynecological Oncology, NOC, Bulgaria, Bulgaria
From 1987 to 1989,192 patients with Stage I endometrial cancer were
treated and follow-up in our institution. The operation-total hyster-
ectomy and billateral adnexectomy, postoperative radiation therapy
and chormonotherapy were performed. For Kaplan-Meier 5, 10 and
15-year survival were used a Software program SPSS Inc., 1989-
2004. Ther is no significant differences betwen 5, 10 and 15-years
survival.The 15-year survival were 78%-94% and depended of the
depth of invasion and grade of the differenciation. Our data show
that Stage Ia well differentiated endometrial adenocarcinoma is
highly curable disease with 15-year survival of 98%.
000207
RELATIONSHIP BETWEEN PRETREATMENT SERUM SQUA-
MOUS CELL CARCINOMA ANTIGEN AND CYFRA 21-1 LEV-
ELS AND SURVIVAL IN PATIENTS WITH INVASIVE
SQUAMOUS CELL CARCINOMA OF THE UTERINE CERVIX
K.H. Chang, H.S. Ryu, J.P. Lee, S.J. Chang
Department of Obstetrics and Gynecology, Ajou University School of
Medicine, Suwon, South Korea
Objective was to determine the relationship between pretreatment
serum squamous cell carcinoma antigen (SCC) and Cyfra 21-1 lev-
els and survival in patients with invasive squamous cell carcinoma
of the cervix. 131 cervical squamous cell carcinoma patients were
included. Pre-treatment levels of SCC antigen and Cyfra 21-1 were
measured, with a 4 year minimum follow up. 32 recurrent disease
(RD) patients were compared to 99 non-recurrrent disease (NRD)
patients with respect to tumor markers, FIGO stage, lesion size,
lymph node status, and parametrial involvement. Statistical analy-
sis of parameters was conducted for relationship with recurrent
disease prediction and survival. Pre-treatment serum SCC antigen
and Cyfra 21-1 levels were significantly higher in the RD group (P
¼ 0.000). Combined SCC antigen and Cyfra 21-1 levels showed
higher sensitivity for prediction of recurrence (90.6%). Pre-treat-
ment SCC antigen and Cyfra 21-1 levels showed significant corre-
lation with high FIGO stage, large lesion size, lymph node status,
and parametrial involvement (p ¼ 0.000). Normal pre-treatment
levels of SCC antigen and Cyfra 21-1 showed a 5-year survival of
93% and 90% respectively, while elevated levels showed signifi-
cantly decreased survival of 63% and 59%, repectively (p ¼ 0.000).
Odds ratio for cumulative survival were 6.87 for SCC antigen, and
5.07 for Cyfra 21-1, p ¼ 0.000). Initial pre-treatment levels of se-
rum SCC antigen and Cyfra 21-1 are closely related to FIGO stage,
lesion size, lymph node and parametrial involvement in patients
with squamous cell carcinoma of the cervix. Also, these markers
may be independent factors in predicting recurrent disease and
survival.
000208
GENOTYPE DISTRIBUTION OF HUMAN PAPILLOMAVIRUS
IN KOREAN WOMEN
D.Y. Chang, K.C. Jeon, E.S. Lee, M.K. Joen
Dept of OB/Gyn, Ilsan Paik Hospital, College of Medicine, Inje Uni-
versity, Goyang, South Korea
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Objectives: To evaluated human papillomavirus (HPV) genotype dis-
tribution and prevalence according to pathology in Korean women.
Patients and Methods: Women who had abnormal cytology or colpo-
scopywas subjected toHPV test in our hospital. HPVdetection and gen-
otyping were done using commercially available kit (HPV DNAChipaˆ).
We searched articles testedHPVgenotype usingHPVDNAChipaˆ inKo-
reanwomen, anddividedHPVgenotype into threegroupsbypathology.
Results: A total of 1283 cases HPV genotype was detected. The most
prevalent genotype in all HPV-positive cases were HPV-16 (39.5%), -
58 (10.3%), -18 (7.4%), -52 (6.1%), -35 (5.5%), -33 (4.5%). In normal,
HPV-16 (28.0%), -35, -52 (each 7.6%), -51, -68 (each 6.4%) were most
prevalent genotype. The most frequently found genotype in cervical
intraepithelial lesion (CIN) and atypical squamous (glandular) cells
of undetermined significance (ASCUS/AGUS) were HPV-16
(31.3%), -58 (13.5%), -52 (7.4%), -18 (6.5%), -35 (5.6%). In cervical can-
cer, HPV-16 (58.3%) was the most prevalent type and -18 (9.6%), -58
(7.4%), -33 (5.6%), -35 (4.4%) were next most prevalent type.
Conclusions: HPV-16 was the most prevalent genotype in all cervi-
cal findings. HPV-58 was more prevalent genotype than Europe and
US. But, our results are similar to that in China and Japanese. This
data can be used in developing HPV vaccine for prevention of cervi-
cal cancer in Korean women.
000209
IMPACT OF FDG-PET ON RECURRENT CERVICAL CANCER
T.C. Chang1, T.C. Yen2, J.H. Hong3, K.K. Ng4, S. Hsueh5, C.S.
Tsai3, S.Y. Ma2, S.M. Jung5, H.H. Chou1, K.G. Huang1
1Gynecologic Oncology, Dept. Ob/Gyn; 2Nuclear Medicine; 3Radiation
Oncology; 4Diagnostic Radiology; 5Anatomic Pathology, Chang Gung
Memorial Hospital Linkou Medical Center, Kweishan, Taoyuan, Taiwan
Since 2001, we have enforced our multimodality team with the incor-
poration of nuclear medicine physicians with their expertise in posi-
tron emission tomography (PET). We hope the adding of PET,
through a weekly multidisciplinary combined conference may allow
a refined approach in determining and providing appropriate treat-
ments for patients with recurrent cervical cancers. Patients and Meth-
ods After primary treatment, cervical cancer patients were followed
regularly. Once a recurrence suspected, the case was presented at in-
stitutional Multi-disciplinary Gynecologic Oncology Combined Con-
ference. Additional study, including image-guided biopsy or PET
study was arranged according to the conclusion of conference discus-
sion. Treatment was suggested in the conference and the final decision
made by the physician in charge. Medical information including age,
stage and histologic type at, and treatment for primary disease, date
and site(s) as the first evidence of recurrence, contemporarily recog-
nized site(s) of recurrence before combined conference, modification
of disease status after the conference, treatment outcome and survival
status were collected prospectively in the study group and were re-
trieved from medical document for the reciprocal historic control
group. Results 250 patients with primary recurrent cervical cancer
were presented at combined conference between February 8, 2001
and December 31, 2004. A reciprocal patient group composed of con-
secutive patients with recurrent cervical cancer treated before Febru-
ary 2001 was taken as control group. Survival outcome and curative-
intent treatment delivered between groups was comprehensively
compared. We will present a complete set of our data at the meeting.
000210
SURGICAL TRAUMA AND TUMOR GROWTH, METASTASES
AND SURVIVAL – AN ANIMAL MODEL
J.R. Chen1, Y.J. Chen2,3, H.F. Liao3, M.L. Hsu3, C.Y. Huang3, K.L.
Wang1,3,4, Y.C. Yang1,2,3,6
1Department of Gynecology and Obstetrics; 2Radiation Oncology; 3Medi-
cal Research, Mackay Memorial Hospital, Taipei; 4National Taipei College
of Nursing, Taipei; 5Mackay Junior College of Nursing, Taipei; 6Taipei
Medical University, Taipei, Taiwan
Objective: Surgery plays an important role in diseases treating,
especially in cancer. The impact of surgical trauma, especially in
suboptimal operations, on treatment outcome has not been ade-
quately studied. We designed an animal model in mice with sub-
cutaneous tumor implantation followed by surgical trauma.
Material and Method: 30 BALB-C mice were used in this animal
study model. 2.5*104 CT-26 colon cancer cells was injected subcu-
taneously without intravasation at mice’s thighs in 17 of these 30
mice (Day 0). The other 13 mice were used as a control group.
After 14 days of cancer cells implantation, half (9/17) of these
cancer growth mice and half of the control group (7/13) under-
went a traditional laparotomy at their abdomen wall without ma-
nipulation of mice’s original tumor (Day 14). The original tumors
were measured. The survival condition was also recorded. Serum
VEGF, IL-6 and TGF-b1 were measured with ELISA kit (R&D
systems Inc.).
Result: No statistic difference in mean tumor size between these two
groups (p = 0.683) was noted. However, the overall survival has sig-
nificant difference in Kaplan-Meier survival analysis (p = 0.003). IL-6
showed significantly difference between surgical group, non-surgi-
cal group and surgery without tumor implantation group (p =
0.031).
Conclusion: In this preliminary study, surgical procedures with-
out removing all tumors in tumor growth mice may affect their
survivorship compared with non-surgical group. With no differ-
ence in tumor size at primary implantation site, we speculate that
the cause of survival difference maybe due to enhanced tumor
metastases in the study group. Further study on this point is
needed.
000211
PATIENTS WITH MALIGNANT OR PREMALIGNANT CERVI-
CAL LESION HAVE INCREASED RISK OF BECOMING HEPA-
TITIS B CARRIER
T.H. Cheung1, K.S. Chan2, S.S. Siu1, C.K. Lin3, S.F. Yim1, W.K. Lo1
1Obs & Gyn Department; 2Department of Microbiology, Prince of Wales
Hospital, Hong Kong; 3Hong Kong Red Cross, Hong Kong, China
HPV Infection is a prerequisite but insufficient for cervical carci-
noma development. HPV infection and related cellular changes are
mostly transient and those with persistent HPV infection have an in-
creased risk of developing CIN and potentially cervical carcinoma.
The clinical course of HPV infection is therefore similar to that of the
Hepatitis B infection. That is vast majority of infected individuals
would recover spontaneously while a sub-group of patients who fail
to eradicate the virus would become carriers, suffer from chronic
hepatitis and might develop hepatocellular carcinoma. We therefore
postulate that women who develop CIN or cervical carcinoma are
immunologically less competent in eradicating the viral infection.
This weakness in the immune system would predispose them to be-
come hepatitis carriers if they are infected with Hepatitis B Virus.
We have collected blood from 156 patients with cervical carcinoma,
361 patients with high grade CIN and 199 women with other obstet-
ric or gynaecological problem for this study. Patients who have been
infected by Hepatitis B in the past were identified by anti-core anti-
body and these patients were tested for Hepatitis B surface antigen.
Among the 84 patients with cervical carcinoma and 130 patients
with high grade CIN that were tested for Hepatitis B surface anti-
gen, 30.4% were positive. This figure is significantly higher than
the 15.7% recorded in the 89 women without cervical malignancy or
CIN. Our data therefore supported our hypothesis that patients who
developed high grade CIN or cervical carcinoma have inherent
weakness in their immune system.
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000212
QUANTITATIVE ANALYSIS OF HUMAN PAPILLOMAVIRUS
TYPE 16 IN CERVICAL NEOPLASM
W.K. Lo1, S.W. Yeung1, T.H. Cheung1, S.S. Siu1, T. Kahn2, Y.F.
Wong1
1Obs & Gyn Department, Prince of Wales Hospital, CUHK, Hong
Kong, China; 2Deutsche Bank AG, Expert Team Life Sciences, Frankfurt,
Germany
The study was conducted to evaluate the relation between HPV 16
viral load and the severity of cervical lesions. Study population was
recruited from colposcopy and general outpatient clinic. Smears
were taken for DNA extraction. The presence of HPV 16 E6 and E7
was detected using HPV 16 specific PCR reaction. The HPV 16 load
in the specimens that were positive for HPV 16 specific PCR, were
quantified by using real-time PCR assay. Among the 394 women re-
cruited, 148, 121 and 125 had high grade (HG) cervical intraepithe-
lial neoplasia (CIN), low grade (LG) CIN and normal cervix
respectively. Sufficient DNA integrity was available in 347 samples.
Among the 121 HPV 16 positive cases, 70 had HG CIN, 34 had LG
CIN, and 17 had normal cervix. With quantitative analysis using
real-time PCR, the percentages of samples with high number DNA
copies were found to increase with the severity of diseases. A sig-
nificant difference in DNA copies among the 3 groups could also be
demonstrated (HG CIN vs. Normal, p , 0.001; HG CIN vs. LG
CIN, p , 0.001). Area under ROC curve of the HG CIN vs. LG CIN
and Normal was 0.836 and indicated that quantitative PCR had
a good diagnostic value in differentiating HG CIN from the LG
CIN and Normal group. Our data suggested evaluation of viral
load might be useful in the management of patient with abnormal
smear.
000213
THE ROLE OF THE PARA-AORTIC LYMPH NODE DISSEC-
TION IN EPITHELIAL OVARIAN CANCER
Y.H. Cho, D.Y. Kim, D.S. Suh, J.H. Kim, Y.M. Kim, Y.T. Kim,
J.E. Mok, J.H. Nam
Asan Medical Center, Seoul, Korea
The aim was to investigate the incidence of nodal involvement
and to identify the role of systematic para-aortic lymphadenec-
tomy in the epithelial ovarian cancer. Between June 1995 and May
2004, 116 women with epithelial ovarian cancer who undertook
optimal debulking surgery and para-aortic lymphadenectomy
were investigated. Pelvic and para-aortic nodal metastases was
43.1% (50/116) and 35.3% (41/116), respectively. The frequency of
LN metastases according to the stage (clinical stage I, II and III-
IV) were 14.6% (6/41), 52.2 (12/23) and 75.0% (39/52), respective-
ly. In patients with stage Ia, Ib and Ic disease, the rates of nodal
involvement were 11.8% (2/17), 0% (0/2), and 18.1% (4/22), re-
spectively. None of 2 patients with stage I and grade I had nodal
involvement. None of 12 patients with mucinous tumors and of 6
patients with endometrioid tumors confined to the ovary had
nodal involvement. Among 116 patients, para-aortic lymph node
sampling (PALNS) was performed on 71 patients and para-aortic
lymph node dissection (PALND) was performed on 45 patients.
There was no significant difference in both groups with respect to
patient’s characteristics. But there was a significant difference in
PFS in advanced stages (p ¼ 0.029). The patients who undertook
PALND in advanced stage showed the better PFS than the pa-
tients who undertook PALNS. Pelvic and PALND is important in
surgical staging in ovary cancer, but could be omitted in patients
with apparent stage I mucinous and endometrioid disease, and
stage I grade I tumor. Systematic PALND may enhance PFS in ad-
vanced stages but not in early stages in the patients with optimal
cytoreduction.
000214
FISH ANALYSIS IN CERVICAL DYSPLASIC LESIONS AND
SQUAMOUS CELL CARCINOMA USING TISSUE MACRO-
ARRAYS
C. Costa1,2, B. Espinet1, F. Alameda1,2, T. Baro´1,2, M.L.
L. Marin˜oso1,2, P. Fuste´2,3, G. Mancebo2,3, R. Carreras2,3, F. Sole´1,2,
S. Serrano1,2
1Laboratori de Citogene`tica i Biologia Molecular, Servei de Patologia,
Hospital Del Mar, IMAS, Barcelona; 2Unitat de Recerca Translacional de
Tumors So`lids-PRBB, Barcelona; 3Servei de Ginecologia, Hospital Del
Mar, IMAS, Barcelona, Spain
Introduction: The change in the copy number of some oncogenes
has been closely related with the progression of the disease. A num-
ber of studies have shown frequent gains and losses of several spe-
cific regions, like gains in 3q, 5p, 8q, 11q, 17q and 20q, and losses in
3p, 4p, 5q and 18q. The genes involved in these regions have not
been fully identified.
Design: The aim of the present study was to analyse of the genetic
changes of the following oncogenes: c-MYC (8q24), HER2/neu
(17q21) and BCL-2 (18q21), ZNF217 (20q13.2), hTERC (3q26) and
hTERT (5p15), using flurescence in situ hybridization (FISH).
Among 66 analysed patients, 45 were diagnosed as CIN (14 CIN I,
15 CIN II, 16 CIN III), 11 as infiltrating squamous cell carcinoma
(ISCC) and 10 were cervical samples with normal epithelium.
Results: The results of the study are shown in the following table (%
of 3 or more copies of gene).
Conclusions: CIN III and ISCC showed an increased number of
cases with three or more copies of all the probes. In some cases these
aberrations were observed together.
000215
PREDICTION OF CERVICAL INVOLVEMENT IN ENDOME-
TRIAL CANCER BY DIFFERENT PREOPERATIVE EVALUA-
TION METHODS: CLINICAL EXAMINATION, D&C AND
HYSTEROSCOPY
B. Almog, G. Gutman A. Avni, J.B. Lessing, R. Gamzu, I. Levin, D.
Grisaru
Department of Obstetrics and Gynecology, Sourasky Medical Center,
Tel-Aviv, Israel
Objective: Endometrial cancer with preoperatively designated cervi-
cal involvement is usually treated with radical hysterectomy, but in
the absence of evidence of cervical invasion, simple hysterectomy is
preferred. The aim of our study was to evaluate the ability to predict
cervical involvement in endometrial cancer of three preoperative
modalities: clinical examination, dilatation and curettage (D&C) and
hysteroscopy.
Patients and Methods: The records of 114 surgically staged consecu-
tive endometrial cancer patients treated at our institution from 1997
to 2003 were retrospectively analyzed. Preoperative staging proce-
dures, surgical pathology reports, adjuvant treatments, follow-up
and demographic data were recorded.
Results: Fourteen (12.2%) patients had cervical involvement (stage 2)
according to the surgical pathology report. Nine (7.8%) patients
were staged 2a and five (4.3%) patients were staged 2b. Clinical
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evaluation by inspection and palpation had failed to reveal any clue
for cervical involvement. The preoperative diagnostic procedures in-
cluded hysteroscopy in eight patients, D&C in five patients and sim-
ple biopsy in one patient. All the hysteroscopy procedures did not
reveal any suspicious lesion in the cervical canal. Overall out of the
14 patients only two patients (14.2%) who had the traditional frac-
tional D&C were the only patients with preoperative evidence of
cervical involvement.
Conclusion: Hysteroscopy and clinical examination are weak tools
for the prediction of cervical involvement in endometrial carcinoma.
Adding cervical canal curettage while performing either hystero-
scopy or D&C can be of value in order to preoperatively properly
predict cervical involvement.
000216
ABERRANT P53 IMMUNOSTAINING AS A PROGNOSTIC
FACTOR IN EPITHELIAL OVARIAN CANCER; THE IMPACT
OF METHODOLOGY
P. De Graeff1, J. Hall2, A.P.G. Crijns1 G.H. De Bock3, G. Gifford2
J. Paul2, S. De Jong4, J.M. Bartlett4, R. Brown2, A.G. J. Van Der
Zee1
1Departments of Gynaecologic Oncology, The University Medical Centre
Groningen, Groningen, The Netherlands; 2Centre for Oncology and Ap-
plied Pharmacology, Cancer Research UK Beatson Laboratories, Univer-
sity of Glasgow; University of Glasgow, University Department of
Surgery; Royal Infirmary, Glasgow, UK; 3Epidemiology and Statistics;
4Department of Medical Oncology, The University Medical Centre Gro-
ningen, Groningen, The Netherlands
Controversies remain on the prognostic impact of the well-known
tumor suppressor gene p53 in ovarian cancer, which might be due to
methodological differences between available studies.
Aim: To analyse and compare the prognostic impact of p53 immu-
nostaining in two large, clinically well-defined groups of ovarian
cancer patients.
Patients and Methods: Paraffin-embedded samples from 555 pa-
tients were collected (227 Dutch and 328 from the Scottish Gynaeco-
logical Clinical Trials Group). P53 expression was determined by
immunohistochemistry (IHC) using the DO-7 antibody on tissue mi-
croarrays (TMA). TMA and IHC were performed in the same labora-
tory for both groups. For statistical analysis different cut-off points
for aberrant p53 expression were used.
Results: In both groups separately as well as in the whole group P53
staining was associated with poor survival in univariate analysis,
but not in multivariable analysis, while P53 staining did not predict
response to chemotherapy. When using p53 staining intensity only
as a factor, the prognostic impact of weak and strongly positive p53
immunostaining was similar in both groups, but significant discrep-
ancies were observed for negative and positive p53 expression be-
tween the Dutch and Scottish series.
Conclusion: Although the prognostic value of strong positive p53
staining is established in this study, the role of negative and moder-
ate immunostaining remains less clear. Differences in storage and
handling of paraffin-embedded tumour samples might explain vari-
ability in outcome of prognostic factor studies.
000217
DIAGNOSTIC VALUE OF P53 EXPRESSION IN THE STUDY
OF SEROUS EFFUSIONS FROM PATIENTS WITH OVARIAN
NEOPLASMS
K. Kaplanis1, R.M. Valeri2, D. Deligiannis1, P. Papakotoulas3,
L. Kampas2, A. Kiziridou2, C.H. Destouni2, J. Stergiou3
1Gynaecology; 2Cytopathology; 3B’ Chemotherapy, Theageneon, Thessalo-
niki, Greece
Introduction: The diagnosis of malignancy in serous effusion can be
difficult because activated mesothelial cells may resemble malignant
cells mainly when the neoplasm is well differentiated or a borderline
lesion. In recent years a large number of monoclonal antibodies have
been evaluated in order to clarify all these problematic cases. P53
mutations are the most frequent genetic changes in human malig-
nancies, including ovarian carcinomas. The purpose of our study
was the investigation of p53 expression in body effusions borderline
or low grade ovarian tumors.
Materials and Methods: A total of 100 peritoneal fluids and 7 pelvic
washings were examined from patients with primary ovarian neo-
plasms. They included 13 of reactived mesothelium, 9 borderline
lesions, 5 benign neoplasms and 90 ovarian carcinomas. The
specimens were prerared by Liquid based Cytology and immunos-
tained with mouse monoclonal antibody. Then, the results of immu-
noexpression were correlated with the cytologic diagnosis and
histologic ones when available.
Results: The percentage of nuclear staining as well as the intensity
of the stain of epithelial cells was evaluated. Moderate to strong pos-
sitivity was observed in most of the low and high grade tumors as
well as in borderline lesions. No expression of p53 protein was ob-
served in benign effusions.
Conclusions: The p53 overexpression represents: a) an indicator for
malignancy b) combined with cytomorphology may be useful in de-
tecting reactive mesothelium borderline or low grade ovarian carci-
nomas. c) Additionally, Thinprep technique offers significant
advantages in the use of immunocytochemistry versus to Papanico-
laou conventional method.
000218
THE DEVELOPMENT OF SUBSPECIALITY TRAINING AS
GYNAECOLOGIC ONCOLOGY TARGETING TO DEVELOP-
ING COUNTRIES
U.K. Devi1, G. Kasturilal2
1Kidawi Memorial Institute of Oncology, KMIO, Bangalore; 2Institute of
Prevention & Palliative Care, Jammu, India
Introduction: The subspeciality of Gynaecologic Oncology has made
many contributions to women’s health care management in the last
few decades in the developed world. Gynaecological cancers form
more than 45% of cancers in Indian women. According to the Na-
tional Cancer Registry Project of the Indian Council of Medical Re-
search, the incidence of this group of malignancies varies between
31.6 and 49.5 per 10,000 population. Cervical Cancer is the most
common cancer affecting Indian Women and is the leading cause of
death from cancer in women in India. However, the medical person-
nel who manage these patients vary in institutions all over the coun-
try. There are very few institutions in which there is a Department of
Gynaecologic Oncology in India. Moreover less than forty Indian
Obstetricians and Gynaecologists who have exclusively restricted
themselves professionally to the subspeciality of Gynaecologic On-
cology
Materials and Methods: The questionnaire has been formulated and
distributed among the post-graduate students, Colleagues of Obstet-
rics & Gynaecology and other subspeciality colleagues including
Medical, Surgical and Radiation oncologists and general practi-
tioners from 2000 onwards and the opinions regarding the referral
system need for ’Gynaec Onco-Wing’ in Medical Colleges need for
certified courses in Gynaecologic Oncology and the duration of the
course. More than two thousand questionnire forms has been dis-
tributed during Continous Medical Education Programme/work-
shops/Conferences and to few Medical colleges.
Results: Majority of the participants are colleagues and post-
graduate students from Obstetrics and Gynaecology and they felt
that the necessity to have ’Gynaec-Onco Wing’ at Medical Colleges
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and to the essentiality to have two years certified courses in Gynae-
cologic Oncology. However it is the surgical or other oncology col-
leagues opined to have 6 months to one year Fellowship Courses.
However, all of them felt that the ’Gynaec Oncology’ is a unique
subspeciality to serve the women with gynaecologic oncology.
Conclusion: The present survey with the questionnaire suggests that
the necessity of the Development of Gynaecologic Oncology as
a Subspeciality in India and other developing countries to properly
manage the women suffering from gynaecological cancers. We need
to formulate the criteria for their training programme, emphasising
its importance to all the universities, Medical Council of India
through the Organisations.
000219
MATRIX METALLOPROTEINASE-1 PROMOTER POLYMOR-
PHISM AND RISK OF OVARIAN CANCER
E. Diker1, M. Ozturk1, M. Arvas2, P. Cagatay3, D. Kosebay2
1Medical Biology Department; 2Department of Obstetrics and Gynecology,
Gynecologic Oncology Unit; 3Biostatistics Department, Istanbul Univer-
sity, Cerrahpasa Faculty of Medicine, Istanbul, Turkey
Matrix metalloproteinase-1 (MMP-1) plays a key role in invasion
and metastasis of tumor cells by degradation of extracellular matrix.
The 2G/1G single nucleotide polymorphism in the MMP-1 promoter
at -1607 bp has been reported to affect the transcriptional activity.
This polymorphism have been reported to associate with various
cancer types. In this study, our aim was to determine if there is an
association between MMP-1 gene promoter polymorphism and
Turkish patients of ovarian cancer. The blood samples were collected
from 42 cases of ovarian cancer and from 43 aged matched control
subject. PCR and RFLP tecniques were used to determine insertion-
deletion (2G/1G) polymorphism in MMP-1 promoter. The geno-
types did not differ between cases and controls (p.0.05). Genotype
frequencies were 2G/2G 78.6%; 2G/G 21.4%; G/G 0% in the pa-
tients and 2G/2G 79.1%; 2G/G 20.9%; G/G 0% in the healthy con-
trols. We did not observed any differences with allele frequencies
between ovarian cancer (89.3%) and control subjects (89.5%) for 2G
allel. There was no relationship between MMP-1 genotypes and tu-
mor behavior (invasive-borderline) or tumor stage (early-advance).
Our results show that MMP-1 promoter polymorphism did not en-
hance the risk of ovarian cancer development and invasion in Turk-
ish patients.
000220
POSITIVE MARGIN OF CONIZATION: WHAT IS THE RISK
FACTOR?
D.Y. Chang, E.S. Lee, M.K. Jeon, Y.A. Kim
Department of OB/Gyn, Ilsan Paik Hospital, College of Medicine, Inje
University, Goyang, South Korea
Background: Conization is the popular procedure in most cases of
CIN III and some cases of early cervical cancer. Many reports show
the conservative management of positive margin is reasonable. Nev-
ertheless, it is generally accepted the positive margin of conization is
the major cause of additional operation such as hysterectomy. The
aim of this study is to evaluate the risk factors of positive margin
and to reduce the positive rate.
Patients and Methods: 283 CIN or early cervical cancer women who
underwent conization by LEEP entered this study. We evaluated
many possible risk factors for positive margin, including age,
weight, height, BMI, gravity, parity, abortion, severity of disease,
glandular involvement, and HPV infection.
Results: Of the 283 patients, 80 (28.2%) had positive margin in their
conization specimens (CIN 19.3%, cancer 60.7%). Statistically high
significant risk factors of positive margin included older age
(P-trend , 0.001), higher BMI (P-trend = 0.036), higher pathologic le-
sion (P-trend , 0.001), and involvement of endocervical gland (OR
= 2.5, 95% CI 1.5-4.2). Parity (P-trend = 0.054) showed statistically
marginal significance. Weight (P-trend = 0.154), height (P-trend =
0.456), gravity (P-trend = 0.194), abortion (P-trend = 0.813), and
HPV infection (OR = 1.2, 95% CI 0.5-2.5) were not statistically signifi-
cant risk factors.
Conclusions: The data of present study demonstrated that older
age, high BMI, and higher pathologic diagnosis are high statistical
risk factors of positive margin we can know preoperatively. Perform-
ing conization, it can reduce a positive rate that gynecologists con-
sider the risk factors.
000221
PROGESTERONE RECEPTOR-B GENE REACTIVATION IN
POORLY DIFFERENTIATED ENDOMETRIAL CANCER CELLS
BY EPIGENETIC MODIFICATION REAGENTS
S.C. Dowdy1, Y. Xiong2, J. Gonzalez1, Y. Zhao2, N.L. Eberhardt2,
K.C. Podratz1, S. Jiang2
1Obstetrics and Gynecology; 2Biochemistry and Molecular Biology, Mayo
Clinic, Rochester, MN, USA
Objectives: Poorly differentiated endometrial cancers are often pro-
gesterone receptor (PR) negative and recalcitrant to the effects of
progestational therapy. Our aim was to determine if epigenetic inter-
ference using DNA methylation and histone deacetylase inhibitors
could restore progesterone receptor-B (PR-B) expression in PR-B neg-
ative endometrial cancer cells.
Methods: PR-B mRNA, protein, and PR-B promoter DNA methyla-
tion levels were measured before and after drug treatment using re-
al-time PCR, Western blot analysis, and methylation-specific PCR.
Dose-response and duration of effect for aza-deoxycytidine (ADC)
and Tricostatin A (TSA) were characterized. Cellular effects of pro-
longed as well as repeated drug treatment were also examined.
Results: Analysis of KLE and HEC-1B cell lines failed to show PR
gene deletion or mutation, but hypermethylation of the PR-B pro-
moter was present indicating that epigenetic silencing is responsible
for the absent PR-B protein expression. Further supporting this, ad-
ministration of ADC and TSA restored PR-B mRNA and protein ex-
pression. The effects of ADC and TSA were seen at doses as low as
0.05 uM and 0.15nM, respectively, and were synergistic, resulting in
up to a 110-fold induction in PR-B mRNA levels. Sustained reactiva-
tion of PR-B mRNA and protein persisted for 48 hours after drug
withdrawal, and was observed during both prolonged and repeated
drug treatment.
Conclusion: Robust and sustainable PR-B reactivation can be
achieved with low concentrations of ADC and/or TSA. These small
molecule epigenetic modifying agents are currently being studied in
phase II clinical trials and may be useful to sensitize PR-B negative
endometrial cancer to progestational therapy.
000222
PREOPERATIVE SERUM IGF-1 AND IGFBP-3 LEVELS IN
PATIENTS WITH GYNECOLOGIC MALIGNANCIES
P. Dursun1, K. Boynukalin1, M. Gultekin1, M. Velipasaoglu1,
Z. Guler1, N. Yordam2, H. Oguz2, K. Yuce1, A. Ayhan1
1Department of Obstetrics and Gynecology; 2Department of Pediatrics,
Hacettepe University Faculty of Medicine, Ankara, Turkey
Background: It has been suggested that IGF and IGFBP may have
a role in the development of malignancies.
Objective: To compare preoperative serum IGF-1 and IGFBP-3 lev-
els in gynecological cancers prospectively.
Patients & Methods: A total of 66 patients with gynecological can-
cer (31, 22 and 13 patients with ovarian, endometrial and cervical
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cancer, respectively) were prospectively evaluated with respect to pre-
operative serum IGF-1 (, 50 vs. .50), IGFBP-3 (, 3000 vs..3000) and
clinico-pathological variables. Chi-square and Kruskal-Wallis tests
are used for the statistical evaluation.
Results: There were no significant differences in age of patients. Mean
IGF-1 levels were 63, 108.8 and 148.6 in ovarian, endometrial and cer-
vical cancers respectively (p = 0.001). IGF-1 levels were .50 in 51.6%
of ovarian cancers while it was 81.8% and 92.3% in endometrial and
cervical cancers respectively (p = 0.009). Inter-group comparison with
respect to IGF-1 showed significantly low levels in ovarian cancers
compared with endometrial and cervical cancers. Mean IGFBP-3 lev-
els were 2754, 3139.2 and 3169.4 in ovarian, endometrial and cervical
cancers respectively (p = 0.032). IGFBP-3 levels were .3000 in 41.9%
of ovarian cancers while it was 59.1% and 76.9% in endometrial and
cervical cancers respectively (p = 0.09). Inter-group comparisons with
respect to IGFBP-3 levels revealed a significant difference only be-
tween ovarian and cervical cancers (p = 0.034).
Conclusion: IGF-1 and IGFBP-3 may have a role in the development
of gynecological cancers. Role of these proteins and their prognostic
significance should be investigated prospectively.
000223
PEGYLATED LIPOSOMAL DOXORUBICINE (CAELYX) IN
HEAVILY PRETREATED PLATIN RESISTANT OVARIAN CAR-
CINOMA: HACETTEPE EXPERIENCE
P. Dursun, M. Gultekin, F. Coruh, Z. Kocak, M. Velipasaoglu,
K. Yuce, A. Ayhan
Department of Obstetrics and Gynecology, Hacettepe University Faculty
of Medicine, Ankara, Turkey
Background: Ovarian carcinoma is the most lethal female genital
cancer. Despite to the agressive primary therapy including cytore-
ductive surgery and platin-taxol based chemotherapy, a significant
rate of these patients still develop recurrent disease. Recurrent pa-
tients can be recruited to different second-line chemotherapeutics,
however the optimal second line therapy is still a debate.
Objective: To analyze the response rates of recurrent platin resistant
EOC patients to pegylated liposomal doxorubicine (Caelyx).
Material and Method: Twenty-nine patients were retrospectively
evaluated for their response to Caelyx salvage therapy with the regi-
men 50 mg/m2 per 28 days by i.v. administration. Patient responses
were evaluated using serum Ca-125 levels (n = 13, 44.8%), clinical re-
sponses (n = 6, 20.7%) and radiologic findings (n = 10, 34.5%). All
patients had initial staging and debulking surgeries followed by ini-
tial first line platine based chemotherapy at Hacettepe University
during 2003-2005. None of the patients had platine sensitive disease.
Results: Mean age of the patients was 49.09 (29-69). Overall, median
number of Caelyx cycles used was 4.63 (1-9). Caelyx was not the first
choice among salvage therapies in any patient. It was used in sec-
ond, third and 4. choice in six (20.7%), eleven (37.9%) and ten pa-
tients (41.4%), respectively. Of these patients, 8 (27.6%) had partial
response, 5 (17.2%) had stabile disease and the remaining 16 (55.2%)
had progressive disease after the Caelyx usage.
Conclusion: Liposomal doxorubicin is a good alternative with compa-
rable effectivity compared to other second line chemotherapeutic agents.
000224
COMPARISON OF CYCLOOXYGENASE-2 (COX-2) EXPRES-
SION IN SQUAMOUS CELL CARCINOMA AND ADENOCAR-
CINOMA OF THE CERVIX
P. Dursun1, M. Gultekin1, A. Usubutun2, T. Kucukali2, K. Yuce1,
A. Ayhan1
1Department of Obstetrics and Gynecology; 2Department of Pathology,
Hacettepe University Faculty of Medicine, Ankara, Turkey
Background: COX-2 expression is an important factor for develop-
ment and distant metastasis of non-gynecologic cancers. However,
COX-2 expression correlations with clinico-pathological variables of
cervical adenocarcinoma (AdenoCa) have not been investigated
properly.
Objective: To compare COX-2 expression in Squamous cell carcino-
ma (SCC) and AdenoCa of the cervix.
Material and Method: We studied COX-2 expression in 74 women
with cervical cancers, including 56 squamous cell carcinomas (SCC),
and 18 adenocarcinomas (ACs), using commercially available poly-
clonal COX-2 antibodies on Formalin-fixed, paraffin-embedded tis-
sues. All patients initially treated with type 3 hysterectomy plus
bilateral pelvic and paraaortic lymphadenectomy.
Results: There were no significant differences with respect to patho-
logical variables of the both groups. However, patients younger than
35 years of age were significantly higher in SCC group (59% vs.16%,
p = 0.02). Significantly higher COX-2 expression was observed in
cervical adenocarcinoma compared with SCC (39.2% vs. 72.2%, p =
0.01). We could not found a significant relationship between COX-2
expression, grade, size of the tumor, LVSI, presence of lymphatic me-
tastasis (p.0.05). Multivariant analysis with logistic regression test
using histology, LVSI, deep stromal invasion, presence of lymphatic
metastasis revealed histological subtype to be only independent
prognostic factor for the expression of COX-2 (p = 0.02, OR: 2.00;
95% CI: 1.12-3.58.)
Conclusion: Higher COX-2 expression may explain the poorer prog-
nosis of cervical adenocarcinomas compared with SCC. Adjuvant
COX-2 inhibitors may show beneficial effects in the treatment of cer-
vical adenocarcinomas. Further clinical studies are needed to investi-
gate these issues.
000225
MECHANISM OF CEA RELEASE FROM ADENOCARCINOMA
CELL LINE
P. Ebadi
Biology, Kazeroon University, Kazeroon, Iran
Carcinoembryonic antigen (CEA) is one of the most frequently used
tumor markers which is over-expressed in a variety of human can-
cers with epithelial origin such as colorectal, gastric, pancreatic,
ovarian, lung and breast cancer. The precise mechanism by which
CEA is released from the cell surface into serum in cancer patients
has not been known so far. CEA is attached to the plasma membrane
by a glycosylphosphatidylinositiol (GPI) anchor. There have been
some evidences indicating a possible role for an enzyme involve-
ment in CEA release from the cell surface. The GPI-anchor is a sub-
strate for specific phospholipases. Considering these information,
we have investigated the possible role of GPI-specific PI-PLD (GPI-
PLD) in hydrolysis and CEA release. We have, therefore, used re-
verse transcription-polymerase chain reaction (RT-PCR) to verify
GPI-PLD expression in some adenocarcinoma cell lines. By measur-
ing the amount of CEA released from a CEA high producer cell line
in the presence or absence of specific activators/inhibitors we have
obtained evidence for the role of an endogenous GPI-PLD as the
effective enzyme.
000226
CAN WE SUBSTITUTE BRUSH CYTOLOGY FOR BIOPSY IN
THE EVALUATION OF CERVICAL LESIONS UNDER THE
GUIDANCE OF COLPOSCOPY?
Z. Eftekhar1, F. Yarandi1, N. Izadi Mood2
1Department of Gynecology Oncology; 2Department of Pathology, Tehran
University of Medical Sciences / Mirza Koochak Khan Hospital, Tehran,
Iran
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In cervical cancer screening, colposcopically-directed biopsy is the
gold standard method for identifying intra-epithelial and occult inva-
sive lesions of uterine cervix. As biopsy needs special expertise and
the procedure is not convenient for the patients, we sought to evalu-
ate the colposcopically-directed brush cytology as a substitute for bi-
opsy of cervical lesions. We studied a series of 150 women who were
referred for colposcopic evaluation. Colposcopically-directed brush
cytology and biopsy were performed for all patients with abnormal
colposcopic findings. A total of 40 samples were excluded due to un-
satisfactory report of brush cytology. Of the remained 110 samples, 34
abnormal pathology were reported in biopsy evaluations, while only
9 abnormal cytology were reported in brush cytology specimens.
Brush cytology sensitivity and specificity were 26% and 97% respec-
tively. We conclude that colposcopically-directed brush cytology is
not a safe substitute for biopsy in the evaluation of cervical lesions.
000227
INCREASED EXPRESSION OF THE EPIDERMAL GROWTH
FACTOR SYSTEM IN ENDOMETRIOID ENDOMETRIAL
CANCER COMPARED TO HEALTHY ENDOMETRIUM
K. Ejskjaer1, B.S. Sorensen1, S.S. Poulsen2, O. Mogensen3,
A. Forman4, E. Nexo1
1Dept. Clinical Biochemistry, Aarhus University Hospital, Aarhus; 2De-
partment of Medical Anatomy, Panum Institute, University of Copenha-
gen, Copenhagen; 3Department of Gynecology and Obstetrics, Odense
University Hospital, University of Southern Denmark, Odense; 4De-
partment of Gynecology and Obstetrics, Skejby Sygehus, Aarhus Univer-
sity Hospital, Aarhus, Denmark
Background: The epidermal growth factor (EGF) system consists of
four receptors, and a number EGF-related peptide growth factors or
ligands. The EGF system is ubiquitous in human organs, and is in-
volved in malignant transformation. Cyclical variation of the EGF-
system in human endometrium suggests a role in control of normal
endometrial growth. As cancer represents abnormal growth, we hy-
pothesise differences in the expression of the EGF system in endo-
metrial cancer compared to normal endometrium.
Methods: RNA was extracted from fifty-two endometrial cancer
samples (patients; age 67.6 (39.6 - 92); FIGO staging: 5 stage IA; 27
IB; 13 IC; 2 II; 4 III and 1 stage IV) and forty-two endometrial sam-
ples from 14 healthy women (controls, age 24 - 41 years). The four
receptors HER1, HER2, HER3 and HER4 and the 6 ligands: epider-
mal growth factor (EGF), epiregulin (EPI), amphiregulin (AR), trans-
forming growth factor alpha (TGF-a), betacellulin (BCL) and
heparinbinding-EGF (HB-EGF) were analysed by real-time PCR.
Results: All receptors and ligands except EGF and BCL are detect-
able in patient and control endometrium. HER1 (p = 0.0428) and
HER3 (p , 0.0001) show significantly lower expression and HER4
higher expression (p , 0.0001) in patient endometrium. AR
(p , 0.0001), TGF-a (p , 0.0001), and HB-EGF (p = 0.0171) show
higher expression in cancer tissue.
Conclusions: mRNA of all EGF-receptors and four ligands, AR,
TGF-a, HB-EGF and EPI are present in endometrioid endometrial
cancer. HER1, HER3 and HER4, and three ligands show significantly
altered expression in cancer compared to healthy endometrium.
000228
INCIDENCE AND MORTALITY OF GYNECOLOGICAL MA-
LIGNANCIES AND BREAST CANCER: COMPARISON BE-
TWEEN CROATIA AND FINLAND
L.J.> Eljuga1, I. Ma´rton2, M. Strnad3, A. Znaor3, G. Grubisˇic2,
D. Eljuga2
1Clinic for Gynecological and Breast Diseases, Zagreb; 2Clinic for Gyne-
cology and Obstetrics, ’sestre Milosrdnice’ University Hospital, Zagreb;
3Croatian Cancer Register, Zagreb, Croatia
The aim of our study was to compare incidence and mortality of the
most common gynecological malignancies, including breast cancer, in
Croatia and Finland. Both countries have about 5 million of inhabitants
and represent a good model for implementing statistical methods. The
incidence analysis of themost common female malignancies was based
upon data from bothNational Cancer Registers reported for 1978-2001.
In the observed period, a significant increase of breast cancer was regis-
tered. Cervical cancer showing a decrease in the late 1980’s, also started
to increase in 2000. Uterine body and ovarian cancer show a slow but
continuous increase in both countries. A nation-wide screening pro-
gram for cervical cancer started in Finland in 1963 and by the beginning
of 1990s, resulted in a 80% decrease both in the age-adjusted incidence
and mortality. On the other hand, Croatia reports a far more greater in-
cidence of cervical cancer than Finland and EU. The incidence ratio of
CIN III and invasive cervical cancer is alsomuchmore favorable in Fin-
land than in Croatia; breast cancer incidence trends flattened in Finland
in the last 20 years. The reasons for the high incidence rates of these can-
cers in Croatia may be found not only in the social-economic status of
our population, but also in the recentwar influencing such increased in-
cidence rates.Mortality and survival rates are quite similar in both conu-
tries, speaking in favor of the Croatian health care. However, Croatia
obviously needs to improve national programs for cancer prevention.
000229
CONSERVATIVE AND FERTILITY-SPARING SURGICAL
TREATMENT OF OVARIAN CANCER: A CONTEMPORARY
STRATGEY
S.A. Farghaly
The Weill Medical College of Cornell University/The New York Presbyte-
rian Hospital-Cornell University Medical Center, New York, NY, USA
The surgical treatment of choice inpatientswith early stageovarian can-
cer is radical and includes hysterectomy and bilateral salpingoophrec-
tomy. However, in young patients with ovarian cancer confined to
a single ovary, surgical treatment could be conservative with presrva-
tion of the uterus and contralateral ovary. Conservative surgery could
be safely performed in patients with stage IA grade 1 disease. Several
requirments for patients toundergoe conservative surgery: stage IAdis-
ease, young patient with low parity, cncapsulated tumor with no ade-
sions,no invasion of the capsule, lymphatic or mesovarium, negative
peritoneal washing, and close follow-up. The surgical management fol-
lows 2 patterns. First pattern,complete initial surgery;several surgical
proceudres are performed including peritoneal cytology, ipsilateral oo-
phrectomy, omentectomy, multiple peritoneal biopsies, uterine curet-
tage, and pelvicand/or paraaortic lymphadenectomy. The second
pattern, incomplete initial surgery;a restaging surgery is performed in-
cluding:peritoneal cytology, ipsilateral salping-oophorectomy if not
performed initially, omentectomy, multiple peritoneal biopsies, pelvic
and paraaortic exploration with or without contralateralovarian biop-
sies, uterine curettage, and appendectomy for those with mucinous tu-
mor. Patients are followed up very closely after surgery. Data will be
presented. To conclude, conservative surgery for patients with with ep-
ithelial ovarian cancercould be considered in young patients with stage
IA grade 1 disease adequately staged and desiring to preserve fertility
potential. The risk of recurrence in the contra lateral ovary is low. It is
recommended that radical surgery be performedwhen the desire of re-
production is no longer being considered.
000230
GYNECOLOGY ONCOLOGY SUBSPECIALTY TRAINING IN
BRAZIL
E.M.A. Figueiredo, H.A. Koch1, G.M. Moralez
Gynecology Oncology, Brazilian National Cancer Institute, Rio de Ja-
neiro, Brazil
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Gynecology Oncology as a subspecialty is a recent fact. The American
Society was founded in 1973, the European Society in 1983, the Inter-
national Society of Gynecology in 1987 and the Brazilian Society in
1997. In Brazil, a few Institutions offer Gynecology Oncology fellow-
ship, and their curriculum program are not the same. Our objective
was to describe who the Brazilian specialist is. A questionnaire was
applied to 50 surgical oncologists that do gynecological-oncology spe-
cialty (GO) and 50 obstetric gynecologists (OG) in order to evaluate
and compare them in respect to: type and time of training, involve-
ment in research, surgical skill, actual practice in specialty. The medi-
an time of training was longer to GO group than OG group. The GO
group received training to stage (100%), treat (100%) and palliate
(88%) gynecology oncology patients, compared with 64%, 25% and
28% of OG. GO do more research and are more able than OG to do
surgical procedures related to urology (98% x 34%), vascular and gas-
trointestinal surgery (94% x 32%), plastic surgery (78% x 10%), pelvic
exenteration (94% X 6%), vulvectomy (96% x 28%). Our results sug-
gest that despite of heterogeneous training of Brazilian gynecology-
oncologists, their management abilities to conduct gynecologic cancer
are better than obstetric-gynecologists, as evidenced in many re-
searches about survival patterns in patients treated by GO.
000231
USING MRS (MAGNETIC RESONANCE SPECTROSCOPY)
FOR PHARMACOKINETICS OF CISPLATIN GIVEN AT A
DAILY LOW DOSE AS A RADIOSENSITISER IN HUMAN
CERVICAL CANCER TUMOURS
Z. Friebe1, A. Roszak2, W. Medycki3, E. Skorupska1
1Department of Gynaecology Poznan University of Medical Sciences,
Poznan; 2Radiotherapy and Gynaecological Oncology Department Great
Poland Cancer Centre, Poznan; 3Institute of Molecular Physics Polish
Academy of Sciences, Poznan, Poland
Objective: Radiotherapy and chemotherapy are often administered
concurrently in an attempt to take advantage of postulated biochem-
ical or molecular interactions between the two modalities. The objec-
tive of this study was to evaluate radiotherapy as a cisplatin-
sensitizer in a cisplatin-esistant cervical cancer cell line.
Methods and Methods: 195Pt spectra were acquired at 37C on
a Bruker AMX-500, spectrometer using a broad band frequency probe.
Typical conditions for 195Pt NMR at 107.28 MHz were: NS = 40 000,
90 pulse ; 30 ls, acquisition time (AT) = 0.1 s. GROUP I: In vivo hu-
man cervical cancers were irradiated with external beam radiation at
doses of 500, 1500, and 4500 cGy in a single fractionation. Twelve
hours after XRT, cells were treated with a dose of cisplatin for 2 hours.
Cell attachement was determined by cell counts using a MRS. GROUP
II: A total of 25 patients with inoperable cervical cancer were treated
by daily radiotherapy; sensitisation was obtained by administration
of 5 mg cisplatin 30 min before each irradiation session. A complete ki-
netic profile of platinum was established after the first dose and at the
end of treatment for 22 patients. Pt was quantified by MRS procedure.
Conclusions: The detection limit for quantifiable cisplatin derivates
is estimated at 500 microM using 195Pt NMR. In addition these
magnetic resonance techniques can provide useful information
about the metabolisms of cisplatin in cervical cancers. The present
findings suggest that a cisplatin in combination with radiation
therapy may lead to a therapeutic benefit.
000232
ROLE OF SUBOPTIMAL TREATMENT IN RESISTANCE TO
CHEMOTHERAPY
C. Gercel-Taylor, D.D. Taylor
Dept of Obstetrics, Gynecology and Women’s Health, University of
Louisville School of Medicine, Louisville, KY, USA
Ovarian cancer is the leading cause of death from gynecological
malignancies. Most patients are diagnosed when disease has
spread beyond the pelvis with a 5-year survival of less than
20%. Patients with advanced disease initially respond to first-line
therapies of cytoreductive surgery and chemotherapy consisting
of a platinum analogue and Taxol. Drug resistance subsequently
develops resulting in treatment failures. Our purpose was to
study the expression of DNA damage genes in ovarian cancer
that survive treatment with carboplatin (Carbo) and paclitaxel
(Tax). Cells isolated from one patient during progression of dis-
ease were used. UL-3A was isolated at initial diagnosis, UL-3B
after failure to cisplatin and paclitaxel, and UL-3C at final stages
of disease. LD30, LD50 and LD70 doses were used to treat cells.
DNA microarray was used to study gene expression patterns.
Sensitivity to Carbo and Tax of surviving cells demonstrated
both significant increase and decrease. Combination of Carbo
and Tax resulted in increased resistance to both agents in UL-3B
cells following treatment. Specific genes were affected by chemo-
therapy. MDM2 and MSH6 expression was increased with Carbo
or Tax treatments while 53BP1, EXT1, H2AFL and UNG expres-
sion was decreased. Combined Carbo and Tax treatments re-
sulted in decreased expression of ATR, CHEK1, PPM1D, PRKDC
and increase in RAD1, CDS1 and ATRX. Analysis of ovarian
cancer cells demonstrates specific gene expression patterns that
may be involved in drug resistance. This novel approach pro-
vides information on the molecular mechanisms involved in
drug resistance that can be utilized in the treatment of these
patients.
000233
NONDYSGERMINOMATOUS OVARIAN TUMORS: CLINICAL
CHARACTERISTICS, TREATMENT, AND OUTCOME
F. Gahemmaghami
Gynecology Oncology Department, Tehran University of Medical
Sciences, Tehran, Iran
In this study, our aim was to determine possible prognostic fac-
tors for relapse and to determine the efficacy of various treat-
ments for managing relapse. We retrospectively reviewed 21
patients who had surgical resection of NDOGCT and received ad-
juvant chemotherapy. The median age at presentation was 18
years with median follow up of 20. Histologic records showed
that patients had the following types of tumors: immature terato-
ma, mixed germ cell tumor, yolk sac tumors, and embryonal car-
cinoma. Initial surgery included unilateral salpingo-oophorectomy
in 16 patients and cystectomy in 5 other patients. Three patients
underwent a surgical laparotomy 1 to 12 months after the initial
surgery. Four patients underwent debulking surgery that included
total abdominal hysterectomy and bilateral salpingo-oophorecto-
my 1 to 6 months after the initial surgery. After the initial sur-
gery, 13 patients immediately began to receive chemotherapy and
the other 8 patients received chemotherapy at a median of 5.5
months (range, 1-40 months) after the initial surgery. Post opera-
tive chemotherapy included the following: bleomycin, etoposide,
and cisplatin (n = 17); vincristin, actinomycin-D, and cyclophos-
phamide (n = 2); methotrexate, etoposide, and cisplatin (n = l);
and cisplatin (n = l). 31% of the patients suffered a relapse after
cisplatin combination chemotherapy. The median disease free sur-
vival was 40 months and the median overall survival was 50
months. The 5 year survival rate was 39%. This study indicates
that there may be a role for aggressive cytoreductive surgery in
advance NDOGCT, and to improve the management of relapse,
we need to be looking for feasible second-line combination che-
motherapy.
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000234
GENETICALLY ENGINEERED ENDOTHELIAL CELLS EXPRES-
SING VRL-LOADED FGFR1/TRAIL/APO-2L CAUSED APOPTOTIC-
INDUCED DRUG DELIVERY (AIDD) IN CHEMORESISTANT
STROMAL BREAST CARCINOMA
J. Giannios1, G. Kanellopoulos1, P. Lambrinos2, N. Alexandropoulos3
1Dept. of Oncology, GSHA and Dept. of Radiation Oncology, IASO; 2Dept.
of Oncology, PF; 3Dept. of Clinical Biochemistry and Genetics, IH, Greece
Inability of intratumoural drug delivery is the mainest cause of che-
motherapy failure. In this study, we use genetically engineered en-
dothelial cells to deliver vinorelbine by apoptosis in chemoresistant
stromal breast Ca overexpressing MDR-1 and bcl-2. We genetically
engineered endothelial cells expressing fusion protein FGFR1/
TRAIL/Apo-2L which we loaded with vinorelbine-tartrate (VRL).
After exposure to the FGFR1 ligand, FGF1 whose expression is ele-
vated in breast tumours causes extensive and irreversible apoptosis
in the VRL-loaded endothelial cells. Breast stromal Ca cells were ob-
tained by surgical excision from a chemoresistant patient. IHC ex-
hibited overexpression of FGF1, MDR1 and bcl-2. Post-treatment of
breast Ca cells with VRL loaded FGFR1/TRAIL/Apo-2L expressing
endothelial cells, we observed by transmission electron microscopy
apoptosis of these endothelial cells forming drug-loaded apoptotic
bodies which were phagocytosed by the breast Ca cells which ex-
hibited irreversible D2 apoptotic signs indicating a bystander killing
effect. Biochemically, we detected TRAIL/Apo-2L induced apoptosis
which activated caspase-8 (FLIP) mediated proteolytic activation
of caspase-3 a and tBID-mediated release of cytochrome-c and mito-
chondrial activation of caspase-9 forming the caspase-9/Apaf-1/cyt-c
complex. Enhanced transport of vinorelbine through permeable apo-
ptotic membranes of endothelial cells into breast Ca cells caused in-
hibition of bcl-2 expression. Flow cytometry exhibited cell cycle
arrest at G2/M phase. MTT and BrdU assays exhibited inhibition of
metabolic activity and DNA synthesis of tumour cells compared to
controls. Concluding, apoptosis induced drug delivery (AIDD) has
induced a bystander killing effect leading to eradication of breast ca
cells by circumvention of chemoresistance caused by MDR-1.
000235
VINORELBINE AND ANASTROZOLE INDUCE APOPTOSIS
AND ANTIANGIOGENESIS IN BREAST DESMOPLASTIC
STROMAL CARCINOMA POSTMENOPAUSAL PATIENTS
OVEREXPRESSING ER AND ECM PROTEINS FIBRONECTIN
AND TENASCIN
J. Giannios1, G. Kanellopoulos1, P. Lambrinos2, N. Alexandropoulos3
1Dept. of Oncology, GSHA and Dept. of Radiation Oncology, IASO; 2Dept.
of Oncology, PF; 3Dept. of Clinical Biochemistry and Genetics, IH, Greece
It was thought until now that the majority of breast Ca was epithelial.
However, the mammary stroma becomes desmoplastic during malig-
nant transformation which is characterised by overexpression of ECM
proteins fibronectin and tenascin. Stromal tumours could circumvent
detection by a mammogram due to their depth inside the breast. We
obtain by surgical excision from 100 breast cancer patients tumour
cells. From these tumours, 44 were epithelial, 37 were stromal and 19
were of both origins. IHC and PCR exhibited overexpression and upre-
gulation of fibronectin, tenascin and ER. Post-treatment with anastro-
zole and vinorelbine-tartrate, we observed downregulation of FN, TN
and ER. Flow cytometry exhibited cell cycle arrest at GG2/M due to
MT depolymerization. BrdU and MTT analysis exhibited exhibition of
DNA synthesis and metabolic activity in tumour cells compared to
untreated controls. Furthermore, TEM exhibited D2 apoptotic signs of
tumour cells characterised by lysis of plasma membrane releasing
apoptotic bodies in the milieu which were phagocytosed by adjacent
tumour cells leading to a bystander killing effect (BKE). Finally, due to
inhibition of fibronectin which is an ECM macromolecule that is medi-
ator of angiogenesis, we observed anti-angiogenesis with a Matrigel
plug assay. Concluding, we induced apoptosis and antiangiogenesis in
stromal breast Ca after the combined administration of anastrazole
and vinorelbine.
000236
TACCALONOLIDE AND VINORELBINE INDUCE PUMA,
HYPODIPLOIDY AND MULTINUCLEATION, SUPPRESSION
OF MICROTUBULE DYNAMICS, CELL CYCLE AT G2/M AND
APOPTOSIS IN ADVANCED BREAST CARCINOMA
J. Giannios1, G. Kanellopoulos1, P. Lambrinos2, N. Alexan-
dropoulos3
1Dept. of Oncology, GSHA and Dept. of Radiation Oncology, IASO;
2Dept. of Oncology, PF; 3Dept. of Clinical Biochemistry and Genetics,
IH, Greece
Low aqueous solubility of vinorelbine is a high substrate for MDR1
and MRP2 inserted in rtumoural plasma membrane. B-tubulin muta-
tions are cross resistant to vinorelbine. We treat with vinorelbine and
taccalonolide advanced mammary adenocarcinoma characterised by
overexpression of bcl-2, MDR1, MRP2 and mutant b-tubulin according
to PCR, WB and IHC. We use a combination of a MT depolymerizing
agent such as VRL with a polymerizing agent taccalonolide which is
more soluble in aqueous solvents than VRL reducing affinity for Pgp
by being a poor substrate. Although these agents share the same target,
they act in different ways. Post-treatment, although VRL and taccalo-
nolide are structurally unrelated, they bind to mutually exclusive sites
on the tubulin unit. After binding of MTCs to MT, there was synergistic
bcl-2 phosphorylation, bax overexpression,circumvention of b-tubulin
polypeptides, MDR1 and MRP2 due to high hydrophilicity of taccalo-
nolide and p53 PUMA. Flow cytometry showed blockage of cell prolif-
eration at the metaphase-anaphase (G2/M). There was enhancement in
hypodiploid population of tumour cells, multinucleation, abberant
spindle formation, nuclear convolution, suppression of MT dynamics
and formation of MT bundling. Both drugs induced release of mito-
chondrial cyt-c. There was immunosuppression by inhibiting T-cell
proliferation. BrdU and MTT exhibited inhibition of tumour cell prolif-
eration. We observed nuclear factor kB-induced apoptosis displayed by
nuclear condensation and fragmentation. Concluding, we observed
synergy between taccalonolide and vinorelbine in potentiation of apo-
ptosis in advanced breast Ca circumventing chemoresistance.
000237
ANGIOGENESIS, ESTROGEN AND PROGESTERONE RECEP-
TOR COUNT IN TAMOXIFEN INDUCED ENDOMETRIAL
PATHOLOGIES
B.O. Goker1, T. Bese2, S. Ilvan3, I. Cansever1, D. Kosebay2
1Istanbul University Cerrahpasa Medical Faculty Obstetrics and Gyne-
cology Department, Istanbul; 2Istanbul University Cerrahpasa Medical
Faculty Obstetrics and Gynecology Department, Division of Gynecologic
Oncology, Istanbul; 3Istanbul University Cerrahpasa Medical Faculty
Pathology Department, Istanbul, Turkey
Introduction: In the current study we tried to find out the possible
mechanisms responsible for tamoxifen (TMX) induced histopathologic
changes in the endometrial tissue, as well as, individual responses
differing between subject, by studying angiogenesis, estrogen recep-
tor (ER) and progesterone receptor (PR) count.
Materials and Methods: Endometrial biopsies were taken from 52
postmenopausal patients who used TMX more than 12 months. To
define angiogenesis, ER and PR concentration in the endometrium,
immunohistochemical dying with CD-31, ER and PR antibodies
were performed. All the results were compared according to the
endometrial pathologies, endometrial thickness and morphologic
appereance.
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Results: The mean age of the patients was 52,6  8,9 years. The
mean thickness of double layered endometrium was 12,3  5,9 mm.
The ratio of pathologic endometrial finding was 66.7% at the endo-
metrial thicknesses equal to or above 10 mm and 45.5% below 10
mm. There was no statistical differences in CD31, ER ve PR numbers
between these 2 groups. The number of CD31 dying was 14.8 1 7.8
in atrophic,inactive, proliferative and secretuar endometrium where-
as this number was 22.5 1 9.4 in polyp, hyperplasia and endometrial
cancer. There was significant difference of microvessel count be-
tween these 2 groups (p = 0.003).
Conclusion: In this study the correlation between endometrial thick-
ness and morphology due to TMX effect and tissue angiogenesis, ER
and PR number cannot be well established. However, the difference
in microvessel count between the benign and pathologic endometri-
al findings may focus the attention to angiogenesis for future studies
investigating nonestrogenic mechanisms of TMX.
000238
THE EFFICACY OF HYPERBARIC OXYGEN THERAPY (HBOT)
IN THE TREATMENT OF PELVIC RADIATION-INDUCED
LATE SIDE EFFECTS
D. Grisaru1, R. Almog1, G. Fishlev2, N. Gal2, T. Safra3, A. Avni1,
J.B. Lessing1
1Department of Obstetrics and Gynecology, Sourasky Medical Center,
Tel-Aviv; 2Institute of Hyperbaric Medicine, Assaf-Harofe Medical Cen-
ter, Zrifin; 3Department of Oncology, Sourasky Medical Center, Tel-Aviv,
Israel
Objective: We investigated the efficacy of hyperbaric oxygen thera-
py in the management of patients with radiation-induced late side
effects, that failed previous interventions.
Patients and Methods: The records of 10 patients were evaluated.
The primary cancer sources were cervix (5), vagina (2), uterus (1), rec-
tum (1) and bladder (1). All patients received a full pelvic dose of ra-
diotherapy. Seven patients were also treated with surgery following
the radiation treatment (hysterectomy-3, colectomy-1, vaginectomy-1,
cystectomy-1 and exanteration-1). Five patients suffered from chronic
cystitis, with 2 cases of vesico-vaginal fistula; 6 patients had chronic
proctitis, with 2 cases of recto-vaginal fistulas; one patient presented
with long standing open skin wound following surgery. All patients
had imaging studies and biopsies to rule out active malignant disease.
All patients received hyperbaric oxygen therapy with 100% oxygen,
at 2 atmospheres, for 90 minutes (2ATA 90 min), each session.
Results: Mean patient age was 59 years (range 32 to 88). Mean time
between completion of radiation therapy and onset of symptoms
was 38 months (range 4 to 228). Patients received an average of 28
HBOT (range 16 to 40). Nine patients reported improvement in blad-
der and bowel symptoms and decrease in vaginal discharge. One
patient completed treatment with symptomatic improvement, but
developed lung metastasis. None of the patients reported side effects
of the HBOT.
Conclusion: HBOT is a safe and effective treatment modality in the
management of radiation-induced late side-effects, such as soft tis-
sue necrosis, cystitis, and proctitis, in patients that other forms of
management have failed.
000239
A ROLE OF INFLAMMATORY DISEASES OF FEMALE GENI-
TAL TRACT IN THE FORMATION AND PROGRESSION OF
ENDOMETRIAL CANCER
D.S. Glyakin, A.G. Gunin
Department of Obstetric and Gynecology Chuvash State University,
Cheboksary, Russia
To reveal possible interrelationships between chronic inflammatory
diseases of female genital tract and endometrial carcinoma, women
with histologically confirmed endometrial adenocarcinoma were ex-
amined to find signs of chronic inflammatory diseases of female gen-
ital tract. Women who were subjected to hysterectomy and in whom
diagnosis of endometrial adenocarcinoma was then verified histo-
logically (n ¼ 73) were involved in the study. It was found that
57.6% of women with endometrial carcinoma had an episode of in-
flammatory pelvic disease in their life. In women with endometrial
cancer who had an episode of inflammatory pelvic disease in their
life, leukocyte infiltration in endometrial stroma of endometrial ade-
nocarcinoma was found in 69.6% of cases, but leukocyte infiltration
on cancer samples was found only in 42.9% of cases in patients who
did not mention inflammatory pelvic disease in their life. Archive
slides of endometrial adenorarcinoma was reviewed to find signs
of inflammation. Leukocyte infiltration was found in endometrial
stroma in 77% of samples with poorly differentiated endometrial ad-
enocarcinoma, in 58.8% of samples with moderately differentiated
endometrial adenocarcinoma, in 42.8% of cases in samples of well
differentiated endometrial adenocarcinoma and in 33.3% of cases of
atypical endometrial hyperplasia. Thus, microscopic examination
showed that leukocyte infiltration in endometrial cancer samples is
more often present in cancers with low degree of differentiation. Re-
sults allow to make preliminary conclusions that inflammatory
response to infection plays a role in the formation of endometrial
cancer and in the progression of this pathology. This work was sup-
ported by grants from RFBR (03-04-48000).
000240
HISTONE DEACETYLASE INHIBITORS ENHANCE ESTRADIOL-
INDUCED PROLIFERATION AND HYPERPLASIA FORMATION
IN THE UTERUS OF MICE
A.G. Gunin, I.N. Kapitiva, N.V. Suslonova
Department of Obstetrics and Gynecology Chuvash State University,
Cheboksary, Russia
It is suggested that estrogen hormones affect mechanisms that man-
age histone acetylation in the cell. However, it is not known how the
level of histone acetylation affect estrogen-dependent processes in
the uterus, especially proliferation and morphogenetic changes.
Therefore, effects of histone deacetylase blockers, trichostatin A and
sodium butyrate, on proliferative and morphogenetic reactions in
the uterus under long-term estrogen treatment were examined.
Ovariectomized mice were treated with estradiol dipropionate or ve-
hicle and trichostatin A or sodium butyrate or with no additional
treatments for a month. In animals treated with estradiol and tri-
chostatin A or sodium butyrate, uterine mass was increased, abnor-
mal uterine glands and atypical endometrial hyperplasia were
found more often. Both histone deacetylase inhibitors enhanced pro-
liferation (the numbers of mitotic cells and BrdU-positive cells) in lu-
minal and glandular epithelia, in stromal and myometrial cells.
Levels of estrogen receptors-alpha and progesterone receptors in
uterine epithelia, stromal and myometrial cells were decreased in
mice treated with estradiol with trichostatin A or sodium butyrate.
Expression of beta-catenin in luminal and glandular epithelia was
decreased under treatment with estradiol with trichostatin A or so-
dium butyrate. Both histone deacetylase inhibitors have similar uni-
lateral effects, however the action of trichostatin A was more
expressed. Thus, histone deacetylase inhibitors exert proliferative
and morphogenetic effects of estradiol in the uterus. Actions of tri-
chostatin A and sodium butyrate are associated with changes in ex-
pression of estrogen receptors-alpha, progesterone receptors and
beta-catenin in the uterus. This work was supported by grant from
RFBR (03-04-48000).
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SIMULTANEOUS ESTIMATION OF THE HPV E2/E6 DNA RA-
TIO BY MULTIPLEX PCR IN CERVICAL PRENEOPLASTIC
AND NEOPLASTIC LESIONS
S.J. Han1, T.G. Ahn1, B.R. Lee2, W.S. Ahn3
1Department of Obstetrics and Gynecology; 2Department of Bio-
chemistry, College of Medicine, Chosun University, Gwangju; 3De-
partment of Obstetrics & Gynecology, Catholic Medical School, Seoul,
South Korea
Background: Integration of HPV DNA into chromosomal DNA is
considered an important change in the carcinogenesis of cervical epi-
thelial cells. The viral E2 gene is often disrupted by this process, re-
leasing the normally suppressed viral E6/E7 oncogenes, a key factor
in oncogenic progression.
Objective: To investigate the methods for evaluating HPV E2/E6
DNA ratio by multiplex PCR in cervical preneoplastic and neoplas-
tic lesions.
Methods: Simple DNA PCR and multiplex PCR were applied for
the detection of an intact HPV E2, E6 gene in infected epithelial cells
from the cervix with LGSL, HGSIL and invasive cervical carcinoma.
33 LGSIL (HPV16: 25, HPV18: 8), 14 HGSIL(HPV16: 9, HPV18: 5)
and 12 ICC (HPV16: 8, HPV-18: 4) samples were analyzed with
MPCR. The correlation between E2/E6 ratio and lesion stage was
examined.
Results: E2/E6 DNA of HPV 6, 11, 16 and 18 were simultaneously
amplified by this MPCR method. With MPCR, 2 LGSIL (HPV16: 2,
HPV18: 0) [6%], 8 HGSIL (HPV16:5, HPV18: 3) [61%] and 12 ICC
(HPV16: 8, HPV18: 4) [100%] samples showed low E2/E6 amplifica-
tion ratio. We found that the more advanced the clinical stage, the
more cases of low E2/E6 ratio there will be. This most likely sug-
gests that the low E2/E6 ratio is correlated with cervical lesion pro-
gression.
Conclusions: E2 gene disruption is a likely early marker to consider
in the prognostic analysis of HPV 16 and 18 chronically infected
women, and multiplex PCR is a simple and sensitive method for de-
tecting E2 gene disruption.
000242
GREEN TEA POLYPHENOL POTENTIATE CYTOTOXIC EF-
FECTS ON CISPLATIN-CULTURED HELA CELL LINES
S.J. Han1, T.G. Ahn1, B.R. Lee2, W.S. Ahn3
1Department of Obstetrics and Gynecology; 2Department of Bio-
chemistry, College of Medicine, Chosun University, Gwangju; 3De-
partment of Obstetrics & Gynecology, Catholic Medical School, Seoul,
South Korea
Objective: Green tea polyphenol (GTP) has been shown to have an-
ti-tumor properties in a wide variety of experimental systems. In this
study, we evaluated the effects of GTP on the cytotoxic effects of Cis-
platin in cultured HeLa cells.
Methods: The HeLa cell and A549 cell lines were obtained from
Korean Cell Culture Bank. GTP was extracted from tea leaves
(Camellia scinensis) by water extraction and organic solvent frac-
tionation. Cells were seeded at 13104 cells/well in RPMI1640 media
in triplicate wells on a Nunc Labware 96 well flat bottom microcul-
ture plate, with and without GTP (100 lg/ml) and at different con-
centrations of Cisplatin (0-1000 lg/ml). After incubating for 2 days,
cell viability was determined using the MTT assay. P53 and mRNA
levels in cells were determined by western blot and semiquantitative
RT-PCR, respectively.
Results: The viability of the HeLa cells was decreased to 43% at
a 600 lg/ml concentration of Cisplatin, and to 15% above 600 lg/ml
as measured by the MTT assay. However, in the co-culture with GTP
(100 lg/ml), the cell viability decreased to 49% at 200 lg/ml of Cis-
platin and to 17% at 400 lg/ml of Cisplatin. The concentration of
p53 protein and mRNA were determined 4 hours after GTP treat-
ment. The p53 protein concentration was increased by GTP treat-
ment, but the p53 mRNA level was not altered by GTP.
Conclusion: These experiments showed that GTP has a potentiating
effect on Cisplatin cytotoxicity, and the increased p53 protein levels
by GTP may have some role in this synergistic outcome.
000243
EXTRAPERITONEAL LYMPH NODE DISSECTION IN PA-
TIENTS WITH CERVICAL CANCER
A. Hasenburg1, D. Denschlag1, G. Gabriel1, C. Mueller-Lantzsch1,
K. Henne2, G. Gitsch1
1Department of Obstetrics and Gynecology; 2Department of Radiotherapy,
University of Freiburg, Freiburg, Germany
Objective: The presence of nodal metastases is the most impor-
tant prognostic factor in cervical cancer. To adjust our therapy to
the true extent of the patient’s disease, an extraperitoneal lymph
node dissection (EPLND) was performed in all patients prior to
radiotherapy (RT) or radical hysterectomy. For patients with stage
I-IIa a radical hysterectomy was abandoned in case of lymph
node involvement and patients received a combination of chemo-
therapy and RT. For patients with advanced disease the level of
positive lymph nodes was evaluated to define the extent of the
RT field. Patients and methods: Fifty-nine patients with cervical
cancer underwent EPLND. The value of this procedure as a diag-
nostic tool was evaluated and treatment-related complications
were monitored.
Results: EPLND changed the clinical management for 11 patients
(31%) from a radical hysterectomy to chemotherapy/RT and for 5
patients (22%) from standard-field RT to extended-field RT. The esti-
mated 5-year overall survival was 64%, lymph node involvment
was the only significant independent prognostic factor for the 5-year
overall survival (p = 0,04). The most common side-effect related to
EPLND was the formation of lymph cysts in 7 patients (12%). Two
patients with the combination of EPLND and radical hysterectomy
developed a severe ileus postoperatively. The treatment approach of
EPLND and chemotherapy/RT was without WHO grade 3 and 4
toxicity.
Conclusion: Our data support surgical staging by EPLND to indi-
vidualize the treatment for patients with cervical cancer. The compli-
cation rate was low.
000244
TOTAL LAPAROSCOPIC RADICAL HYSTERECTOMY (TYPE
III) WITH PARAAORTIC & PELVIC LYMPHADENECTOMY. A
RECENTLY REPORTED CASE IN A GREEK TERTIARY CENTER
G.E. Hilaris1,2, T. Tsoubis1, A. Daveta1
1IASO and IASO Genreal Hospital, Athens, Greece; 2Center for Special
Minimally Invasive Pelvic Surgery, Stanford University Medical Center,
Palo Alto, CA, USA
Background: The role of laparoscopy in the management of abdomi-
nopelvic malignancies is evolving. Data from new randomized and
nonrandomized controlled trials demonstrate that laparoscopic sur-
gical staging has equal efficacy (lymph node counts, disease free sur-
vival) compared to traditional open cases and can be safely
performed in selected patients
Materials and Methods: We report a recent, in our country, case of
laparoscopic radical hysterectomy and lymphadenectomy per-
formed in a tertiary center in a 44 yo G1P1 female with squamous
cell carcinoma of the cervix, stage IIA. After a thorough preoperative
assessment, informed consent was obtained and a surgical team,
with experience in laparoscopic surgical staging, was assembled and
performed the surgery.
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Results: A laparoscopic radical hysterectomy type III with para-
aortic and pelvic lymphadenectomy was carried out. Nineteen no-
des were retrieved two of which (2/19) were positive for metastasis.
She suffered a left lower extremity venous thrombosis for which she
underwent standard DVT treatment with parenteric heparin and
eventually oral coumadin. The patient required only one (1) analge-
sic suppository for postoperative pain control and remained afebrile
throughout her hospitalization. She received adjuvant chemoradia-
tion due to risk factors and is now under a standard surveillance
schedule.
Conclusion: The performance of this procedure in a tertiary center
in our country supports the fact that laparoscopic surgical staging, is
gaining steadily wide acceptance by both patients and physicians,
throughout the world. To our knowledge a total laparoscopic radical
hysterectomy with bilateral para-aortic and pelvic lymphadenec-
tomy has not been previously described in our country.
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